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7ABSTRACT
Protein-based therapeutics play an increasingly important role in medicine, and the
exquisite bio-recognition properties exhibited by antibodies has also led the their use
in a number of other fields apart from medicine.  The increasing use of these
molecules requires more efficient methods of purification.  A review of the current
purification strategies was conducted.  Of all the purification methods studied, peptide
epitope/mimotope affinity chromatography proved to be the method of choice –
resulting in antibodies exhibiting high specific immunoreactivity. The need to tailor
unique affinity ligands for each antibody to be purified by peptide epitope/ mimotope
affinity chromatography was identified as the major problem with this technique.  A
review of the technologies available to regulate the antibody-antigen interaction was
conducted.  Little was published on the use of phage display for the discovery of
peptide ligands for use in peptide mimotope affinity chromatography.
Experiments were conducted using a polyvalent phage display library to identify
novel peptide ligands for the purification of the therapeutic monoclonal antibody
C595.  A novel peptide was isolated which demonstrated improved chromatographic
performance compared to the standard epitope peptide used to purify mAb C595 from
biological supernatants.  Circular dichroism showed that the novel peptide had a more
highly ordered structure at 4oC and room temperature than the epitope peptide, and
fluorescence quenching revealed a higher equilibrium association constant.
A method for the optimisation of peptide mimotopes derived from phage display,
cross-reactive with an anti-steroid antibody was investigated.  Improvements relating
to the selection of lead peptide sequences are described, and the use of mimotopes in
an assay to determine concentrations of steroid in solution has been demonstrated.
The optimised mimotope was used as an effective paratope-specific affinity ligand.
A novel method for selecting high affinity antibody fragments in vivo is described.
The C595 scFv gene was fused to a gene encoding  green fluorescent protein and
incorporated into the phagemid vector pCANTAB 5E.  The fusion protein could not
be expressed at high levels and could only be detected using epitope affinity
chromatography in combination with ELISA.
8ACKNOWLEDGEMENTS
I would like to thank all my colleagues at the Cancer Research Laboratories at the
University of Nottingham for their help and support.
I thank my supervisor Dr Charlie Laughton and Dr Kevin Brady for their helpful
advice during my research.  Thank you to my late supervisor Professor Mike Price,
for his encouragement and motivation.  I also thank Dr Andrea Murray for her
guidance in the initial stages of my research.
I thank Dr Sotiris Missailidis for providing help with some of the biophysical
techniques used in this thesis.  Thanks also go to Mr Ian Davies for his help with the
biopanning experiments and good humour.
I also thank the BBSRC for kindly providing funding for my study, and Dr Steve
Howell and Dr Andy Badley of Unilever research, for the use of their BIAcore.
Thank you to Dr Neil Thomas of the Chemistry department at the University of
Nottingham for the use of their facilities.
Finally I would like to thank my parents for their support.
9GLOSSARY OF TERMS
bp – Base pairs
BSAU – Biopolymer synthesis and analysis unit
BSA – Bovine Serum albumin
CD – Circular dichroism
CDR – Complementarity determining region
cDNA – Complementary DNA
DNA – Deoxyribonucleic acid
E-3-G – Estrone-3-glucuronide
E. coli – Escherichia coli
EDC – 1-[3-(Dimethylamino)proyl]-3-ethylcarbodiimide
ELISA – Enzyme linked immunosorbent assay
Fab – Antigen binding fragment
FACS – Fluorescence activated cell sorting
Fc – Constant fragment
FDA – Federal Drug Administration (USA)
Fv – Variable fragment
FQ – Fluorescence quenching
GFP – Green Fluorescent Protein
HIC – Hydrophobic interaction chromatography
HIV – Human immunodeficiency virus
HPTFF – High performance tangential flow filtration
IgG – One class of Immunoglobulin
IPTG – Isopropyl-β-D-thiogalactopyranoside
KA- Equilibrium association constant
KD – Equilibrium dissociation constant
kon – Association rate constant
koff – Dissociation rate constant
LB – Luria broth
mAb – Monoclonal antibody
MRNA – Messenger ribonucleic acid
NHS – N-Hydoxysuccinimide
OD – Optical density
10
PBS – Phosphate buffered saline
PBSA – PBS containing the preservative sodium azide
PCR – Polymerase chain reaction
PECS – Periplasmic expression with cytometric screening
pfu – Plaque forming units
rpm – Revolutions per minute
RNET – Replacement Net
RU – Resonance units
SB – Super broth
scFv – Single chain variable fragment
SELEX – Systematic evolution of ligands by exponential enrichment
SPCL – Synthetic peptide combinatorial library
SPR – Surface plasmon resonance
Taq polymerase – Thermus aqauaticus DNA polymerase
TBE – Tris-borate-EDTA buffer
UV – Ultra violet
VH – Heavy variable chain
VL – Variable light chain
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Chapter 1 Antibody Purification.
1.1 Introduction
1.1.1 Antibodies
Antibodies are members of a family of proteins known as Immunoglobulins.
Immunoglobulins are the most critical components of an organism’s immune system.
The exquisite specificity of recognition demonstrated by Immunoglobulins enables
the initiation of a defensive response to foreign substances introduced into an
organism.  B-lymphocytes carrying specific receptors recognise and bind to the
antigenic determinants of the foreign antigen which then stimulates a process of
division and differentiation – transforming the B-lymphocytes into plasma cells which
synthesize antibody.
Immunoglobulins are divided into five major classes according to their heavy chain
components: IgG (γ), IgA (α), IgM (µ), IgD (δ) and IgE (ε).  The IgG class of
antibody is the most useful tool of the immunochemist as a result of their overall
stability, this is the class of antibody described here and later in this thesis.  IgG exists
in four subclasses in humans as a result of minor amino acid differences in each class.
The IgG antibody has a molecular weight of approximately 150 kDa.  Its structure
consists of four polypeptide chains (figure 1.1), two heavy (H) chains (approximately
50 kDa each) linked to two light (L) chains (approximately 25 kDa each) by means of
interdomain disulphide bonds.  The two variable regions (Fv) contain the antigen
recognition elements.  These regions contain amino acid sequences that are hyper-
variable between different antibodies, these regions which interact with the target
antigen are termed complementarity determining regions (CDRs).  Each Fv region
contains six of these CDRs.
Chapter 1 Antibody Purification.
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Figure 1.1: Representation of the protein structure of an IgG molecule.  The globes
represent the various domains in the heavy- and light-chain antibody molecules which
is a tetrameric structure made up of two heavy chains (H) and two light chains (L).
Light chains are linked to heavy chains by single interdomain disulphide bonds, heavy
chains are linked by two interdomain disulphide bonds.  The binding specificity is
determined by the VH and VL segments.  Fv represents fragment variable, and Fab
represents fragment antigen binding and Fc represents the constant region. (Taken
from Kay, 1996).
1.1.2 Monoclonal and engineered Antibodies
The arrival of hybridoma technology in 1975 allowed the production of large amounts
of murine monoclonal IgG antibodies from continuous cultures of fused cells (Kohler
and Milstein 1975).  This source of a single, homogeneous antibody of defined
antigen specificity enabled (through the application of genetic engineering and protein
engineering techniques – see below) the production of recombinant Fv fragments, Fab
fragments (Pluckthun and Skerra, 1989) single chain Fv (scFv) molecules, diabodies,
triabodies, tetrabodies (Hudson and Kortt 1999, Hudson, 1999); and the creation of
chimeric antibodies (human constant regions and murine variable (VH and VL)
regions) and humanized antibodies (the entire mouse molecule is replaced by human
sequence, except for the CDRs of the variable regions)(Chamow and Ashkenazi
1999).
Chapter 1 Antibody Purification.
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Antibodies can be expressed in E.coli. in the form of a Fv fragment.  Heavy- and
light-chain variable domains (VH and VL) (see figure 1.1) are separately expressed
into the periplasmic space where they associate to from a Fv which retains the binding
specificity of the parent antibody.  However there is a tendency for the Fv fragment to
dissociate in some clones (Kay, 1996).  This problem has been overcome by joining
the genes encoding the heavy- and light-chain variable domains with DNA encoding a
flexible linker peptide.  This results in the expression of a single protein with
covalently linked heavy- and light-chain variable regions and is termed a single-chain
Fv (scFv) molecule.  The other molecules described above (diabodies, triabodies and
tetrabodies) are formed by varying the length of the linker peptide (Hudson, 1999).
Fab fragments in which the heavy chain variable region, along with its first constant
domain, associates with a whole light chain, have also been constructed (Pluckthun
and Skerra, 1989).  The association between the constant domains means that this
heterodimer is also more stable than the Fv fragment.
1.1.2.1 Applications of monoclonal and engineered antibodies
The use of monoclonal antibodies as therapeutic reagents is well documented
(Hudson 1999; Murray et al. 2000) and as more molecules receive FDA approval and
new targets are discovered, their use is likely to increase (Hudson 1999).  The
exquisite biorecognition properties displayed by antibodies and antibody fragments
can also be put to good use in many consumer goods and industrial reagents.  Some of
the potential uses of antibody fragments in non-pharmaceutical sectors are outlined in
table 1 (Harris 1999). Current examples of the use of antibodies in consumer goods
include home pregnancy testing kits, home ovulation tests(Unipath, Bedford, UK),
and personal contraceptive systems.  Many other examples of the use of antibodies
and antibody fragments exist particularly in biosensors.
The use of whole antibodies in consumer goods and industrial reagents does have
limitations, because antibodies are large and contain redundant material that is not
required in their biological recognition function.  Genetically engineered antibody
fragments are much more preferable. The use of genetically engineered antibody
fragments has many other advantages over whole antibodies: the recognition
properties of a particular fragment have the potential to be fine-tuned for a particular
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application using the technologies outlined in chapter two.  Fusion proteins can also
be developed (Kerschbaumer et al. 1996; Kerschbaumer et al. 1997; Chamow and
Ashkenazi 1999; Griep et al. 1999), including bispecific recognition elements as
described in the biosensor application below.  Different expression systems can be
utilised (including transgenic milk (Pollock et al. 1999), bacteria, insect cells, plants
and mammalian cells) for the expression of the reagents at high concentrations.
(Badley et al. 1999) describe a biosensor utilising an engineered bispecific antibody
(Figure 1.2), whereby the bispecific antibody can be reversibly displaced from its
immobilised anchor (a lower affinity analogue of the analyte) by the analyte.  The
second binding site on the displaced complex is then captured by a second, different
immobilised capture molecule.  This capture process can then be monitored either
electrochemically or by surface plasmon resonance (SPR).  The patent also describes
a different format for this biosensor.  The bispecific antibody is replaced by an
antibody-mimotope fusion (see section 1.7.3.3 for description of a mimotope),
whereby the initial anchor consists of an antibody immobilised onto the surface,
which binds to the mimotope in the mimotope-antibody fusion.  The mimotope-
antibody fusion is displaced by the analyte (for which the peptide is a mimotope) and
the antibody binding to a different site is measured.  The regulation of the mimotope
recognition reaction by monoclonal antibodies is crucial to the design of this type of
sensor.
Chapter 1 Antibody Purification.
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Antibody fragments as
specific binding agents
Application
Food industry Inhibition of enzymes that cause food spoilage.
Protection of sensitive motifs during processing.
Molecular mimics to enhance or mask flavours and
odours.
Antimicrobial preservatives.
Cosmetics and
toiletries Antibacterials and antifungals for toothpastes andmouthwashes.
Inhibition of enzymes that cause body odours.
Specific antibacterials against dandruff.
Detergents
Stain removal.
Environmental
protection Removal of microorganisms and viruses from water.Removal of organic pollutants from water (e.g.
pharmaceuticals).
Bioremediation of land.
Detection of contaminants.
Manufacturing
industry Separation of products from their intermediates.Clean up of process waters.
Military
Detection of chemical and biological weapons of mass
destruction.
Detection of explosives.
Table 1: Potential uses for antibody fragments in non-pharmaceutical sectors.
Adapted from Trends in Biotechnology July 1999 (Vol 19), B.  Harris – Exploiting
antibody-based technologies to manage environmental pollution.
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Figure 1.2: Reproduced from (Badley, et al. 1999).  (A) First surface (2), second surface (2'), analyte of interest (3), structural analogue of
analyte (1), bispecific antibody (5), analyte binding site of bispecific antibody (4), capture moiety (7), binding site of bispecific antibody which
has binding specificity for the capture moiety (6); (B) First surface (2), Immunoglobulin with affinity for capture moiety on second surface (not
shown) (11), binding site which binds to capture moiety on second surface (12), analyte of interest (8), mimotope of analyte of interest (10),
immobilised antibody with lower affinity to mimotope than to analyte of interest (9).
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1.2 Examples of a therapeutic and a commercially applied
monoclonal antibody
The majority of work presented in this thesis involves the murine monoclonal
antibodies C595 and 4155.  These are described below.
1.2.1 C595 monoclonal antibody  (NCRC48)
C595 mAb is a murine IgG3, κ-light chain monoclonal antibody raised against human
MUC1 mucin (Price, et al. 1990).  PCR and cloning technology have been used to
determine the primary amino acid sequences of the heavy chain variable region (VH)
and the light chain variable region (VL) of C595 mAb, enabling modelling of the
variable region of C595 mAb to be conducted (Denton, et al. 1995).  This
development facilitated the production of engineered antibodies and fragments,
namely a recombinant single-chain fragment (scFv) (Denton, et al. 1997), a
recombinant diabody (Denton, et al. 1999), a human chimera and a humanized
antibody all reactive with MUC1 antigen, synthetic peptides and tumour cells
(Personal communication Dr. B. Lo, University of Nottingham).
1.2.1.1 MUC1 mucin
MUC1 mucin is a large molecular weight glycoprotein that is composed of over 50%
carbohydrate, having a protein core rich in serine, threonine, glycine and alanine
(Shimizu and Yamauchi 1982).  The protein core contains a large domain of a
variable number of highly conserved 20 amino acid repeat sequences
(PDTRPAPGSTAPPAHGVTSA) (Gendler, et al. 1988).  Variation in the number of
tandem repeats leads to extensive polymorphism  (Swallow, et al. 1987).  The
unmasking of epitopes in the protein core; the appearance of novel carbohydrate
epitopes, resulting from aberrant glycosylation and expression at elevated levels in
malignant cells, mean that MUC1 has been comprehensively studied as an effective
tumour marker.  A large number of monoclonal antibodies have been developed
which are reactive with various epitopes contained within MUC1 (Rye and Price
1996).  Monoclonal antibody C595 is one such antibody.
Chapter 1 Antibody Purification.
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1.2.1.2 Clinical uses of C595 mAb
The use of antibodies in the diagnosis and treatment of disease has previously been
reviewed (Murray, et al. 2000).  The C595 mAb has been used for in vivo diagnostic
tests to enable the identification of malignant ovarian tumours using
immunoscintigraphy (Perkins 1993) and also to measure circulating mucin in breast
cancer patients in vitro using immunoassay (Dixon, et al. 1993).  Intra-vesicle
administration of radiolabelled (111Indium) C595 mAb followed by gamma camera
imaging has been used to detect bladder tumours (Hughes, et al. 2001).  This work
has been followed by the use of Technetium-99m labelled C595 mAb, improving the
quality of imaging (Murray, et al. 1999; Simms, et al. 2001).  188Re – C595 antibody
conjugates are currently being used for radioimmunotherapy of transitional cell
bladder cancer (Murray, et al. 2001).  Figures 1.3 and 1.4 provide an excellent
example of the benefits of immunoscintigraphy compared to more conventional
techniques.  Figure 1.3 shows the tumour as a poorly visible opaque region, but figure
1.4 clearly defines a red “hot-spot” where the radiolabelled antibody has accumulated.
The image in figure 1.4 is clearly a much greater aid to diagnosis than the grainy
image displayed in figure 1.3.
1.2.2 mAb 4155
Monoclonal antibody 4155 is a commercially developed  murine IgG1 anti-steroid
antibody (Unilever Research, UK), raised against estrone-3-glucuronide (E-3-G)
(Badley, et al. 1999).  E-3-G is a urinary metabolite of estradiol.  A rise in the levels
of E-3-G in female urine can be used to determine the start of the most fertile period
in the human menstrual cycle.  A surge in the urinary concentration of luteinizing
hormone (LH) can also be used to mark the end of this fertile period.  MAb 4155 and
an anti-LH mAb have been incorporated in a commercial test-kit (PersonaTM,
Unipath, Bedford, UK) to enable the determination of the most fertile period in the
human menstrual cycle (May 1994).
Chapter 1 Antibody Purification.
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Figure 1.3: Intravesical urogram. Bladder is filled with a contrasting agent. There is a
suspicion of  the presence of a tumour which takes the form of a filling defect (arrow).
Figure 1.4: Radioimmunoscintigraphy reveals the tumour and corresponds to the
region of the filling defect. Tissue at this site later identified as being cancerous by
histopathology.  (Pictures courtesy of Dr A. Murray, University of Nottingham).
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1.3 Approaches to antibody purification
The increasing use of antibodies and engineered antibody fragments in medicine,
consumer goods and as industrial reagents necessitates the application of
methodologies for the efficient purification and concentration of these reagents from
biological media.    Protein purification techniques require the selective adsorption of
either the biomolecule of interest or contaminating molecules to produce a pure
homogeneous product.  The adsorption medium can be presented to the feed in a
number of different ways, each with there own unique advantages.
1.3.1 Column chromatography
Column chromatography is the conventional technique used to house a variety of
matrices; including media for ion exchange chromatography, hydrophobic interaction
chromatography, affinity chromatography and gel filtration.  Conventional column
chromatography necessitates clarification of the crude feed before application to the
column, to prevent fouling of the column.  Clarification of the crude feed requires
centrifugation and microfiltration steps to remove particulate matter.  Centrifugation
is time consuming and with the microfiltration step, fouling of microfiltration
membranes can occur.  Product may also be lost by degradation in the clarification
process.  All of these factors add to the operational cost of the process when dealing
with industrial scales of biological material (feed).
1.3.2 Fluidized bed and expanded bed adsorption
Fluidized bed and expanded bed adsorption eliminate the need for clarification of the
crude feed.  The adsorbent is first expanded and equilibrated by applying an upward
liquid flow to the column.  The balance between particle sedimentation velocity and
upward liquid flow velocity creates a stable fluidized bed.  Unclarified feed is applied
to the expanded bed in the upward liquid flow.  The target proteins bind to the
adsorbent and contaminants pass through.  Non-specifically weak binding
contaminants are then washed through.  Liquid flow is then stopped and the absorbent
material settles in the column.  The column adapter is then lowered onto the surface of
the sedimented bed.  The direction of buffer flow is reversed and using a suitable
buffer the target protein is eluted from the column.  The column can then be
regenerated ready for use.  This technique can be used with an affinity ligand on the
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adsorbent and also in ion exchange techniques.  An overall yield >90% obtained by an
expanded bed ion exchange adsorption procedure, followed by a final affinity
chromatography polishing step has been reported (Hansson, et al. 1991).
1.3.3 High performance Tangential Flow Filtration (HPTFF)
HPTFF is a separation technique that exploits differences in both the size and the
charge characteristics of biomolecules.  These differences in size and charge are used
in conjunction with membranes with a carefully controlled pore size to elicit effective
separations.  The technique requires the samples to be in a reasonably pure state
already, otherwise membrane fouling can occur.  Membrane fouling occurs when the
pores of the membrane become blocked with debris present in the sample, perturbing
the carefully engineered properties of the membrane.  Charged membranes are often
used to enhance the selectivity of the separation.  Similar to ion exchange
chromatography, adjustments in pH and ionic strength enable the maximisation of the
differences in charge and size between the product and the impurity.  The separation
is carried out with a transmembrane pressure gradient to elicit the separation.  HPTFF
enables the purification of proteins in a single purification step.  But as with ion
exchange chromatography, when selecting purely using the parameters of size and
charge, there is no guarantee of the standardisation of the immunoreactivity of the
purified antibody.  Since this is a 2D-separation technique – separating by both size
and charge, the likelihood that proteins with similar biochemical characteristics will
be co-purified is less than in ion exchange chromatography.
1.3.4 Magnetic beads
Magnetic beads are available from a number of manufacturers.  These include
magnetic beads coated with streptavidin and magnetic agarose beads incorporating
Fe3O4 (Magnogel (Dean, et al. 1985)) in the interior of the gel beads.  These reagents
have applications in situations where column operation is not favoured, for example
with viscous solutions or in the presence of partly soluble cell debris.  The cost of
such beads in comparison to other media used in expanded bed and fluidized bed
techniques generally prohibits their use in large-scale industrial applications.
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1.4 Physical separation techniques
Physical separation techniques are based on the differences in biochemical properties
(such as overall charge, size of molecules, and hydrophobicity) between the protein of
interest and the contaminants to elicit a separation of the two.
1.4.1 Ion exchange
Ion exchange chromatographic separation techniques utilise the overall charge of the
protein to effect a separation.  Utilising buffers at different pH it is possible to impose
a particular charge on the biomolecule.  Antibodies for instance have isoelectric
points within the range 6-8 (Danielsson, et al. 1988).  Thus if the pH of the buffer
containing the antibody is lower than the pI for the antibody, the antibody will have a
net positive charge, since both acidic and basic moieties will be protonated.
Conversely increasing the pH of the buffer containing the antibody above the pI for
the antibody will give the antibody a net negative charge.
Ion exchange chromatography can be used either as a positive chromatographic step
(protein of interest is retained on the matrix and the contaminants pass through); or as
a negative chromatographic step (contaminants bind to the matrix and the protein of
interest passes through).  When used as a positive chromatographic step for the
purification of antibodies, pH < pI (antibody) the antibody has a net positive charge
enabling a cation exchange matrix to be used to bind antibody.  When used as a
negative chromatographic step, pH ~ 7 and an anion exchange column is used; at this
pH immunoglobulins pass through (relatively de-ionised at this pH) and many
contaminating proteins including albumin (pI ~ 4.7) bind to the matrix.  Isolation of
mAb C595 from murine hybridoma cell culture supernatant utilising a cation
exchange matrix has been reported (Denton, et al. 2001).
The use of ion exchange chromatography to purify monoclonal antibodies has the
disadvantage that the activity of the purified antibody is not standardised.  That is, all
of the antibody purified may not be fully immunoreactive.  There is also no guarantee
that proteins with similar biochemical parameters to those of the antibody will not be
co-purified.  Ion exchange chromatography can be used in the conventional column
format and in an expanded bed or fluidized bed format.
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1.4.2 Gel filtration
The process of gel filtration molecules in solution are separated according to
differences in their sizes as they pass through a column packed with a
chromatographic medium which is a gel.  Gels manufactured for use in gel filtration
contain a carefully controlled range of pore sizes.  Relatively small molecules are able
to diffuse into the gel from the surrounding solution, whereas relatively large
molecules are prevented by their size from diffusing into the gel and are confined to
the outside solution.  The mixture containing the molecules to be separated is applied
to the top of the column in solution.  The sample zone moves down the bed as eluent
is added to the top.  Small molecules that are able to diffuse into the gel are retarded
in their passage through the column compared to the larger molecules that cannot
enter the pores.  Larger molecules elute from the column first, followed (in order of
size) by smaller molecules.  Gel filtration can also be used as an effective desalting
step, where the larger biomolecules pass through the column unretarded compared to
the salt ions.  Gel filtration is superior to dialysis techniques, where considerable
levels of product loss can occur.  Gel filtration was used to desalt samples eluted
under chaotropic conditions in the experiments described in this Thesis.  Gel filtration
is conducted in a conventional column chromatography format.
1.4.3 Hydrophobic Interaction Chromatography (HIC)
HIC utilises the differences in hydrophobicity between proteins to effect separations.
Purification techniques use the reversible interaction between the protein and the
hydrophobic surface of the chromatographic medium.  Samples are bound to the
column in high ionic strength buffer and are eluted by a decreasing salt gradient.
Target proteins may also be eluted by adding chaotropic species; adding detergents;
changing pH; changing temperature; or reducing eluent polarity (ethylene glycol
gradient up to 50%).  HIC is useful for removing major serum contaminants such as
albumin and transferrin, which are washed straight through the column.
1.5 Affinity Purification Techniques
Affinity purification techniques involve the selective adsorption of a specific binding
agent (e.g. a monoclonal antibody) onto a solid phase adsorption matrix from which
the specific binding agent can subsequently be eluted.  The solid phase material may
take one of a number of formats.  These include the use of chromatography columns
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that hold a conventional packed bed of adsorbent (onto which the target ligand is
immobilised); fluidized bed adsorption; expanded bed adsorption and magnetic beads.
None of the physical techniques discussed in the previous sections generally produce
the degree of purity and concentration achieved with the relative ease of using affinity
techniques.  Several different steps may need to be incorporated into a purification
strategy using physical separation techniques (Amersham Pharmacia Biotech. 2000).
1.5.1 Fc Binding Proteins
Protein A (Forsgren and Sjoquist 1966) and protein G (Olsson et al. 1987) are
bacterial proteins from Staphylococcus and Streptococcus respectively, which bind
specifically to the Fc region of polyclonal and monoclonal IgG type antibodies.
Immobilised on a matrix they can be used to purify monoclonal IgG type antibodies.
Synthetic and recombinant mimics of protein A also exist which also elicit effective
purification (Fassina, et al. 1996; Li, et al. 1998).  Protein G elution is conducted by
changing the pH of the running buffer.  Protein A elution can be conducted by
changing the pH, using denaturing agents or chaotropic salts.  Protein A and Protein G
have the disadvantages that both active and inactive antibody is potentially purified,
and by the nature of their action (Fc binding) are unable to purify antibody fragments.
1.5.2 Recombinant Protein Tags
A common method employed in the purification of antibody fragments is the use of
protein affinity tags.  Genetic engineering techniques enable the addition of
specifically designed tags to create gene fusions for use in affinity purification.  A
large number of affinity tails have been developed to facilitate the downstream
processing of recombinant proteins (Nygren, et al. 1994; Boldicke et al. 2000).  Kits
based on several of these tails have been produced commercially where the expression
vector is manufactured with the corresponding affinity resin.  A number of affinity
tail/binding partner systems exist, they can be divided into three categories:-
(i) EPITOPE TAGS
Commonly used epitope tags include the FlagTM peptide – an 8aa peptide
DYKDDDK (Gama and Breitwieser 1999) that binds to a specific mAb (IBI Kodak,
USA); the E-tag – a 13aa peptide GAPVPYPDPLEPR (Krammer 1998) that binds to
a specific mAb  and is incorporated into the pCANTAB vector in the RPAS
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expression system (Pharmacia, Sweden).  The peptide tag CLDKSGLPSDRFFA has
also been used to purify a fusion protein by immunoaffinity chromatography
(Boldicke et al. 2000).
(ii) METAL CHELATORS
These consist of polyhistidine tails enabling the purifying of recombinant protein by
immobilised-metal-ion affinity chromatography (IMAC) (Novagen, USA; Invitrogen,
USA; Qiagen, USA).
(iii) PROTEIN PROTEIN INTERACTIONS
 Commonly used protein tags include fusions with glutathione-S-transferase (GST),
GST binds to glutathione (Pharmacia, Sweden); fusions with maltose-binding protein
(MBP),  MBP binds to amylose (New England Biolabs, USA); staphylococcal protein
A and its derivative ZZ, binding to IgG (Pharmacia, Sweden).
Another example which does not fit into these categories is the PinPointTM system
which utilises the in vivo biotinylation by E.coli of a 13kDa sequence attached to the
target protein, combined with affinity purification of the fusion protein on monomeric
streptavidin (Promega, USA).
Gene fusion strategies introduce an additional problem into the downstream
processing since a site-specific cleavage is required to remove the affinity tag.  A
large number of chemical and enzymatic methods are available to facilitate this
(Nygren, et al. 1994).  Purification of antibody fragments using this method has the
disadvantage that inactive recombinant antibody fragments may be co-purified
alongside active antibody fragments.
1.5.3 Paratope specific binding ligands
The paratope of an antibody is the binding cleft in the structure of the antibody that
binds specifically to a particular antigen or hapten molecule.  Paratope specific
binding ligands offer the unique advantage that purified antibodies are of high and
standardised immunoreactivity, since only functional molecules bind to the affinity
matrix and are later eluted.  The key feature of this purification method is the need to
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discover and fine tune the ligand used.  Some ligands may have too high affinity for
the matrix (E3G – 4155 mAb interaction (Badley, et al. 1999) and the elution
conditions needed may be too harsh; other ligands will have too low affinity and so
not effectively concentrate antibody from the feed.  Hence the need for the regulation
of the affinity of the recognition process of epitopes/mimotopes by monoclonal
antibodies.
1.5.3.1 Antigen affinity chromatography
Antigen affinity chromatography enables the purification of a specific antibody from
a polyclonal antiserum.  It enables the purification of monoclonal antibody samples
contaminated with irrelevant or unreactive immunoglobulin protein, or other
contaminants.  The antigen is coupled to an appropriate matrix.  Large amounts of
antigen may be required in the preparation of the matrix, and there may be significant
loss as well as inactivation during successive rounds of use.  It is these problems of
antigen availability, high cost, poor chemical and biological stability that prohibit the
large-scale use of this technique.   For this reason the use of smaller more stable
ligands immobilised onto the affinity matrix is much more preferable.
1.5.3.2 Epitope affinity chromatography
The regions of a protein antigen that are recognised by the combining sites of an
antibody are known as antigenic determinants or epitopes.  Epitopes can be divided
into two types: - continuous and discontinuous epitopes.
Continuous epitopes
Sequences obtained by screening peptide libraries are often identical to those of the
recognition sequences of the corresponding natural ligands (Katz 1997).  There are
many examples where the core consensus sequences of phage-displayed epitopes
recognised by monoclonal antibodies are similar to the sequences of the proteins
against which the antibodies were originally raised (Cwirla, et al. 1990; Scott and
Smith 1990; Felici 1991; Stephen and Lane 1992; Katz 1997; Tighe, et al. 1999).
C595 monoclonal antibody has been demonstrated to bind to the RPAP motif found
in phage libraries (Laing, et al. 1995; Smith 2000); and synthetic peptide libraries
(Murray, et al. 2000).  The RPAP motif is present in the primary sequence of the
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antigen to which the antibody was originally raised (Price, et al. 1990).  The RPAP
motif is termed a continuous epitope.
Discontinuous epitopes
Examples of discontinuous epitopes exist where the sequences of the proteins against
which the antibodies were originally raised bears no relation to sequences derived
from phage display or other peptide libraries (Felici, et al. 1993; Luzzago, et al.
1993).  Such epitopes are made up of residues that are not contiguous in the sequence
but are bought together by the folding of the peptide chain (Regenmortel 1995).
These discontinuous epitopes may also be termed as structural epitopes since the
binding properties of the residues in the antigen are directly as a result of the structure
of the antigen and not the primary sequence.
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C595 produced in
Hybridoma cells
using CELLine membrane
technology
Supernatant clarified
by centrifugation &
microfiltration
Supernatant circulated
thorough affinity matrix
at 4oC (CNBr activated 
Sepharose used to 
couple peptide) Column washed 
with 10 column
volumes PBSA
Chaotropic agent
(NaSCN) used to
elute bound Ab
Chaotrope removed using
Sephadex G25 column
(large scale production)
Chaotrope removed using
PD10 column (Pharmacia)
(small scale experiments)
Antibody ready for use.
Radiolabelling
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work
Figure 1.5: Strategy for the purification of mAb C595 from hybridoma supernatant.
a b
Figure 1.6: Peptide affinity purification of monoclonal antibody C595 from tissue
culture supernatant.  Arrow (a) illustrates colour change of column upon antibody
binding (column flow bottom – top); arrow (b) illustrates band movement through the
column upon elution using 3M sodium thiocyanate.  The second picture also shows
the G25 column used to de-salt the eluted fractions.  The G25 column was used in line
with the peptide affinity column, and fractions were collected from the eluent of the
G25 column.
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The critical binding region represented by the epitope is typically synthesized using
conventional solid phase techniques, and then covalently linked to a chromatographic
matrix.  A variety of chemical coupling methods are available to ensure optimal
presentation of the ligand to the target molecule (Wilchek and Miron 1999).  The
smaller peptide (compared to the whole antigen) is likely to be much more stable with
less risk of inactivation during successive rounds of use.  However since the peptide is
synthesized from naturally occurring (L) amino acids, the peptides may be susceptible
to proteolysis (Guichard, et al. 1994).  Overall synthetic peptide ligands have many
advantages over using whole antigens; notably they are generally resistant to both
chemical and biochemical degradation, are sterilizable in situ and can be produced at
an affordable price.
Epitope affinity chromatography is the technique that is currently used to concentrate
and purify C595 mAb from hybridoma supernatant for clinical and laboratory use
(Murray, et al. 1997; Murray 1998; Denton, Murray et al. 1999).  Figure 1.5 outlines
the overall purification strategy.
1.5.3.3 Mimotope affinity chromatography
A mimotope is a molecular sequence which mimics the epitopic region of a particular
antigen, but which does not contain the specific amino acid sequence that comprise
the epitope.  A mimotope is structurally distinct from the primary structure of an
epitope (for proteinaceous ligands), but functionally very similar and capable of
binding in a similar fashion to the binding cleft of the antibody (Paratope) directed to
the antigen containing the particular epitope (Katz 1997).
Peptide sequences have also been discovered that are mimics of antigens that are non-
proteinaceous.  These include biotin peptide mimotopes that bind to streptavidin
(Giebel, et al. 1995), peptide mimotopes of carbohydrate antigens (Agadjanyan, et al.
1997; Kieber-Emmons 1998), peptide mimotopes of DNA (Sibille, et al. 1997) and
peptide mimotopes of a steroid hormone (Murray, et al. 2001).  A review of the
discovery and applications of mimotopes is given by (Meloen, et al, 2000).
Mimotope affinity chromatography is identical to epitope affinity chromatography,
except that a mimotope peptide is immobilised onto the affinity matrix instead of an
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epitope peptide.  Mimotope peptides can have higher as well as lower affinities for a
particular monoclonal antibody, and so elution conditions for a particular antibody
may well differ between epitope and mimotope matrices.  Peptide analogues can be
synthesized replacing the L-amino acid residues with D-amino acid residues (Murray,
et al. 2000), reducing their susceptibility to proteolysis Other examples of peptide
analogues include the replacement of  L-amino acid residues by unnatural residues
(e.g., sarcosine and β-alanine) and the modification of peptide bonds  (Guichard, et al.
1994; Farlie, et al. 1998).
Mimotope affinity chromatography using mimotopes derived from phage display has
been demonstrated to effectively purify and concentrate C595 mAb from hybridoma
supernatant (Smith, et al. 2002).  Mimotope affinity chromatography using an
affinity-matured mimotope (N/C terminal reduction, replacement net analysis),
derived from a phage display library has been demonstrated to effectively purify and
concentrate 4155 mAb from hybridoma supernatant (Murray, et al. 2001).
As with epitope affinity chromatography, the same problems of natural target
availability, high cost, poor chemical and biological stability that prohibit the large-
scale use of the natural target as an affinity ligand are overcome by mimotope affinity
chromatography.  Small short peptide sequences stable to sanatization, less
susceptible to proteolysis (synthesized using (D) amino acids), cheap and easy to
synthesize are much preferable to using the immobilised natural target molecule.
Non-proteinaceous, paratope specific affinity ligands
The anti-steroid antibody mAb 4155, raised against estrone-3-glucuronide (E-3-G) (as
described in section 1.2.2) is purified using lower affinity analogues of the target
ligand (Badley, et al. 1999).  Mab 4155 cross-reacts with several analogues of E-3-G,
the structures of which are shown in figure 1.7.  The hapten to which the antibody was
raised (E-3-G) has the highest affinity for the antibody, followed by 17 beta-Estradiol
3-(beta-D-glucuronide), Estriol 3-(beta-D-glucuronide) and finally estrone with the
lowest affinity.  For the purification of mAb 4155 estrone is linked to beaded agarose
through the hydroxyl group of estrone (Pharmacia epoxy 6B Sepharose).  Hybridoma
feedstock clarified by centrifugation is then applied to a column containing the
chromatography media.  The interaction of mAb 4155 with the estrone immobilised
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on the column is a high affinity interaction that is not perturbed by non-denaturing
buffers, allowing contaminating proteins to be washed off the column.  The higher
affinity analogue estradiol 3-(beta-D-glucuronide) is then applied to the column to
desorb the bound antibody, which is then passed down a gel filtration column to
remove unbound estradiol 3-(beta-D-glucuronide).
 
O
H
H
OH
H
OH
OH
OH
CH3
O
OHO
O
H
H
OH
H
OH
OH
OH
CH3
OHO
OH
O
H
H
OH
H
OH
OH
OH
CH3
OHO
OH
OH
HO
CH3
O
(1)
(2)
(3)
(4)
Figure 1.7: (1) Estrone beta-D-glucuronide (“Estrone-3-glucuronide”), (2) 17beta-
Estradiol 3-(beta-D-glucuronide), (3) Estriol 3-(beta-D-glucuronide) and (4) Estrone.
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The affinity-purified antibody has estradiol 3-(beta-D-glucuronide) bound, allowing
subsequent use in a competition assay format.  This resultant antibody-hapten
complex (the antibody is bound to blue latex particles) is used in the PersonaTM
(Unilever, UK) test kits, where the bound estradiol 3-(beta-D-glucuronide) is
competed from the antibody by E-3-G present either in the urine sample, or E-3-G on
the test-strip.  The intensity of the blue latex beads on the test strip gives a direct
indication of E-3-G levels in the urine sample (May 1994).
Another example of a non-proteinaceous paratope-specific binding ligand, is the use
of DNA-aptamers as specific affinity ligands.  Purification of a human L-selectin-Ig
fusion using an immobilised DNA-aptamer has been described (Romig, et al. 1999).
1.6 Summary
Epitope / mimotope affinity chromatography is the method of choice for the
purification and concentration of monoclonal antibodies and engineered antibody
fragments.  These methods produce a product of standardized and high
immunoreactivity from biological feedstocks.  Epitope / mimotope affinity
chromatography enables the single-step purification and concentration of monoclonal
antibodies and engineered antibody fragments raised against proteinaceous and non
proteinaceous species utilising matrices linked to non-costly, easily synthesized robust
ligands, which can be sanitised in situ.
The discovery of epitopes / mimotopes is crucial to the design of ligands for
application in epitope / mimotope affinity chromatography; and for the application of
mimotopes in biosensors used to detect proteinaceous or non-proteinaceous analytes
utilising monoclonal antibodies and engineered antibody fragments.
The fine-tuning of the recognition properties of engineered antibody fragments and
fusion proteins is also crucial to their application alongside mimotopes in biosensors.
The next chapter outlines the methodologies which can be used to manipulate the
recognition of peptide epitopes / peptide mimotopes by monoclonal antibodies and
antibody fragments.
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2 Chapter 2 Regulation of peptide antibody interactions.
2.1 Introduction
As outlined in the previous chapter, the fine specificity of the interaction between
antibodies and their derivatives, and the species they bind to, has led to these
molecules being used in a wide range of applications.  The work contained within this
thesis has sought to look at the two components of this interaction.
In regulating the interaction between antibodies and peptide epitopes / mimotopes two
different approaches can be taken:
1. The antibody (or antibody fragment) can be considered as constant and methods
employed to vary the structure of the binding moiety such that the affinity of the
antibody for the specific binding moiety is up regulated or down regulated.
2. The binding ligand can be considered as constant and methods employed to vary
the structure/residues contained within the Paratope of the antibody or antibody
fragment, or the residues outside the Paratope can be changed in order to influence
the binding characteristics of the antibody.
The question may be asked why one may need to down regulate the affinity of
interaction in such binding events.  The need to be able to regulate the affinity of the
interaction is important in a number of areas.
(i) The affinity purification of proteins.
It is of little use discovering a novel binding peptide to purify a particular protein (e.g.
antibodies) from biological media, if the conditions required to break the interaction
and release the protein are too harsh and result in the permanent destruction of the
recovered protein (an example of this was given in chapter one (section 1.5.3.4)).  It is
also of little use if the interaction between the peptide and the protein is too weak to
elicit an effective separation of the protein of interest from the biological milieu.
Hence the need to regulate the affinity of the interaction such that the protein-ligand
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interaction can easily be perturbed, allowing the recovery of active product; and also
to regulate the affinity of an interaction so that an efficient separation can be
achieved.  Chapters 4 and 5 of this thesis describe work that has been conducted to
investigate the regulation of peptide recognition by a monoclonal antibody, in this
case the affinity of the monoclonal antibody for the ligand was increased relative to
the native epitope sequence.
(ii) Competition ELISA.
The dynamic range of a competition ELISA is intrinsically linked to the affinity of the
antibody for the immobilised ligand.  High affinity ligands (small KD) will be useful
for measuring small concentrations of competing analyte in solution within the
normal timescale of an assay.  The kinetics of the interaction mean that high
concentrations of analyte will not be easily measured with high affinity ligands, since
the time taken for the assay to reach equilibrium conditions may well be outside the
timescale in which the assay is performed.  Hence high affinity ligands will be limited
to low analyte concentrations, and lower affinity ligands will be limited to higher
analyte concentrations.  For a useful assay (one occurring on a practical timescale)
which is measuring a particular analyte that could be present over a range of
concentrations it is desirable to have a combination of low affinity and high affinity
ligands.  This work is described in chapter 5.
(iii) Therapeutic applications.
The use of antibodies and their derivatives as “magic bullets” delivering therapeutic
reagents to specific sites within the body, and for diagnosis is well documented.
Higher affinity antibodies could reduce the amount of antibody required for use as a
diagnostic reagent for tumour markers displayed on the cell surface.  However high
affinity antibodies may reduce tumour penetration as a result of strong binding to cells
immediately outside capillaries, reducing the overall uptake of the reagent by the
tumour.  There is a continuing debate as to whether MUC1 antigen displayed on the
cell surface is internalised, internalisation of antigen bound to the therapeutic antibody
would favour the use of higher affinity antibodies.  Chapter 6 describes work carried
out to construct a library of scFv mutants displayed on the surface of bacteriophage,
which could be interrogated by selecting for binding and isolated by fluorescence
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activated cell sorting (FACS).  The eventual aim being the isolation of scFv molecules
with increased affinity for the target molecule.
Determining the key components involved in the regulation of antibody affinity for
peptide epitopes / peptide mimotopes will enhance our understanding of the antibody
recognition process.  The aim of this chapter is to outline the different library
technologies that are currently available and provide a rationale for the choice of
library technologies that were used to conduct the work described in this thesis.
2.1.1 Library Technologies
Libraries can be divided into two distinct types: non-biological libraries containing
synthetic, low molecular weight compounds; and biological libraries consisting of
nucleic acids, peptides and proteins.  Figure 2.1 illustrates this.  When a library is
constructed, the information detailing the composition of the compound must be
readily recoverable.  Examples used for both biological and non-biological libraries
include the use of array technology to allow a particular compound to be linked to a
spatial address in a matrix, and various labelling systems including nucleotide tags for
example (see section 2.2.3).
Biological libraries can be further classified into two different types: Displaying
systems, (where a protein or peptide is physically linked to the genetic information
encoding it, thus enabling the recovery of sequence information for a particular
peptide or protein) see table 2.1; and “Display-less” systems (where the link between
a protein or peptide and the genetic information encoding it is purely a spatial
association with no direct physical link) see table 2.2.
The displaying and “display-less” systems can be further divided into two more
categories: in vivo and in vitro systems.  In vivo systems all rely on the use of cells
and/or virus particles.  These methods are subject to biological constraints associated
with protein export and presentation that may compromise the viability of the cell or
virus.
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The size of these libraries is also limited by the particular transformation efficiency of
the cells used.  These constraints impose an upper limit of diversity obtained using in
vivo systems of ~ 109 recombinants, although exceptional libraries of >1010 members
have been described (Fitzgerald, 2000).  In vitro systems are not subject to the
biological constraints associated with cell and virus viability, and since whole cells
are not used, the transformation efficiency is not a relevant factor.  In vitro libraries
are thus capable of exhibiting a much larger diversity since they are limited only by
the quantity of DNA that can be physically added to cell-free protein synthesis
systems (potentially up to 1014 –1015 molecules (Fitzgerald, 2000).
2.1.2 The distinction between screening and selection in library technologies
It is important to note the distinction between the interrogation of libraries by either
screening or selection.  Selection strategies are much more powerful than screening
strategies.  In a screen, variants are analysed on an individual basis for a given
property (e.g. the ability to bind to a particular ligand) to obtain the variant with the
“best” properties.  Selection involves a pool of all the variants.  The whole pool is
subjected to a selection step that directly yields molecules that exhibit the “best”
properties.  The enriched pool can then be propagated and re-selected.  The key
consequence of the selection and propogation steps is the enrichment process which
enables the rapid isolation of mutated proteins from the library.  The rapid isolation of
binding protiens from the library enables the surveying of a greater portion of
sequence space.   For example, the mutation of muliple residues in the protein enables
the study of complex “non-additive” combinatorial effects that could not have been
predicted a priori.  This has led to the use of libraries as sources of proteins exhibiting
de novo binding activities.  One example is the use of filamentous bacteriophage
displaying antibody repertoires to mimic immune selection (Hoogenboom and Winter,
1992).  This work demonstrated that human antibody fragments with specific binding
affinities could be made entirely in vitro.
The use of “second generation” libraries, enables the sequence landscape around a
clone isolated from an initial selection process (“first generation” library) to be
examined to find local optima.  The second-generation library consists of variants of
the sequence of a particular clone isolated from the first generation library.  The
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second-generation library of variants is typically constructed using the mutagenesis
techniques as described in section 2.5.
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Table 2.1: Displaying selection systems, showing larger library sizes are achieved using in vitro systems compared to in vivo systems,
where the limiting factor is the transformation efficiency of the cells used.  Also shown is the link between genotype (code) and
phenotype (encoded entity).  Note the valency of the displayed entity.
Library size Encoded
entity
Valency of
encoded entity
Linker Code
Viral display 109-1010 Protein / Peptide Monovalent
or polyvalent
Viral capsid DNA
Peptide on plasmid 106 Peptide Monovalent DNA binding DNA
Peptide Barcode 106 Protein Monovalent Protease clevage site Peptide sequenceIn
 
vi
vo
Cell-based display 106 Protein / Peptide Polyvalent Prokarytic or
Eukaryotic cells
DNA
Ribosome display 1014 - 1015 Protein / Peptide Monovalent DNA binding DNA / RNA
Covalent Display
Technology
>1012 Protein/ Peptide Monovalent Physical
Attachment
DNA
RNA-peptide fusions 1014 - 1015 Peptide Monovalent Physical
Attachment
DNA
D
isp
la
yi
n
g
sy
st
em
In
 v
itr
o
Non-biological
Display
106 Protein / Peptide /
other components
Monovalent
or polyvalent
Physical
attachment
DNA / spatial address/
chromatographic
property
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Library size
(transformants)
Encoded
Entity
Valency of
encoded entity
Linker Code
Protein expression 106 Protein Monovalent Spatial address DNA
In
 
vi
vo
Periplasmic expression
with cytometric
screening (PECS)
106 Protein Monovalent Periplasmic space
inside the cell
DNA
D
isp
la
y-
le
ss
sy
st
em
In
 v
itr
o
Man-made cell
compartments
>107 Protein
(catalyst)
Monovalent Aqueous cells in
oil/water emulsion
DNA
Table 2.2: Display-less selection systems.  Note that for display-less systems the link between the encoded protein/peptide and the DNA is a
spatial association.
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Screening of synthetic peptide libraries still has an important role to play in analysing
the interaction between antibodies and the antigens they bind.
2.2 Synthetic Peptide Libraries
The foundations of synthetic peptide libraries lie with the work of Mario Geysen
(Geysen, et. al. 1984) who developed mimotope libraries and Lam, et al. 1991 and
Furka et al. 1991, who described methods for synthesizing peptides on individual
beads.   The work of Geysen allowed the concurrent synthesis of large peptide
libraries on derivatized polyethylene or polypropylene pins arranged in a microtitre
plate format allowing ELISA to be conducted to measure antibody binding (Murray,
et. al. 2000).  These synthetic peptide libraries enable the study of epitopes defined by
antibodies reactive with antigens of known primary structure.  Critical information
concerning the role of individual residues in a particular antigen can be determined
using the methods described below.
2.2.1 Pepscan – The application of synthetic peptides in epitope mapping.
A set of overlapping peptides are synthesized that span the length of the antigenic
sequence of interest.  As such this method is limited to the discovery of continuous
epitopes where knowledge of the primary antigenic sequence already exists.  This set
of peptides spanning the antigenic sequence is linked to derivatized polyethylene or
polypropylene pins, allowing them to be placed in the wells of microtitre plates so
that ELISA can be used to measure antibody binding. (Murray, et al. 2000).  This
enables the  linear epitope to be defined for a particular antibody.  The application of
this technology to been used to characterise the epitopes of a number of MUC1 mucin
antibodies (Blockzjil, 1998).  This information can then be used to synthesize a
second library to probe the influence of individual residues on antibody binding (see
section 2.2.2).
2.2.2 Replacement Net (RNET) analysis
RNET analysis allows the contribution of the individual residues in an epitope to the
binding interaction between a peptide and an antibody to be determined.  It is usually
found that several of the residues in a continuous epitope can be replaced by many or
Chapter 2 Regulation of peptide antibody interactions.
41
even all of the 19 amino acids without affecting the binding (Getzoff, et al. 1988;
Briggs, et al. 1993; Pinilla, et al. 1993).  The peptides are synthesized on derivatized
polyethylene or polypropylene pins as described in 2.2.1 allowing ELISA to be used
to measure antibody binding.  A library of peptides is synthesized on the pins, where
each of the residues in the epitope is substituted by each of the other 19 naturally
occurring amino acids.  RNET analysis has been used to investigate the fine
specificity of epitope recognition by C595 mAb (Briggs, et al. 1993; Murray, et al.
1998).  It was demonstrated that in the RPAP epitope, the arginine at position one and
a proline residue at position four are essential to bind to the antibody.
2.2.3 Combinatorial peptide libraries
Random peptide libraries can be produced from organic synthesis using amino acids
polymerised on inert solid support such as beads.  A split and mix strategy is used for
generating such combinatorial libraries (Lam, et al. 1991).  The solid support is
aliqouted into 20 portions and a different amino acid is coupled seperately to each
portion.  The portions are pooled, resplit and the process repeated.  The resulting bead
mixture can then be directly used to select for binding peptides, which could be
detected colourmetrically and the beads physically removed from the mixture for
microsequencing.
An alternative approach is the synthetic peptide combinatorial library approach
(SPCL) (Houghton, et al. 1991).  Here the mixture generated from the split and mix
methodology is split into 20 portions prior to the coupling of the final amino acid, so
only the final amino acid residue of a particular sequence is known.  Each of the 20
pools is assayed for binding to the target protein.  The pool containing the best
binding amino acid is resynthesized, but the last residue is kept constant (identified
previously according to pool), the mixture being split into 20 portions prior to the
addition of the penultimate amino acid.  The penultimate amino acid is added
(according to which pool the mixture is in).  The amino acid residue selected in the
previous round is then coupled to each of the 20 portions.  The process is repeated,
selected the best-binding pool, working back along the peptide chain until the best
binding peptides are selected.
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Microanalysis is a limiting factor in the identification of compounds from these
libraries.  Several methods of tagging each of the individual components of the library
during the synthesis process, so linking the phenotype to an easily interpreted
“genotype”, have been used.  Strategies include the tagging of beads with nucleotide
sequences synthesized in parallel to the peptide sequence (Needels, et al 1993).  The
individual beads are thus readily identifiable by PCR.
2.3 Biological libraries
As outlined in the introduction, biological libraries can be divided into two classes: in
vivo and in vitro libraries.  In vivo libraries are subject to selection pressure pertaining
to the particular host.  For example the phage display of particular peptides and
proteins in a library is dependent upon efficient phage coat assembly.  Displayed
proteins may be toxic to filamentous phage assembly or incompatible with bacterial
secretion pathways.  In vivo libraries are free of these selection pressures and have the
capacity for subsequent chemical or biochemical modifications of the peptides.
2.3.1 In vivo libraries
Phage Display Libraries
Phage display libraries have been used to display short peptide libraries and a variety
of small proteins (Clackson and Wells 1994; Smith and Petrenko 1997).  The most
ubiquitous of these small proteins are antibody-related species such as the single-
chain Fv (scFv) and Fab fragments.  Random peptide libraries are akin to the work of
Geysen  who used solid phase peptide synthesis techniques to probe the structure of
epitopes (Geysen, et al. 1987).  Phage display has a number of advantages over the
synthetic strategies:  (i)  Much larger library size achievable; (ii)  Choice of
monovalent or polyvalent display; (iii) Phage display enables selection instead of
screening.
The relatively small number of nucleotides used to code for a short peptide mean that
it is practical to chemically synthesize a single-stranded degenerate oligonucleotide
insert, from which a clonable double-stranded DNA insert can be assembled.  A
number of different methods have been utilised to produce clonable library inserts
from chemically synthesized single-stranded DNA (Cwirla, et al. 1990; Devlin, et al.
1990; Scott and Smith 1990; Christian, et al. 1992; Kay, et al. 1993; Sparks, et al.
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1996).  Digestion of the restriction enzyme recognition sequences within the constant
regions of the degenerate insert enable the cloning of the random DNA library into the
display vector.
Encoding a degenerate library using NNN (where N is an equimolar representation of
all four bases) produces all 64 possible codons – including 3 stop codons.  The
presence of the 3 stop codons reduces the effective size of the library.  This is
circumvented by synthesizing a degenerate insert using a NN(G/T) or NN(G/C)
scheme.  32 codons are used to encode all 20 amino acids, but only one stop codon –
the frequency with which this stop codon appears in the library is only a problem
when very large peptides (>50 amino acids) are encoded for (see figure 4.2 – chapter
4).  Degenerate inserts can also be synthesized from mixtures of trinucleotide codons
representing all 20 amino acids, and containing no stop codons.  But the construction
of this library requires more complex manipulation of the nucleotides than the
NN(G/T), NN(G/C) strategy.
Genomic libraries have been constructed using total chromosomal DNA, potentially
all of an organism’s genetic complement is represented among the displayed peptides.
In cDNA libraries the inserts are DNA copies of messenger RNAs (mRNAs)
extracted from some tissue or cell population.  All or parts of specific protein domains
can be displayed, positions in the domain can be randomised in some way to create a
library of sequence variants to enable the selection of rare clones with enhanced
function.
Several different viral systems have been used to display peptides, each with their
own display advantages: -
Lysogenic filamentous phage (Smith and Petrenko 1997) remains the most commonly
used phage display system, with commonly used phage strains including M13, fd, and
f1 vectors. Synthetic oligonucleotide libraries can be cloned as fusions to genes III or
VIII of M13 bacteriophage (Rodi and Makowski 1999).  Random peptide libraries
fused to pIII or pVIII have been used to identify immunodominant peptide sequences
of antigens, to generate peptide competitors of antigen-antibody interactions, to map
accessible and/or functional sites of numerous antigens, and to identify peptide
ligands for a variety of receptors (Kay,  1996).
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T7 bacteriophage is a lytic phage display system.  T7 is a double-stranded DNA
phage.  Phage assembly takes place inside the host E.coli cell and mature phage are
released by cell lysis.  Unlike the filamentous systems, peptides or proteins displayed
on the surface of T7 do not need to be capable of sectretion through the cell
membrane, a necessary step in filamentous phage assembly.  Small peptides (up to
~50 amino acids) can be polyvalently displayed (415 copies) on the T7 capsid 10B
protein.  Larger proteins can be displayed at a lower copy number (0.1-1 per phage)
on the capsid, including E. coli β-galactosidase (1015 aa) (Rosenberg, et al. 1996).
Lytic lambda phage has been used to express the entire β-galactosidase at the C
terminus of protein V with full enzymatic activity (Maruyama, et al. 1994).
T4 bacteriophage  has also been used as a surface display vector (Efimov, et al. 1995).
Phage display libraries are typically limited by transfection efficiency to less than 109
independent members (Roberts and Szostak 1997).  The upper  limit on library size
(around 109) is set by the transformation efficiency of E.coli and by the volume of
cells that can be handled. Libraries of 107 –108 are typical (Clackson and Wells 1994).
2.3.1.1 Cell based display
Cell based display can be divided into two sections – intracellular selection systems
and extracellular display systems.
2.3.1.1.1 Extracellular display
Antibody and peptide libraries have been displayed on the surface of a number of cell
types including yeast and E. coli.  These cell display technologies allow the display of
thousands of each polypeptide clone on the surface of each cell.  (Compare this with
pIII fusions in phage that display one to five copies, and the 10B fusions in T7 phage
(Rosenberg, et al. 1996) that can display a maximum of 415 peptide clones).
Screening of antibodies and peptides displayed on the cell surface by flow cytometry
allows finer affinity discrimination compared with the panning of phage on
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immobilised antigen (Boder and Wittrup 1997)  Examples of extracellular display
include the display of random peptide libraries on the pili (Rondot, et al. 1998) and
flagellin (Lu, et al. 1995) of E. coli, by fusing random nucleotide libraries to the
respective genes (F-pilin and flagellin).  The display of peptides on the flagellin of E.
coli was used to successfully map three different epitopes (Lu, et al. 1995).
As with phage display, affinity maturation of antibodies by E. coli display is limited
by potential library bias due to expression of members in a prokaryotic host poorly
adapted for post-translational processing of mammalian proteins.  A C-terminal fusion
of a randomly mutated scFv library, to the Aga2p mating adhesion receptor of the
yeast Saccharomyces cerevisiae has been used for the selection of scFv antibody
fragments with threefold antigen dissociation rate (Boder and Wittrup 1997).
2.3.1.1.2 Intracellular display – The yeast two-hybrid system
Intracellular display systems express both the combinatorial library and protein target
inside living cells.  The advantage of these systems is that the proteins are expressed
and selected in an intracellular environment, ensuring the function of the selected
protein is retained when expressed in that particular cell type.
Fields and Song (Fields and Song 1989) utilised the modular structure of eukaryotic
transcription factors to show that transcription of a yeast reporter gene could be used
to detect the interaction between two proteins.  One protein was fused to a DNA-
binding domain, the other to an activation domain. They proposed that libraries (Prey)
fused to an activation domain (encoded by a vector producing activation domain-Prey
fusions) could be screened for members that interact with a given protein (Bait) fused
to a DNA-binding domain.  When the activation domain and DNA-binding domain
are in the same vicinity of one another the transcription factor becomes active, and a
reporter gene (e.g. E. coli lacZ) downstream of the DNA binding site (recognised by
the DNA –binding moiety of the bait) is activated.  The Prey-plasmid insert is isolated
from cells that exhibit an interaction phenotype, enabling sequencing and
identification of the interacting protein.  More advanced techniques based on this
technology have been reviewed (Colas and Brent 1998).
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2.3.1.2 Peptide-on-Plasmid
The link between peptide and genetic material is achieved through the use of DNA
binding proteins.  One such example is the use of the LacI DNA binding protein.
Peptides are fused to the C-terminus of the lac repressor LacI by cloning degenerate
oligonucleotides at the 3’ end of the repressor gene (lacI) present on a plasmid.  The
DNA binding activity of the repressor protein physically links the peptides to the
plasmid encoding them by binding to the lac repressor binding sites on the plasmid.
These peptide-Lac-I-plasmid complexes are screened in a manner analogous to the
phage systems, allowing the enrichment of specific peptide ligands from a random
population.  After lysis of cells containing the random library, those plasmid-
repressor-peptide complexes that specifically bind to an immobilised receptor are
enriched by affinity purification.  Transformation of E coli with recovered plasmids
allows additional rounds of panning or sequencing of isolated clones. Using this
technique, a monoclonal antibody was screened and peptides displaying consensus
sequences similar to a segment in the antigen (to which the antibodies were raised)
were identified (Cull, et al. 1992).
2.3.1.3 Barcode systems
A number of systems are described in the literature which involve the use of unique
“barcode” tags to label the members of a library.  These include a commercially
available system (BIODISPLAYTM, Biovation, England) (Fox, 2000) which utilises
an expression vector incorporating a 20mer 3’ peptide barcode.  A library of Fab
genes are cloned into the vector and expressed as a soluble peptide-Fab fusion.  The
20mer peptide barcode is unique to each particular Fab clone in the library.   Fab
fragments are selected for their ability to bind to antigen.  Non-binders are then
washed away.  The peptide barcode is then released by protease digestion of a
protease cleavage site linking the Fab fragment to the 20mer barcode peptide.  The
barcode is then sequenced by tandem mass spectroscopy enabling the design of
primers which can be used to directly isolate the Fab genes.  Other systems include
multicolour optical coding based on wavelength and intensity multiplexing
(Quantum-dots) (Han, et al. 2000); and a method based on the tuneable optical
properties of porous silicon nanoparticles to dramatically increase the number of
colour codes available compared to quantum-dots (Cunin,  et al. 2002).
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2.3.1.4 Periplasmic expression with cytometric screening (PECS)
This technique utilises the bacterial cell envelope to selectively retain receptor-
fluorescent probe complexes but not free ligand.  E. coli cells expressing a library of
receptors secreted into the periplasmic space are incubated with a fluorescent
conjugate to the target ligand.  Flow cytometry is then used to isolate cells exhibiting
increased fluorescence.  The cell envelope is effectively being used as a dialysis bag
to retain the protein-ligand complexes.  PECS has been used to isolate high affinity
scFv molecules to digoxigenin (Chen, et al. 2001).  PECS can be used to screen
existing libraries constructed for display on bacteriophage without the need for
subcloning.
2.3.2 In vitro libraries
As outlined in the introduction in vitro libraries are immune from the major biological
constraints found in in vivo libraries.  This results in the opportunity to interrogate
much larger areas of sequence space, potentially enabling the isolation of much higher
affinity ligands (a proposed direct correlation exists between library size and binding
affinities of isolated ligands for a particular target (Pearlson and Oster 1979)).  The
lack of transformation or infection steps when using in vitro selection systems enables
automation of the procedures, allowing ligand discovery to be conducted on the
genomics scale.
2.3.2.1 Ribosome display
The construction of large libraries in the previously described biological systems is
limited by the initial transformation following the assembly and ligation of the library
into the host vector.  In ribosome display a mRNA-ribosome-protein complex creates
a link between the genotype and phenotype in vitro, completely circumventing the
problems of transformation efficiency associated with in vivo methodologies.  All
steps of ribosome display are carried out completely in vitro, allowing the reaction
conditions of individual steps to be tailored to the requirements of the protein species
investigated (but under conditions that preserve the integrity of the ribosome-mRNA-
peptide ternary complex).  A comprehensive review of  ribosome display as a method
for totally in vitro protein selection has been conducted (Roberts 1999).  Examples of
the use of ribosome display for the selection and evolution of antibodies in vitro have
been published (Hanes, et al. 1998; Makeyev, et al. 1999; Schaffitzel, et al. 1999)
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2.3.2.2 RNA-peptide fusions
The next development from ribosome display is the use of RNA-peptide fusions.
These systems have the advantage of being more robust than the ribosomal display
systems.  The peptide becomes directly attached to the mRNA that encodes it by a
stable covalent linkage.  The peptide-mRNA fusion can then be enriched from a
complex mixture of peptide-mRNA fusions.  In vitro translation of synthetic mRNAs
that carry puromycin (a peptidyl receptor) at their 3’ end creates a covalent fusion
between a mRNA and the peptide or protein that it encodes.  This system has been
used to enrich a myc epitope peptide from a pool of random sequence mRNA-peptide
fusions (Roberts and Szostak 1997).
2.3.2.3 Covalent Display Technology (CDT)
CDT is a proprietary in vitro library platform (Actinova Ltd., Cambridge UK; David
Andrews and Yun Li, McMaster University, Hamilton, Canada) which exploits the
properties of a replication initiator protein (P2A) from the E. coli bacteriophage P2.
P2a is a DNA-binding protein that attaches covalently to its own coding sequence
(Fitzgerald 2000).  Concurrent in vitro transcription and translation of gene fusions
comprising the coding sequence for P2A and the coding sequences for potential
target-binding proteins (containing “random” sequences) results in the formation of
covalently linked DNA-protein complexes.  This library can then be interrogated and
those members of the library which bind to a particular ligand by affinity selection.
Specifically binding complexes can then be propagated by amplification using the
polymerase chain reaction (PCR) for subsequent rounds of selection or cloning into a
bacterial host for example.
2.3.2.4 Man-made cell-like compartments for molecular evolution
A different approach to linking genotype to phenotype has been demonstrated using
aqueous compartments of water-in-oil emulsions (Tawfik and Griffiths 1998).  Here a
substrate was attached to a random library of genes, and dispersed into the water-in-
oil emulsion such that only single genes occupied each aqueous compartment.  Genes
that encode for catalysts converted the substrate attached to the gene that encoded it to
product, all other compartments that did not contain catalysts remain unmodified.
Those compartments containing functioning catalysts can then be isolated (using
Fluorescence Activated Cell Sorting (FACS) for example).  The coding information
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contained in the cell can then be isolated by PCR and used in subsequent rounds of
selection or expression of functional enzyme.
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Fig.  2.1: Library technologies, illustrating the division between totally synthetic
compounds (generated using combinatorial chemistry techniques), and those based on
biological compounds.  Differences between display-less and display systems are
shown.
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2.4 Other non-peptide ligands
2.4.1 Synthetic Libraries
2.4.1.1 Non-peptide chemical libraries
The principal advantage of solid phase techniques over the other biologically based
combinatorial approaches, is the opportunity to greatly vary the chemistry involved
within the library.  Biological systems are restricted to the 20 naturally occurring
amino acids, or 4 nucleotide bases (see section 2.5.2.1), however with chemical
libraries other elements can be introduced that increase the structural diversity of the
library.  These include peptoids (Simon and al 1992) vinylogous polypeptides
(Hagihara, et al. 1992) unnatural D-amino acids and other templates to induce
secondary structural motifs (Farlie, et al. 1998).  Cyclic peptide libraries not limited to
disulphide constraints can also be synthesized (Zuckerman 1993).
2.4.2 Biological Libraries
2.4.2.1 Nucleotide Libraries
The ability of different nucleic acid sequences to fold into distinct three-dimensional
shapes, which are chemically complementary to the surface of a particular target
molecule, has lead to the use of nucleotide libraries as sources of receptor binding
ligands (Bacher and Ellington 1998). The SELEX (the systematic evolution of
ligands by exponential enrichment) process allows the rapid isolation of rare
oligonucleotide sequences from large random single-stranded sequence libraries.
The initially chemically synthesized library can be amplified using PCR; binding
species are selectively eluted from the receptor, these binding species can then be
amplified by PCR.  The process of selecting for binding sequences is then repeated.
An enrichment process takes place similar to that observed in the other biological
systems.  This technique has been applied to the affinity purification of a human L-
selectin-Ig fusion protein from Chinese hamster ovary cell-conditioned medium by
using a DNA-aptamer discovered using the SELEX process (Romig, et al. 1999).
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The initial random sequence pool which is typically generated by chemical DNA
synthesis contains a core of randomised nucleotides flanked by constant regions,
which are required for enzymatic amplification (these constant regions may include
specific restriction sites that aid cloning of selected species as well as promoter
sequences to enable in vitro transcription of RNA.  Unnatural nucleotides can also be
included in the DNA or RNA polymerisation reaction to generate different
chemistries.
2.5 Mutagenesis
Why conduct mutagenesis of proteins?
As outlined in the introductory section of this chapter, the application of
combinatorial selection approaches enable the simultaneous mutation of multiple
residues in a protein to produce “non-additive” changes that could not have been
predicted a priori.  It has been demonstrated that combinatorial approaches can be
used to select binding antibodies from  naïve immunoglobulin libraries (Gram, et al.
1992).  Combinatorial approaches can also be applied to existing proteins in order to
select for particular attributes, or analyse function.
There are three different approaches for the molecular evolution of a protein involving
mutagenesis:
(i)  Point mutations
These types of mutations can be divided into two classes: site directed mutations and
random mutations.  Specific residues within a protein may be selected for directed
mutation, based on an analysis of the crystal structure of the protein binding to a
ligand.  Residues can be selected that are in the binding site.  Using site directed
mutagenesis, the contribution to binding made by cavities, salt links, van der Waals
contacts and hydrogen bonds can be analysed.  One example of such an approach was
given by (Dougan, et al. 1998).  Here 14 amino acid residue replacements were made
at six contact residues in a scFv fragment by site-directed mutagenesis.  From a
kinetic analysis of the interactions between the antigen and the mutants, the role of
hydrophobic (van der Waals contacts), hydrogen bonds, salt links and the importance
of cavity bound water molecules in the binding of the scFv fragment to the antigen
were determined.
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Another approach to improving antibody affinity is the point mutation of residues
throughout the CDR regions of an antibody.  One such technique is termed CDR
walking mutagenesis.  This involves the systematic mutagenesis of individual
residues in the CDR regions of antibodies and selection for fitness with monovalent
phage display.  One example of the application of CDR walking mutagenesis is the
optimisation of the affinity of a human antibody to the human envelope glycoprotein
gp120 of human immunodeficiency virus type 1 (HIV-1) (Yang, et al. 1995).
Another example introduced random mutations into specific “hot-spots” within the
variable regions of an antibody.  These “hot-spots” were identified as being prone to
hypermutations, random mutations were introduced into a few of these hot spots to
produce libraries.  Panning of these libraries yielded mutants with up to a 55-fold
increase in affinity compared a 4-fold increase observed from a library constructed in
which mutagenesis was done outside the hotspots (Chowdhury and Pastan 1999).
(ii)  Random mutagenesis
Random mutagenesis utilising error-prone PCR (Cadwell and Joyce 1994) has been
used to select phage antibodies by binding affinity (Hawkins, et al. 1992).  Error-
prone PCR was used to introduce mutations into antibody genes in vitro, and affinity
selection using biotinylated hapten  (4-hydroxy-5-iodo-3-nitrophenacetyl-(NIP)-
caproic acid) was used to select for mutants with improved affinity.  A mutant was
isolated with a four-fold increase in affinity to the hapten (Kd =9.4 ( + 0.3) nM).
A quantitative analysis of the effect of mutation frequency on the affinity maturation
of scFv antibodies has been conducted on a high affinity scFv antibody that binds to
cardiac glycoside digoxigenin (Daughterty, et al. 1999).  Error prone PCR was used to
generate libraries of mutants displayed on E. coli.  Three libraries were constructed
with; (i) a low error rate (m) of 1.7 base substitutions per gene; (ii) a moderate error
rate m=3.8; and (iii) a high error rate m=22.5.  The moderate and high error rate
libraries were found to give rise to clones exhibiting the greatest affinity
improvement.  The majority of scFv mutations leading to higher affinity clones
corresponded to residues distant from the binding site.  The mutations distant from the
binding site could not have been predicted from molecular modelling studies.  This
highlights the advantages of using such “irrational” techniques over  “rational”
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techniques based on crystal structures of binding sites and molecular modelling
studies alone.
An example of the use of random mutagenesis to select for improved stability was
published by (Sieber, et al. 1998).  A repertoire of variants was displayed between the
N2 and CT domains of the gene-3-protein of the fd phage.  The infectivity of the
phage is lost when the two domains are disconnected by the proteolytic cleavage of
unstable protein inserts.  Using this method proteins were selected from a library of
variants with improved stability.
(iii) DNA Shuffling
A segment of DNA is amplified by PCR and purified free of primers.  The amplified
segment is then cleaved into small, random fragments with DnaseI and size selected.
The fragments are denatured, annealed and extended with DNA polymerase in the
absence of any primers.  After several cycles the restored fragment is amplified by
PCR.  The fragment is then digested with restriction enzymes outside the area targeted
for mutagenesis, to generate a cassette for cloning.  The process of reassembling can
be mutagenic in the absence of a proof-reading polymerase.  A combination of
directed and random mutagenesis (DNA shuffling) has been used to construct
libraries of mutants from which scFv’s can be selected with improved stability.  A
library of scFv fragments was generated and phage display selection was carried out
under selective pressures for higher thermodynamic stability.  Stable mutants were
isolated which exhibited increased thermodynamic stability, increased expression
levels and a 20-fold better binding constant than the wild-type scFv (Jung, et al.
1999).
(iv) Cassette Mutagenesis
Cassette mutagenesis can be used to introduce mutations at particular site(s) within a
coding region.  A “cassette” of double stranded DNA containing the required
mutation(s) is produced and cloned into the region of interest by conducting a
restriction digest followed by a ligation reaction.  Several methods are available to
generate the cassette, utilising either oligonucleotides as the method for introducing
mutations, or error-prone PCR (1996).
Chapter 2 Regulation of peptide antibody interactions.
55
(v) Random Elongation Mutagenesis
This technique exploits the stabilising capacity in certain proteins, of terminal arms of
amino acids that fold across a susceptible part of the structure, stabilising it under
unfavourable conditions such as high temperature.  A partially randomised
oligonucleotide is inserted ahead of the stop codon in an expression vector in order to
introduce short chains – 16 amino acids in length – onto the carboxyl terminus of a
protein (Scopes 1999).
(vi) Bacterial mutator strains
Another method, which can be employed in the evolution of proteins, is the use of
bacterial mutator strains.  These bacteria introduce random mutations into a particular
plasmid.  The disadvantage with such systems is that the library size is reduced by
mutations that take place outside the cloning region, in restriction sites, and promoters
for example.  (Low, et al. 1996).
2.6 Aims and Objectives of the research
Epitope / mimotope affinity chromatography was demonstrated to be the method of
choice in chapter one for the purification and concentration of monoclonal antibodies
and engineered antibody fragments to a standardised and high immunoreactivity in a
single step, from biological feed stocks.  Use of this procedure necessitates the
discovery of Paratope-specific binding ligands.  A review of the different
combinatorial approaches available has lead to the conclusion that a polyvalent, lytic
phage display system offers the most efficient way of searching sequence space for
ligands that interact with the antibody in a similar orientation to ligands immobilised
on a chromatographic matrix.  The T7 phage display system was investigated for its
ability to discover high affinity peptide ligands which are capable of functioning as
paratope-specific peptide-mimotope affinity ligands.
The process of discovery and refinement of paratope specific binding ligands, such as
peptide mimotopes, leads to the generation of peptide ligands exhibiting tuneable
affinities for antibodies and their derivatives.  Whilst the higher affinity mimotopes
may well find use as paratope-specific ligands for application in the affinity
purification of antibodies, the range of affinities that can be achieved using these
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peptide mimotopes may also find application in biosensors.  An investigation into the
use of solid phase peptide synthesis techniques to further refine lead peptide
sequences derived from phage display was conducted.  The use of mimotope peptides
(derived from this process) for the detection of non-protein analytes was also
investigated.  The aim was to determine whether such mimotopes could be employed
in assays for non-protein analytes.
Manipulation of the ligand offers one method for increasing the affinity of the
antigen-antibody interaction.  Whilst this is useful for the purification of target
antibodies, the use of antibody-related molecules for in vivo diagnostic purposes
requires the optimisation of the binding properties of the antibody-related molecule.
The use of molecular biology techniques enables the construction of novel gene-
fusions, which can be expressed as bi-functional proteins.  The aim of the final part of
research presented in this thesis was to construct a scFv-GFP gene fusion consisting
of a library of randomly mutated scFv genes fused to green fluorescent protein.  The
aim was to screen the library using FACS to obtain scFv clones exhibiting a higher
affinity for the target antigen expressed on tumour cell lines.
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3 Chapter 3 Materials and Methods.
3.1 Reagents
Clontech Laboratories, Inc., Palo Alto, CA, USA
Anhydrotetracycline
Pierce, Rockford, Illinois, USA.
Succinimide ester of biotin.
Difco Labs. Ltd. , west Molesey, U.K.
Bacto agar
Bacto tryptone
Bacto yeast extract
BDH Biochemical reagents, Poole, U.K.
Glycerol
Hydrochloric acid
Sigma-Aldrich Company Ltd., Gillingham, Dorset, U.K.
Ampicillin
Boric acid
Bovine Serum Albumin
Casein
Citric acid
Deoxynucleotide 5’ –triphosphates (dNTPs)
N-ethyl-N’-(3-dimethyl-amino propyl)-carbodiimide hydrochloride (EDC)
Ethanol
Ethanolamine
Ethidium Bromide
Ethylenediaminetetraacetic acid (EDTA)
Extravidin-Peroxidase
Glacial acetic acid
Glutaraldehyde
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Glucose
Hydrogen peroxide
Isopropanol
Magnesium Chloride
Mercaptoethanol
Mineral oil, light
N-hydroxysuccinimide (NHS)
Nalidixic acid
Phenol : chloroform : isoamyl alcohol
Polyoxethylene-sorbitan monolaurate (Tween 20)
Sodium azide
Sodium chloride
Sodium dodecyl sulphate (SDS)
Trichloroacetic acid (TCA)
Tris-(hydroxymethyl)-aminomethane (Trizma base)
BSAU - Queens Medical Centre, Nottingham, U.K
Peptides APDTRPAPG, APDTRPAPGC, APDTREAPG, RNREPARGKICS,
KSKAGVC, GLFED, GLFYD, (D) DYFLG were synthesised by the Biopolymer
Synthesis and Analysis Unit (BSAU) (Queens Medical Centre, Nottingham, U.K.).
The purity of the peptides was established to be >97% by reverse phase high
performance liquid chromatography and mass spectroscopy.
Flowgen Instruments Ltd., Sittingbourne, U.K.
Low melt NuSieve agarose
High melt agarose
BIACORE AB, Uppsala, Sweden.
Pioneer Sensor Chip F1
Sensor Chip CM5 (research grade)
HBS-EP buffer
Surfactant P20
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Promega Corporation, Madison, WI, USA.
Wizard Plus SV Minipreps DNA Purification System
Invitrogen BV, Groningen, The Netherlands.
TOPO TA cloning kit
Chemically competent E. coli TOP10 cells
Amersham Pharmacia Biotech U.K. Ltd., Little Chalfont, Bucks., U.K.
CNBr-activated Sepharose 4B
PD10 column (containing Sephadex G-25 M)
Anti-E Tag Antibody
pCANTAB 5 E phagemid vector
3.2 Enzymes
Advanced Biotechnologies, Epsom, Surrey, U.K.
Taq DNA polymerase (isolated from Thermus aquaticus, 5 Units/µl).
New England Biolabs (U.K.) Ltd., Hitchin, Herts., U.K.
Bgl II (10,000 U/ml)
Hind III (10,000 U/ml)
Sfi I (20,000 U/ml)
Not I (10,000 U/ml)
T4 DNA ligase (400,000 units/ml)
USB Corp., Cleveland, Ohio, USA.
Shrimp alkaline phosphatase (1.0 U/µl).  [One unit of enzyme catalyses the hydrolysis
of one µmole of p-nitrophenyl phosphate per minute at pH 10.7 (glycine/NaOH
buffer) and 370C.
Sigma biochemicals
Exonuclease I
Extravidin-Horseradish peroxidase
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3.3 Buffers and Solutions
All buffers were prepared with de-ionised double distilled water.  Buffers used for
FPLC, fluorescence quenching, circular dichroism or biosensor analysis were sterile
filtered and degassed prior to use.
Phosphate buffered saline (PBS) –pH7.3
PBS was prepared by dissolving 1 PBS tablet (Oxoid, Basingstoke, Hants, U.K.) in
100 ml of water.
Tris Buffered saline (TBS) – pH 7.5
TBS was prepared by dissolving Tris HCl (7.9g, pH 7.5) and sodium chloride (8.8g)
in water 1 litre of water.
Tris-Borate-EDTA (TBE) buffer (10x stock)
Was obtained as 10x concentrate from sigma-aldrich.  Consisted of 0.89M Tris
Borate, pH 8.3 conatining 0.02 M EDTA
PBSA – pH 7.3
Sodium azide (NaN3) was added to PBS buffer to a final concentration of 0.05 %
(w/v).
PBS/Tween – pH 7.3
PBS/Tween was prepared by adding Tween 20 to PBS to give a final concentration of
0.1% (v/v).
PBS + 0.1% Casein – pH 7.3
The PBS + 0.1% casein solution was prepared by dissolving 100 mg of casein in
100ml PBS solution.
TBS + 0.1% Casein – pH 7.5
The TBS + 0.1% casein solution was prepared by dissolving 100 mg of casein in
100ml TBS solution.
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PBS + 1% Bovine Serum Albumin – pH 7.3
The PBS + 1% bovine serum albumin (BSA) solution was prepared by dissolving 1g
BSA in 100ml PBS.
HBS-EP buffer
The buffer was purchased from BIACORE (Uppsala, Sweden).
N- [2-Hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] (HEPES) (0.1M, pH 7.4),
sodium chloride (0.15M), Ethylenediaminetetraacetic acid (EDTA) (3mM) and
Surfactant P20 (0.005% v/v).
Disruption Buffer
Sodium dodecyl sulphate (0.1% w/v) was dissolved in sodium dihydrogen
orthophosphate buffer (0.1M, pH 7.2). β-mercaptoethanol (5ml) was added
immediately before use.
Citrate Phosphate Buffer – pH 4.0
Anhydrous disodium hydrogen phosphate (4.06g) and citric acid (4.53g) were
dissolved in 450ml water.  The pH of the solution self adjusted to pH 4.0
2-Azino-di- (3-ethyl benzthiazoline-6-sulphonic acid)-diammonium salt (ABTS)
Solution.
ABTS solution was prepared at a concentration of 0.05% (w/v) ABTS in citrate
phosphate buffer.  Shortly before use, hydrogen peroxide (~30% vol) was added to the
ABTS solution to produce a final concentration of 140µl per 100ml.
LB growth medium pH 7.5
LB growth medium was prepared by dissolving Bacto Tryptone (DIFCO) (10g),
Yeast extract (DIFCO) (5g) and sodium chloride (10g) in 1 litre of water.  The pH of
the solution was adjusted to 7.5 with 1N sodium hydroxide.  The LB growth medium
was autoclaved for 20 minutes prior to use.
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Sodium dodecyl sulphate solution (SDS) – 1 % w/v
1% w/v SDS solution was prepared by dissolving 1g of sodium dodecyl sulphate in
100ml water.
LB Agar Plates
LB Agar plates were prepared by dissolving 7.5g of agar in 500ml of LB growth
medium – pH 7.5.  The mixture was then autoclaved for 20 minutes, left to cool to
50oC and poured into 10cm petri dishes.  After the plates cooled they were stored at
4oC until used.
LB Top Agarose
LB Top Agarose was prepared by dissolving Bacto Tryptone (1g), Yeast extract
(0.5g), sodium chloride (0.5g) and agarose in 100ml of water.
Coupling Buffer – pH 8.3
Coupling buffer was prepared by dissolving NaHCO3 (8.4g) and NaCl (29.2g) in 1
litre of water, the pH was adjusted to 8.3.
Tris-HCl Buffer pH 8.0
Tris-HCl Buffer pH 8.0 was prepared by dissolving Tris-HCl (15.8g) and sodium
chloride (29.2g) in 1 litre of water and adjusting the pH to 8.0.
SOBAG (SB) Medium
Water (~900 ml) was added to Bacto-tryptone (20g), Bacto-yeast extract (5g) and
sodium chloride (0.5g) and the mixture autoclaved.  After the mixture had cooled to
50~60 oC, MgCl2 (1 M, 10 ml), ), sterile glucose (2 M, 55.6 ml) and sterile-filtered
ampicillin (20% w/v, 5.0 ml) were added
SOBAG – N Medium
SOBAG medium containing nalidixic acid.  SOBAG-N plates were made by adding
bacto-agar (15g) before autoclaving.
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SOBAG-AG (SB-AG) Medium
SB medium containing 100µg/ml ampicillin and 2% glucose.
SOBAG-AI (SB-AI) Medium
SB medium containing 100µg/ml ampicillin and 1 mM IPTG.
20% Trichloroacetic acid (TCA) solution
First 100% trichloroacetic acid (TCA) was prepared by adding 227 ml of distilled
water to TCA (500 g). The TCA was allowed to completely dissolve.  TCA (200ml,
100%) was added to 800 ml of distilled water to make 1 litre of 20% TCA.
TES buffer
A solution containing Tris-HCl (0.2 M, pH 8.0), EDTA (0.5 mM) and sucrose (0.5 M)
was prepared and filter sterilised using a 0.2 µM filter (Sartori, Gottingen, Germany).
The solution was stored at 4oC.
Triethanolamine Buffered Saline
Sodium chloride (7.5g) and triethanolamine (2.8 ml) were added to water (800 ml).
The pH was adjusted to 7.5 with concentrated HCl, water was then added to a total
volume of 1 litre.
4-chloro-1-napthol (4-CN) substrate
A stock solution of 4-CN was prepared by dissolving 4-chloro-1-napthol (30 mg) in
methanol (10 ml).
Substrate was prepared for use by adding 4-CN stock solution (4.0 ml) and hydrogen
peroxide (30%, 10=µl) to triethanolamine buffered saline and mixing well.
Acetate Buffer pH 4.0
Acetate Buffer was prepared by dissolving sodium acetate (8.2g) and sodium chloride
(29.2g) in 1 litre of water and adjusting the pH to 4.0.
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2x Bacteriophage T4 DNA ligase mixture
Tris HCl (pH 7.6, 1 M, 1.0 µl), MgCl2 (100 mM, 1.0 µl), dithiothreitol (200 mM, 1.0
µl), ATP (10 mM, 1.0 µl), dH2O (5.5 µl) and bacteriophage T4 DNA ligase (1 Weiss
unit) were mixed in a tube stored on an ice bath. (Sambrook, Fritsch et al. 1989)
10x mutagenic PCR buffer
10x mutagenic PCR buffer was prepared by dissolving magnesium chloride (70 mM)
and potassium chloride (500 mM) in Tris buffer (100 mM, pH 8.3).  Gelatin was
added at 0.1% w/v.
10x mutagenic dNTP mix
The 10x mutagenic dNTP mix was prepared by diluting dGTP (2 mM), dATP (2
mM), dCTP (10 mM) and TTP (10mM) in water.
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3.4 Methods
3.4.1 Monoclonal Antibody Production
The murine anti-MUC1 monoclonal antibody C595 (IgG3 subclass) was originally
prepared by conventional hybridoma technology using spleen cells from a BALB/c
mouse immunised against purified urinary MUC1 mucin (Price, et al. 1990).
Hybridoma supernatant was clarified by ultracentrifugation (40,000g, 30 min) and
ultrafiltration through a 0.2µm filter (Sartorius, Gottingen, Germany).  The antibody
was stored at 4oC with sodium azide (0.05% w/v) as a preservative.
3.4.2 Biopanning of phage library
The T7Select415-1b vector containing a degenerate oligonucleotide insert was kindly
donated by Dr. P. Tighe (Division of molecular and clinical immunology, The
University of Nottingham, UK).  The oligonucleotide insert was synthesized,
containing EcoRI and HindIII restriction sites to enable insertion into the cloning
region of the T7Select415-1b vector. Measurements of phage titer were carried out
using a plaque assay. E.coli strain BL21 were grown to mid-log phase, and aliquots
inoculated with phage preparations serially diluted in LB media.  These were then
mixed with top agar and poured onto LB plates.  The plates were then incubated at
37oC for 3h.  The number of phage plaques was then counted and the initial phage
titer determined.
The phage library was screened against antibody passively adsorbed onto Maxisorb
immunotubes (75x12 mm; NUNC).  The library was first screened against an
“irrelevant” antibody that would not be expected to bind specifically to MUC1
epitopes.  Anti-Estrone beta-D-glucuronide antibody (Badley, et al. 1999) was used
for this purpose.  The antibody (2.5ml @ 10µg/ml in TBS buffer (50mM Tris HCl pH
7.5, 150mM NaCl) was passively adsorbed onto Maxisorp immunotubes by
incubation at room temperature for 4h.  Unbound target protein was removed by
washing the tubes three times with TBS buffer.  The tubes were then incubated for 1h
at room temperature with 2.5ml of blocking solution (1% w/v casein in TBS).  The
tube was then washed five times with deionised water and once with TBS buffer.
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The phage library (2.5ml phage lysate) was incubated in the immunotube (with anti-
estrone beta-D-glucuronide antibody adsorbed) for 30 minutes at room temperature.
The phage lysate in the tube was then gently agitated and transferred to an
immunotube with C595 antibody adsorbed (10µg/ml) and incubated at room
temperature for 30 minutes.  The phage lysate was then decanted from the
immunotube and the tube was washed five times with TBS buffer containing 0.05%
Tween20.  A one-minute incubation was used for each wash.  Excess buffer was
removed by blotting on a paper towel.  Bound phage were eluted using a 20 minute
incubation with sodium dodecyl sulphate (SDS, 1% (w/v), 2.5ml), and transferred to a
sterile glass tube.  An aliquot of the eluted phage solution (250µl) was then added to
50 ml of E. coli BL21 grown to mid-log growth phase (OD600 ~ 0.5 AU) and
incubated in a 250ml baffled flask with shaking at 37oC until lysis of the culture was
observed.  The phage lysate was then purified from the cell debris by centrifugation at
8,000g for 10 minutes.  The supernatant was transferred to a sterile glass tube.  The
phage titer of the eluted phage was determined using a plaque assay as described
above.  The amplified phage were used in the next round of biopanning.  The phage
titer of the eluted phage (prior to amplification) was monitored after each round of
biopanning using the plaque assay.
3.4.3 PCR analysis of individual phage clones
Two primers (R1FOR  5’GCT AAG GAC AAC GTT ATC GGC CTG TTC ATG C3’
and R2REV  5’CGT TGA TAC CGG AGG TTC ACC GAT AGA CGC C3’) were
designed to allow PCR amplification of the region surrounding the degenerate
oligonucleotide insert.  A third primer was designed to anneal inside this PCR
amplification product  (SEQFOR 5’GGT ACT GTT AAG CTG CGT GAC TTG GC3’)
to enable direct sequencing of the PCR product (see fig. 4.1 – Chapter 4).  A scrape
from an individual phage plaque was dispersed in 100µl of 10mM EDTA, pH 8.0.
The tube was briefly vortexed and heated at 65oC for ten minutes.  The mixture was
cooled to room temperature and clarified by centrifugation at 14,000 g for 3 minutes.
PCR reactions were performed in 50µl aliquots, each reaction was set up as follows: -
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10 x Buffer 5=µl
10 mM dNTP’s 1 µl
25 mM MgCl2 3 µl
Primers (25 pmol each) 2 µl
Phage DNA Template 1 µl
dH2O 37 µl
49 µl
Light mineral was added to the top of the reaction to prevent evaporation of reagents
during the cycling reaction.  The reaction was conducted on an OmniGene Thermal
Cycler Controller (Hybaid, Teddington, UK); and consisted first of a “hot-start” by
heating the tube for 5 minutes prior to the introduction of 1µl Taq DNA polymerase
(ABGene); 35 cycles of 94oC for 50s, 50oC for 60s, 72oC for 60s; and a final
extension at 72oC for 6 minutes.  Agarose gel electrophoresis was used to analyse the
PCR products to ascertain that only a single PCR product of the expected size was
present before sequencing.  Agarose gels (1%) were prepared by dissolving NuSieve
agarose (Flowgen, Sittingbourne, UK) in TBE buffer (0.09 M Tris-borate, 0.02 M
EDTA).  Ethidium bromide (0.2µg ml-1) was incorporated into the gel before pouring.
Samples were diluted with DNA loading buffer (sigma biochemicals).  After
electrophoresis, DNA was visualised using a Spectroline TM-312A Ultra Violet
Transilluminator, and photographs were recorded using a Polaroid DS-34 Direct
Screen Instant Camera.
Primer notation
Primers denoted FOR in this thesis refer to primers that bind to the 3’-5’ antisense
strand.  Primers denoted REV in this thesis refer to primers that bind to the 3’-5’
sense strand.
3.4.4 Direct sequencing of PCR products
Exonuclease I (Exo I) (Sigma Biochemicals) was used to degrade excess single-
stranded DNA (Phage DNA and excess primers); and Shrimp Alkaline Phosphatase
(SAP) (Sigma Biochemicals) was used to cleave 5’ phosphate groups from excess
single stranded DNA preventing the incorporation of primers/degraded fragments and
phage DNA into the sequencing reaction.  Exo I (5U) and SAP (1U) were added to
5µl of PCR product, heated at 37oC for 15 minutes and then heated at 80oC for 15
minutes. Sequencing reactions were conducted (ABI PRISM Big-Dye Terminator
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Cycle Sequencing reaction) in 10µl aliquots using 0.1µM SEQFOR primer, 5µl of Big
Dye sequencing buffer (Tris-HCl (80mM, pH9.0) and MgCl2 (2mM)), 2.5µl of
enzyme treated PCR product and 2µl Big Dye mix; on an OmniGene Thermal Cycler
Controller (Hybaid, Teddington, UK).  Using a program consisting of 96oC for 90s;
25 cycles of 96oC for 30s, 50oC for 15s, 60oC for 240s; and a finally 28oC for 1
minute.  Prior to sequencing an ethanol precipitation step was conducted to remove
excess dye terminator in the reaction mix.
Ethanol precipitation.
Water (20 µl) was added to the completed sequencing reaction (10µl).  This mixture
was then added to a centrifuge tube containing sodium acetate (2µl, 3M, pH 5.0) and
95% ethanol (50µl).  The mixture was then vortexed and placed on ice for ten
minutes.  The tube was then placed in a bench-top centrifuge and spun at full speed
for ten minutes.  All liquid was then aspirated off, and the pellet washed with 70%
ethanol (250 µl).  The tube was again centrifuged at full speed for ten minutes.  All
liquid was aspirated off and the remaining pellet was allowed to dry in open air for a
few minutes.
Sequence analysis was performed on an ABI 373A DNA Sequencer (ABI).
3.4.5 Phage Capture ELISA
C595 antibody was adsorbed onto the wells of a microtitre plate (96 well NUNC) by
incubation at 37oC for 4 hours.  After blocking non-specific binding sites by
incubation with PBS + 0.1% casein, phage preparations were titrated by serial dilution
with 50µl added per well.  After incubation for 2 hours, the plates were washed four
times with PBS/Tween.  Antibody C595 was biotinylated using the succinimide ester
of biotin as outlined in (Sambrook, et al. 1989).  Biotinylated C595 antibody was
added at 50µl per well.  After 2 hours incubation, the plates were washed four times
with PBS/Tween and HRP-conjugated avidin (ExtrAvidin® - Sigma Biochemicals)
was added at 50µl per well.  Plates were incubated for 1 hour, washed four times with
PBS/Tween.  ABTS substrate  was added to the wells at 50µl per well.  Colour
development was measured using a Milenia Kinetic Analyser (Diagnostic Products
Corporation, Llanberis, UK).
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3.4.6 Sepharose Bead Assay
The peptide of interest was conjugated to beaded agarose (cyanogen-bromide
activated Sepharose 4B) at a concentration of 1 µmole peptide per ml gel using
conjugation procedures as recommended by the manufacturer.  A standard ELISA
procedure was conducted using approximately 50µl of the peptide coupled swollen
beads as follows: -
 In an eppendorf tube, the beads were first washed with PBS/Tween wash buffer.  The
beads were suspended in the wash buffer (1.0 ml) and gently agitated by inverting the
tube four times.  The tube was then placed in a centrifuge and briefly spun.  The
liquid was carefully aspirated from above the beads, and replaced with fresh wash
buffer.  This process was repeated four times.  After the final wash the liquid above
the beads was replaced with blocking buffer (PBS + 0.1% casein, 1.0 ml) to block
non-specific adsorption sites.  The tube was gently agitated on a roller for one hour at
room temperature.  The tube containing the bead suspension was briefly centrifuged.
The blocking solution was carefully aspirated from above the beads, and replaced
with the antibody solution at the appropriate dilution.  The beads were re-suspended
in solution by gentle agitation.  The tube was gently agitated on a roller for one hour
at room temperature.  The tube was then briefly centrifuged and washed with
PBS/Tween wash solution as described above.  The wash solution was aspirated from
above the centrifuged beads and replaced with marker antibody (rabbit anti-mouse
IgG peroxidase conjugate, 1.0 ml) at 1/1000 dilution in PBS.  The beads were
incubated with the marker antibody for one hour, with agitation on a roller at room
temperature.  The beads were then washed again in wash buffer as described above.
Finally ABTS solution was used to suspend the beads.  After colour development the
tube was spun in a centrifuge and the liquid dispensed into the wells of an ELISA
plate (NUNC) and the endpoint measured using a Milenia Kinetic Analyser
(Diagnostic Products corporations, Llanberis, UK).
3.4.7 Peptide Affinity Chromatography
Data acquisition and analysis was performed using FPLCdirector Software
(Pharmacia Biotech).
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3.4.7.1 Preparation of Immunoaffinity Matrices
Synthetic peptides were linked to beaded agarose (Sepharose 4B, Pharmacia) via their
N-termini using CNBr-activated matrix.  Peptides were coupled at a ratio of 1 µmole
peptide per ml gel using conjugation procedures as recommended by the
manufacturer.
3.4.7.2 FPLC
Chromatography columns (10mm internal diameter, Amersham Pharmacia Biotech)
were packed with 2 ml of each affinity matrix.  Chromatography was performed using
an automated FPLC system (Amersham Pharmacia Biotech).  Columns were first
equilibrated with 10 column volumes (20 ml) of PBS at a flow rate of 1.0 ml/min.
Loading of antibody solutions in PBS (100ml) was conducted at room temperature
(unless stated otherwise) at a flow rate of 1.0 ml/min.  Loading of clarified hybridoma
supernatant (100ml) was carried out at 4oC, with the supernatant circulating around
the column for 48 hour.  The columns were then washed with 10 column volumes (20
ml) of PBSA at 1.0 ml/min, or until the trace from the UV monitor returned to zero.
All elutions were conducted at room temperature.  The gradient elution consisted of a
linear gradient of NaSCN (Buffer B), in PBS (Buffer A) from 0 to 3M NaSCN over
20ml.  At the end of the gradient Buffer B was held for 5 ml before switching to
buffer A for a further 15 ml.  Samples containing NaSCN were detected using filter
paper previously soaked with copper sulphate solution (1% w/v) and dried.  Eluted
fractions were desalted using PD10 columns (Amersham Pharmacia Biotech)
containing Sephadex G25 matrix, according to the manufacturers instructions.  The
step gradient consisted of an immediate switch from buffer A to buffer B (33%) and
back to buffer A after 20 ml for a further 15 ml.  Eluted fractions were desalted using
PD10 columns containing Sephadex G25.
3.4.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
Affinity-purified C595 antibody was electrophoresed on a PhastSystem separation
and control unit (Pharmacia) in conjunction with PhastGel precast gels (homogeneous
acrylamide, 12.5 % w/v) using SDS buffer strips (Pharmacia).  Silver staining was
performed using the PhastGel silver-staining kit on the PhastSystem development
unit.
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3.4.9 Circular Dichroism
The structural content of the peptides was evaluated using Circular Dichroism (CD).
The peptides were used at concentrations of 4µM and CD spectra for the peptides
were recorded in the far UV region (190-250nm) both at room temperature and at
4oC.
The monoclonal antibody C595 and peptides were used at a concentration of 4µM and
at a ratio of 1:1 of peptide to antibody binding site in 50 mM phosphate buffer for the
room temperature measurements and for the temperature denaturation of the antibody.
The thermal denaturation of the antibody was measured in the absence of the peptides
as a control and in the presence of individual peptides at a 1:1 ratio to assess the
possible stabilisation effect of the peptide binding to the antibody binding-pocket. For
this experiment, pre-made mixture of peptide-antibody complex was used to measure
the CD spectrum of the antibody at 25, 35, 45, 55, 65, 75 and 85oC. CD spectra were
recorded under N2 using a Jasco J720 Spectrometers (Jasco Inc., Tokyo, Japan). All
measurements were taken using a 0.05 cm optical path length quartz cell. The band
width was 2 nm and the slit width controlled automatically, the sensitivity was set at
20 mdegrees with a time constant of 4 (arbitrary units), a step resolution of 0.2 nm
and scan speed of 10 nm sec-1. One scan was sufficient for accumulating spectra with
high signal to low noise ratios.
3.4.9.1 Analysis of CD data versus temperature and pH
The CD signal from the C595 antibody in the presence and absence of antigenic
peptides was recorded at 220 nm. The signal was analysed versus temperature to
determine the melting temperature (Tm) of the antibody molecule and the possible
∆Tm (were ∆Tm = Tm of bound Ab - Tm of free Ab) obtained as the difference
between free and peptide-bound antibody stability. The Van’t Hoff equation was used
to fit the experimental results (Missailidis, et al. 1997) and to determine the Tm of the
antibody.
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Where El is the Lower Temperature CD limit, Eu the Upper Temperature limit, T the
Temperature mid-point (Tm), Ex the Experimental CD at Temperature Tx and k is a
constant related to entropy and enthalpy and the cooperativity of the melting. For
every antibody, two curves were plotted, one (d(t) vs t, solid line in graphs) from the
theoretical values calculated from the above equation for t = 100, 101,...,500 and
another (Exi vs 273+Ti, x’s in graphs) from the experimental data. i= 1...n where n is
the number of experimental data.
3.4.10 Fluorescence Quenching Immunoassay
The antibody solution (2.5 ml in a 3 ml quartz cuvette, 1 cm path length) in PBS (pH
7.4) and previously filtered through a Minisart NML 0.2 µm pore membrane
(Sartorius, Gottingen, Germany), was excited at 290 nm and the emitted light was
measured at 345 nm using a Perkin Elmer LS-5 luminescence spectrometer (Perkin
Elmer, Beconsfield, UK). The excitation slit width was set at 5 nm and the emission
slit width was set at 10 nm. The test peptides were titrated into the antibody from a
concentrated stock solution (~200µM) until maximum fluorescence quenching of the
antibody was observed. Dilution effects of titrating a peptide solution into the Ab
solution were ascertained by titrating PBS solution into 2.5 ml of antibody solution as
a control and were used for correction of the actual peptide titration data. The values
of Fo (observed intensity of fluorescence in the absence of peptides) and F (observed
intensity of fluorescence in the presence of varying amounts of peptides) were noted
during all the titrations. In order to obtain equilibrium constants from the results for a
single mode of binding, the following formula (Missailidis, et al. 1997) was used:
Acalc P0( ) E1 E2( ) 1 K D. K P0.( ) 1 K D. K P0.( )
2 4 K. K. D. P0..
2 K.
E2 D. 1
D
.
where E1 is the minimum value of Fo/F, E2 is the value of Fo/F corresponding to the
fluorescence of the Ab on its own, K is the binding constant and D is the molar
concentration of the Ab in solution. Using the observed Fo/F experimental data and
the peptide molar concentrations added to the Ab solution, the Acalc(P0) values were
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calculated by a method of computation involving an iterative procedure designed to
satisfy the above equation.
3.4.11 Conjugation of peptides to BSA using glutaraldehyde
Sodium hydrogen carbonate buffer (500 µl, 0.1M, pH 8.4) was added to bovine serum
albumin (BSA) (8.0 mg), and mixed by pipetting followed by rolling.  Peptide
(10µmole) was then dissolved in sodium hydrogen carbonate buffer (1.0 ml, 0.1M,
pH 8.4).  The BSA solution was then added to a clean glass vial, and the following
were added in the given order: -
Sodium hydrogen carbonate buffer (2.5 ml, 0.1M, pH 8.4)
Peptide solution (1.0 ml)
Glutaraldehyde (10.0 µl)
The vial was sealed and agitated on a roller for 4 hours at room temperature.  The
resulting solution was then dialysed in 30cm of dialysis tube, against sodium chloride
solution (0.9% w/v) for 24 hours at 4oC with stirring.  The conjugate was stored at –
20oC until ready for use.
3.4.12 Production of a BSA-Estrone Conjugate
Estrone (102.2mg, 378 µmole) was dissolved in a stirred mixture of dioxane (5.11ml)
and sodium hydroxide (2M, 5.11ml).  Epichlorohydrin (15.5µl, 189µmole) was added
to the stirred mixture.  The mixture was left stirring overnight at room temperature.
Bovine serum albumin (2g) was dissolved in PBS (100ml, pH 10.0).  The
epichlorohydrin-estrone mixture (10.0ml) was then added to the BSA solution (10.0
ml) and stirred overnight at room temperature.  The resulting solution was dialysed
against five litres of PBS over the period of a weekend (at 4oC with stirring).
3.4.13 Enzyme linked immunosorbent assay (ELISA)
The antigen was dispensed into the wells of a microtitre plate (NUNC) at 50 µl/well.
Antigen was either BSA-synthetic peptide conjugate or BSA-Estrone conjugate.  One
row of the plate was filled with PBSA (50 µl/well) only, to serve as an antigen blank.
The plate was dried overnight to allow the conjugates to adsorb onto the wells.  The
plate was then washed four times with PBS/Tween wash buffer.  After the final wash,
care was taken to ensure that all wash buffer was removed from the wells.  To remove
all remaining non-specific adsorption sites, the plate was then blocked by dispensing
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100µl of 1% BSA/PBS solution into the wells and incubated for one hour at room
temperature with agitation.  After the blocking step, blocking buffer was removed and
antibody dilutions were dispensed at 50µl/well and incubated at room temperature
with agitation for one hour (this incubation period was varied for some experiments).
After incubation the antibody solutions were removed and the plate washed four times
with washing buffer as before.  The marker antibody (usually rabbit anti-mouse IgG
peroxidase conjugate) was dispensed at 50µl/well at 1/1000 dilution (as recommended
by the manufacturer) in PBS, and incubated for one hour at room temperature with
agitation.  Again the plate was washed four times in washing buffer.  Finally ABTS
solution was dispensed into each well at 50µl/well and colour development was
measured using a Milenia Kinetic Analyser (Diagnostic Products corporation,
Llanberis, UK).
3.4.13.1 Investigation of the blocking of 4155 Ab binding to a synthetic peptide
library tethered to polyethylene pins by estriol-3-glucuronide.
A Replacement Net (RNET) array of peptides tethered to the heads of polyethylene
pins (as described in Chapter 1) was used to probe the specificity of 4155 antibody.
The RNET array consisted of peptides based on the general sequence GXFED,
GLXED, GLFXD and GLFEX where residue X was replaced with each of the 20
naturally occurring amino acids.  Each individual peptide was synthesised on two
different pins.
4155 antibody (10µg/ml) was incubated overnight at 4oC with estriol-3-glucuronide at
several different concentrations (100, 000 and 10, 000 times the antibody
concentration).  The estriol-3-glucoronide / antibody mixture was dispensed into the
wells of a microtitre plate, such that one pair of the RNET peptide pins would be
incubated.  The other duplicate peptide was incubated with antibody 4155 only
(150µl, 5µg/ml).
To ensure that antibody could be effectively desorbed from the pins after each
experiment, the background level of binding was assessed using steps (i), (iv), (v) and
(vi) of the protocol listed below.  If a significant level of antibody to the pins was
detected, step (vi) was repeated and the level of binding reassessed prior to continuing
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with the next stage of the assay.  The next stage of the assay involved using all of the
steps given below to determine the binding of mAb 4155 to the pins.
(i) The pins were immersed into the wells of a microtitre plate containing
blocking buffer (200µl/well), for one hour with agitation; to minimize non-specific
binding.  The pins were then removed from the plate and excess blocking buffer was
shaken off the pins, and the pins placed onto a thickness of tissue paper for five
minutes to allow the draining of any remaining buffer.
(ii) The primary antibody reaction mixture was diluted to the appropriate
concentration in blocking buffer and dispensed into the wells of a microtitre plate
(150µl/well).  The pins were then immersed in this plate and incubated at 4oC
overnight.
(iii) The pins were removed from the microtitre plate and washed.  (The washing
consisted of four washes, of five minutes duration each.  In each wash the pins were
immersed in a bath of PBS/Tween and agitated for the duration of the wash.)
(iv) Rabbit-anti-mouse horseradish peroxidase labeled IgG secondary antibody
conjugate was diluted in PBS and dispensed into the wells of a microtitre plate
(150µl/well).  The washed pins were then immersed in the wells of the plate and
incubated for one hour with agitation.
(v) The pins were then washed (as in (iv)).  ABTS substrate was prepared
immediately before use and dispensed into the wells of a microtitre plate (150µl/well).
The pins were immersed in the substrate solution for 15 minutes and then removed to
stop the reaction.  The OD of each well was determined by using a Milenia Kinetic
analyzer at a wavelength of 405nm.
(vi) Antibody was removed from the pins by sonication in disruption buffer at
60oC for the appropriate time period (four hours for Ab4155/GLFED RNET and  two
hours for C595 RPAP RNET).  The pins were then rinsed four times with distilled
Chapter 3 Materials and Methods.
76
water at 60oC, and immersed in methanol for ten minutes.  The pins were then
allowed to dry fully in air.
3.4.13.2 Measurement of Mimotope Peptide Binding to 4155Ab By Competitive
Inhibition ELISA
BSA-epichlorohydrin-estrone conjugate was dried overnight onto the wells of a
microtitre plate (NUNC) at a concentration of 3µg/ml BSA in PBS.  The general
ELISA protocol described above was conducted; but the antibody dilutions consisted
of mimotope peptides ((d)DYFLG, (d)GLFYD, (l)AAERGLFED) and a negative
control peptide ((l)KSKAGVC), which had been incubated overnight at 4oC with the
antibody dilutions.
3.4.13.3 Empirical Binding Rate Experiments
Synthetic peptides conjugated to BSA, or Estrone conjugated to BSA were dried
down onto the wells of a microtitre plate (NUNC) overnight (10µg/ml BSA diluted in
PBS, 50µl/well).  A standard ELISA procedure was used as described above to
determine the levels of antibody binding at a number of different incubation periods.
3.4.14 Surface Plasmon Resonance (SPR) analysis of the C595 – mucin core
peptide APDTRPAPG interaction
Analysis of the results of kinetic experiments was conducted using BIAevaluation
software, version 3.0.2 (BIAcore, Uppsala, Sweden).
3.4.14.1 Determination of the binding kinetics between antibody C595 and the
MUC1 mucin related peptide APDTRPAPG.
The MUC1 mucin core peptide APDTRPAPG was immobilized onto the surface of a
BIAcore Pioneer (Carboxymethyl dextran surface) F1 sensor chip. Experiments were
conducted to reduce the surface binding capacity of the resulting sensor chip; and so
reduce the effects of mass transport (Schuck and Minton 1996) (Edwards 1999),
streric hinderance, crowding, avidity and aggregation (Myszka 1999). The aim was to
minimize the amount of peptide immobilised onto the surface of the sensor chip;
while still giving a measurable signal for the interacting antibody.  Initial optimization
experiments were conducted on a BIAcore 2000 instrument.  This had the advantage
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of automation and the presence of four flow cells on each sensor chip.  Kinetic
experiments were then repeated on a BIAcore-X instrument.
3.4.14.2 Optimization of ligand immobilization level
Several methods were tested to reduce the amount of peptide ligand APDTRPAPG
immobilized onto the surface of the activated sensor chip.  These included the use of
competing ligands which would be non-specific for C595 antibody and varying the
pH of buffer used so as to bring the charge of the peptide and the activated surface
into effect.  The most efficient way discovered to reduce the amount of peptide
immobilized onto the activated surface was to vary the volume of peptide passed over
the activated surface.  This was achieved using the Pioneer CMD F1 sensor chip, with
the shortened dextran matrix, rather than the BIAcore CMD CM5 chip.
To activate the carboxymethyl dextran surface, a 30 µL mixture of EDC/NHS was
injected through flowcell one over a pioneer F1 sensor chip surface at a flow rate of
10 µL/min.  The peptide (1 mM, 50 µL) was injected into flowcell one in HBS buffer
at a flow rate of 5 µL/min.  This was followed by 20 µL injection of ethanolamine-
HCl (pH 8.5) to cap the remaining activated carboxyl groups.  Two pulses of sodium
hydroxide (250 mM, 5 µL) at 5 µL/min, followed by a third pulse (250mM, 5 µL) at
30 µL/min were used to wash out any unbound peptide.  Flowcell two was then
activated as above.  The same procedure was conducted individually for flowcells
two, three and four respectively, except that 40 µL, 35 µL and 30 µL of peptide
(1mM) were injected into each of the respective activated flowcells.
To ascertain the level of binding that could be observed when antibody bound to the
peptide; the flow path was changed to include all four flow cells. Monoclonal
antibody C595 (3.0 µM) in HBS buffer was then injected into the flowcells at a flow
rate of 30 µL/min, and allowed to associate for 600s, and dissociate for 350s.
Regeneration was conducted using two 5s pulses of sodium hydroxide (250mM).
3.4.14.3 Measurement of  kinetics of the interaction
A second sensor chip was then set up using the optimized conditions of peptide
immobilization derived from the previous experiment.  A second flow cell was
activated and deactivated without coupling the peptide as a control surface for
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refractive index change and nonspecific binding.  Monoclonal C595 antibody samples
contained 3.0 µM, 2.5 µM, 1.5=µM, 1.0 µM and 0.5 µM protein.  To perform kinetic
binding studies, the flow path was changed to include both flow cells and the data
collection rate was set to high. The sample (100 µL) was injected at a flow rate of 30
µL/min with a 200 s dissociation phase.  After the end of the dissociation time, the
flowcells were washed with 250 mM sodium hydroxide to regenerate the sensor
surfaces.  Each antibody sample was injected in random order.  The effect of flow rate
was assessed by injecting C595 antibody (1.0 µM) at 5,=15=and 75 µL/min.
3.4.14.4 Data analysis
The raw sensor data were prepared for global analysis by subtracting the average
response over 15 s prior to the antibody injection and zeroing the time of injection for
each flow cell.  The responses obtained from the control surface were subtracted from
the peptide surface data – to correct for refractive index changes and nonspecific
binding events.  The corrected data was then analyzed using BIAevaluation software
(BIAcore, version 3.02) by direct curve fitting to a several different models.
These models included:
1:1 (Langmuir) binding model – (A + B = AB)
two state reaction (conformation change)
heterogeneous ligand  - (parallel reactions)
bivalent analyte
1:1 binding with mass transfer (BIAcore, 1997)
Modelled data sets were generated by numerical integration of the differential
equations that describe the reaction.  These were fitted to the association and
dissociation phase sensor data at all antibody concentrations simultaneously using the
algorithms described.  The closeness of fit is described by the value χ2.  This figure
represents the average squared residual per data point for sensorgram data.  Values
below 10 are acceptable, since if the model fits the experimental data precisely, χ2
represents the mean square of the signal noise (BIAcore, 1997).
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3.4.15 SPR analysis of the interaction between peptide conjugate BSA-
(D)DYFLG, and the anti E3G monoclonal antibody 4155.
To reduce the effects of the biosensor surface on the interaction between the peptide
mimotope (D)DYFLG and the anti-E3G monoclonal antibody 4155, the interaction
between the monoclonal antibody and the peptide BSA-conjugate was studied.
Studying this interaction had the advantage that the reaction could be studied with
either partner immobilised.  A comparison was made between the kinetics observed
when (i) the antibody was immobilised and (ii) the BSA-peptide conjugate was
immobilised.
3.4.15.1 Immobilisation of monoclonal antibody 4155 onto the surface of Pioneer
F1 CMD sensor chip.
The monoclonal antibody was immobilised using NHS/EDC coupling chemistry.  To
activate the carboxymethyl dextran surface, a 35 µL mixture of NHS/EDC was
injected over the sensor surface at a flow rate of 5 µL/min.  The 4155 mAb (50µg/ml)
was injected in sodium citrate buffer (pH 3.5) in flowcell one until the desired level of
immobilisation was achieved – determined by experiment to give a signal of less than
100 RU on binding of the BSA–peptide conjugates.  This was followed by 20 µL
injection of 1M ethanolamine-HCl (pH 8.5) to cap the remaining activated carboxyl
groups.  The same procedure was conducted using flowcell two, immobilising an
irrelevant monoclonal antibody under the same conditions.  The surface was
conditioned by passing two short pulses of the regeneration buffer through both flow
cells (20 mM HCl, 10 µL pulses).
3.4.15.2 Immobilisation of the peptide (D) DYFLG-BSA conjugate onto the
surface of a pioneer F1 CMD sensor chip.
Peptide (D)DYFLG was conjugated to bovine serum albumin at a concentration of 2.5
mg/ml.  The surface of a sensor chip was activated by passing a mixture of EDC/NHS
through flowcell one of a Pioneer F1 sensor chip.  The peptide conjugate was injected
into flowcell one in 10mM acetate buffer at a rate of 5 µL/min.  This was followed by
a 20 µL injection of ethanolamine-HCl (pH 8.5) to cap the remaining activated
carboxyl groups.  Flowcell two of the sensor chip was also activated identically.  An
irrelevant BSA-peptide conjugate was immobilised onto this flowcell under the same
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conditions as flowcell one.  The surface was conditioned with two pulses of the
regeneration buffer through both flow cells (20 mM HCl, 10µL pulses).
3.4.15.3 Investigating the kinetics of the interaction.
3.4.15.3.1 Immobilised antibody.
BSA – peptide conjugate samples were prepared containing peptide at concentrations
of 500, 200, 100 and 50 nM.  To perform kinetic studies the flowpath was set to
include both flowcells one and two, and the data collection rate was set to high.  The
sample was injected at a flow rate of 5µL/min with a 180s association phase and a
500s dissociation phase.  After the end of the dissociation phase, the flowcells were
washed with 20mM HCl to regenerate the sensor surfaces.  Each peptide sample was
injected in random order.
3.4.15.3.2 Immobilised peptide – BSA conjugate.
Antibody samples containing 500, 200, 100 and 50 nM protein were prepared.  The
flowpath was set to include both flowcells one and two, and data collection was set to
high.  The sample was injected at a flowrate of 30 µL/min with a 500s dissociation
phase.  At the end of the dissociation phase, the flowcells were washed with 20 mM
HCl to regenerate the sensor surfaces.  Each antibody sample was injected in random
order.
3.4.15.3.3 The effect of temperature on the interaction.
The effect of temperature on the kinetic parameters of the interaction between
immobilised antibody an BSA-peptide conjugate was investigated.  Kinetic
parameters were obtained by globally fitting a Langmuir association model (simple
1:1 interaction) to each data set (using conjugate concentrations at 500, 200, 100 and
50 nM) for each temperature studied (10, 15, 20 and 30 oC).
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3.4.16 Production of pCANTAB-5E [C595scFvGFP].  A Phagemid expression
vector containing a C595 ScFv – Green Fluorescent Protein Gene fusion.
3.4.16.1 Preparation of Electrocompetent Cells
LB growth media (1 litre) was inoculated with 1/10 volume of fresh overnight culture.
The cells were grown at 37oC with shaking (200 rpm).  When the cells had reached
early to mid log phase growth (OD600nm of ~ 0.5), they were harvested as follows.
The flask was chilled on ice for 30 minutes and then the contents were centrifuged in
a cold rotor at 4000 x g for 15 minutes.  The cell pellets were resuspended in ice cold
dH2O (1 litre), and centrifuged as before.  The cell pellets were again resuspended in
ice cold dH2O (0.5 litre), and centrifuged as before.  The cell pellets were resuspended
in ~20 ml of the cryoprotectant (10% v/v glycerol), and centrifuged as before.  Finally
the cell pellets were resuspended to a final volume of 3.0 ml in 10% glycerol.  The
resuspended pellets were stored at –700C ready for use.
3.4.16.2 Transformation of competent cells - electroporation
Transformations by electroporation were conducted using a commercially available
electroporator.
3.4.16.3 Isolation of the plasmid vector pCANTAB-5E containing C595 single-
chain Fv (scFv) gene.
E.coli strain HB2151 were transformed with the plasmid vector pCANTAB-5E
containing the C595 scFv gene (Denton, et al. 1997).  The transformed E.coli bacteria
were spread on LB-agar plates containing ampicillin (50 µg/ml), and incubated at 37
oC overnight.  One colony of transformed bacteria was picked and incubated at 37 oC
in LB medium (25 ml) containing ampicillin (50 µg/ml), with shaking (300 rpm)
overnight.  Plasmid DNA was isolated from cells using the protocol described in the
Wizard Plus SV miniprep DNA purification system (Promega Corporation, Madison,
USA).   A restriction digest using restriction enzymes Sfi I and Not I was conducted
to confirm the integrity of the Sfi I and Not I restriction sites flanking the ScFv gene
(see section 2.4.16.10).
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3.4.16.4 Isolation of the plasmid vector pTRACER-cmv containing the Green
Fluorescent Protein Gene.
Chemically competent E.coli strain TOP10 (Invitrogen BV, Groningen, The
Netherlands) were transformed with the pTracer-CMV expression vector containing
the GFP gene, according to the manufacturers instructions.  The transformed bacteria
were spread on LB-agar plates (containing ampicillin (50 µg/ml)) and incubated
overnight at 37 oC.  An  LB-agar plate containing individual colonies was placed on a
Spectroline TM-312A Ultra Violet Transilluminator, and a fluorescing colony was
picked and grown up in LB (25 ml) containing ampicillin (50 µg/ml).  The culture
was incubated overnight with shaking (300 rpm) at 37 οC.  Plasmid DNA was isolated
from cells using the protocol described in the Wizard Plus SV miniprep DNA
purification system (Promega Corporation, Madison, USA).
3.4.16.5  Design of primers to amplify the C595 single-chain Fv gene.
Primers were designed to amplify the C595 ScFv gene in the pCANTAB-5E vector.
The primers enabled the retention of the unique Sfi I restriction site at the 5’ end of
the gene; and mutated the unique Not I restriction site at the 3’ end of the gene to
another unique Bgl II restriction site (in the scFv gene). (See figure 7.3 – chapter 7)
3.4.16.6  Design of primers to amplify Green Fluorescent Protein Gene.
Primers were designed to amplify the GFP gene in the pTracer-CMV vector.  The
primers enabled the introduction of a unique Bgl II restriction site at the 5’ end of the
gene; and the introduction of a unique Not I restriction site at the 3’ end of the gene.
(See figure 7.3 – chapter 7)
3.4.16.7 PCR amplification of ScFv and GFP genes.
PCR reactions were performed on plasmid minipreps (Wizard PlusSV minipreps,
Promega, USA), the amount of DNA was visually estimated by gel electrophoresis
(~10µg/100µl) , in 50 µl aliquots using 25 pM of each primer and 2.5 mM of each
dNTP.  Each reaction was set up as follows: -
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10 x Buffer 5=µl
10 mM dNTP’s 1 µl
25 mM MgCl2 3 µl
Primers (25 pmol each) 2 µl
DNA Template 1 µl
dH2O 37 µl
49 µl
Each reaction was overlaid with 25 µl of light mineral oil.
A hot start was conducted prior to the addition of Taq polymerase (2.5 units),
consisting of heating the reaction mix to 95 oC for 5 minutes.  The PCR program
initially consisted of 30 cycles of 94 oC for 45s, 60 oC for 45s and 72 oC for 90s
(representing denaturation, annealing and elongation temperatures respectively);
followed by a single extended elongation step of 72 οC for 30 min.  The extended
elongation step was present to ensure that all PCR products are full length and 3’
adenylated (necessary for an efficient TOPO-TA cloning reaction).
Experimentation showed that the number of PCR cycles could be reduced from 30 to
10, still enabling the PCR band to be visualised on an agarose gel.
3.4.16.8 Low-Melt Agarose purification of PCR products.
Agarose gels (1%) were prepared by dissolving low-melt NuSieve agarose in TAE
buffer.  Ethidium bromide (0.2 µg/ml) was incorporated into the gel before pouring.
Samples were diluted with DNA loading buffer, and electrophoresis was performed.
DNA was visualised using a Spectroline TM-312A Ultra Violet Transilluminator, and
photographs were recorded using a Polaroid DS-34 Direct Screen Instant Camera.
The band of interest was excised using a sharp scalpel.
3.4.16.9  TOPO-TA cloning of amplified PCR products.
The gel slice was placed in a microcentrifuge tube and incubated at 65 oC until the gel
slice melted.  The tube was then placed at 37 oC to keep the agarose gel melted.  A
sample of the melted agarose (4 µl) containing the PCR product was mixed with the
TOPO TA cloning vector (1 µl) (Invitrogen BV, Groningen, The Netherlands) and
incubated at 37 οC for 10 minutes.  A sample of the mixture (4=µl) was transformed
directly into TOP10 one shot cells using the method as described by the manufacturer.
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A small number of the resulting white colonies were analysed (blue colonies contain
no insert and so were not picked) using M13 Forward and M13 Reverse primers as
described by the manufacturer.  A pick from each colony to be analysed was
suspended in 20 µl of LB media and vortexed.  1.0 µl of the suspended sample was
used in each PCR reaction.
Positive clones (those containing an insert of the correct size) were then grown by
inoculating LB media (10.0 ml) containing ampicillin (50 µg/ml) overnight at 37 oC
with shaking (300 rpm).  Plasmid DNA was isolated from cells using the protocol
described in the Wizard Plus SV miniprep DNA purification system (Promega
Corporation, Madison, USA).  The positive clones were then analysed using
restriction analysis to confirm that the Sfi I, Bgl II and Not I restriction sites were
functional. Restriction digestion of the C595 ScFv TOPO clones containing the
unique Sfi I and Bgl II restriction sites was conducted by performing individual Sfi I
and Bgl II digests; alongside a double digestion of the vector with Sfi I and Bgl II
restriction enzymes.  Restriction digestion of the GFP TOPO clones containing the
unique Bgl II and Not I restriction sites were conducted by performing individual Bgl
II and Not I restriction digests; alongside a double digestion of the vector with Bgl II
and Not I.  See section (3.4.16.10) for details of restriction digests.  Positive TOPO
clones (PCR and Restriction analysis) were sequenced using M13 forward and M13
reverse drivers.
3.4.16.10  Digestion and ligation of TOPO-cloned genes.
Cleaving a DNA substrate with two restriction endonucleases simultaneously (double
digestion) enables more efficient restriction digests to be conducted, providing a
reaction buffer can be selected in which both enzymes function effectively.  This was
the case with the restriction enzymes used in this case.  The Sfi I/ Bgl II and Bgl II /
Not I digests were used to confirm the integrity of the restriction sites resulting from
the previous PCR.  The restriction digests were set up as follows: -
Restriction analysis of C595 ScFv TOPO clones
The optimium functional temperture for the restriction enzyme Sfi I is 50oC, but the
optimum functional temperature for Bgl II I is 37oC.  In order to perform the
sequential digestion using the Sfi I and Bgl II restriction enzymes in the same reaction
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mixture, the reaction was first incubated at 37oC for three hours followed by an
incubation at 50oC for three hours to enable the efficient digestion of both the Bgl II
and Sfi I restriction sites respectively.
Sfi I digest
10 x NEB 2 buffer          2.5µl
Sfi I (20,000 units/ml)    0.25µl
100 x BSA                      0.25µl
Plasmid DNA                 22.0µl
Bgl II digest
10 x NEB 2 buffer          2.5µl
Not I (10,000 units/ml)   0.5µl
100 x BSA                      0.25µl
Plasmid DNA                 21.75µl
Sfi I / Bgl II digest
10 x NEB 2 buffer          2.5µl
Not I (10,000 units/ml)   0.5µl
Sfi I (20,000 units/ml)    0.25µl
100 x BSA                      0.25µl
Plasmid DNA                 21.5µl
A control reaction was set up consisting of plasmid DNA, 100 x BSA and 10 x NEB 2
buffer to ensure that no contamination of the reagents with restriction enzyme had
occurred.
Restriction analysis of GFP TOPO clones
The optimum functional temperatures for the Bgl II and Not I restriction enzymes are
identical at 37oC, enabling the sequential digestion using Bgl II and Not I restriction
enzymes to be conducted at the same temperature.  The restriction digests were
conducted at 37oC for three hours.
Bgl II digest
10 x NEB 3 buffer          2.5µl
Bgl II (10,000 units/ml)  0.5µl
100 x BSA                      0.25µl
Plasmid DNA                 21.75µl
Not I digest
10 x NEB 3 buffer          2.5µl
Not I (10,000 units/ml)   0.5µl
100 x BSA                      0.25µl
Plasmid DNA                 21.75µl
Bgl II / Not I digest
10 x NEB 3 buffer          2.5µl
Bgl II (10,000 units/ml)  0.5µl
Not I (10,000 units/ml)   0.5µl
100 x BSA                      0.25µl
Plasmid DNA                 21.25µl
A control reaction was set up consisting of plasmid DNA, 100 x BSA and 10 x NEB 3
buffer to ensure that no contamination of the reagents with restriction enzyme had
occurred.
Restriction digests of TOPO clones for ligation
A Hind III / Bgl II double digest was used to isolate the scFv and GFP genes prior to
the ligation reaction.  Hind III was chosen instead of Sfi I or Not I since the pCR 2.1
TOPO cloning vector contains a unique Hind III restriction site close to the cloning
region, and this enables the use of the original primers to amplify the ligation product.
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Digests incorporating Sfi I and Not I would have resulted in products with shortened
termini resulting in a less efficient final PCR reaction. The optimum functional
temperatures for the Bgl II and Hind III restriction enzymes are identical at 37oC,
enabling the sequential digestion using Bgl II and Hind III restriction enzymes to be
conducted at the same temperature.  The restriction digests were conducted at 37oC
for three hours.
Bgl II / Hind III digest
10 x NEB 2 buffer               2.5µl
Bgl II    (10,000 units/ml)   0.5µl
Hind III (10,000 units/ml)   0.5µl
Plasmid DNA                    21.5µl
3.4.16.10.1 Low melt agarose purification of products from restriction digests
Agarose gels (1%) were prepared by dissolving low-melt NuSieve agarose (Flowgen,
Sittingbourne, UK) in TAE buffer.  Ethidium bromide (0.2 µg/ml) was incorporated
into the gel before pouring.  Samples were diluted with DNA loading buffer, and
electrophoresis was performed.  DNA was visualised using a Spectroline TM-312A
Ultra Violet Transilluminator, and photographs were recorded using a Polaroid DS-34
Direct Screen Instant Camera.  The band of interest was excised using a sharp scalpel.
3.4.16.10.2 In-gel ligation of excised scFv and GFP genes
The excised slices of gel continaing the scFv and GFP gene fragments were placed in
separate, labelled microfuge tubes.  The tubes were heated to 70 oC for 15 minutes to
melt the agarose.  Aliquots (5 µl each) of the melted bands to be ligated were
combined in a prewarmed ependorf tube (37 oC).  The molar ratio of the two genes
was estimated to be roughly equal.  The reaction was incubated for 10 minutes at
37oC.  Ice cold 2 x bacteriophage T4 DNA ligase mixture (10 µl) was added to the
tube, and mixed well with the contents of the tube before the gel hardened.  The
reaction was incubated at 16 oC for 16 hours.  The agarose in the ligation mixture was
then remelted by heating to 70 oC for 15 minutes.  A 1µl aliquot of the remelted
mixture was then used in a PCR with C595 SfiI FOR and GFP NotI REV primers,
following the protocol outlined in section 3.4.16.7.  A TOPO-TA cloning reaction of
the PCR product was then carried out using the protocol outlined in section 3.4.16.9.
and the insert sequenced to verify ligation of the two gene fragments.  The clone
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containing functional Sfi I and Not I restriction sites and containing the correct
sequence was named  pCR2.1-TOPO[C595scFvGFP].
3.4.16.10.3 In-gel ligation of C595-ScFv – GFP fusion into pCANTAB-5E
vector.
Double digestions were carried out on the pCANTAB-5E and pCR2.1-
TOPO[C595scFvGFP] vectors to enable isolation of the pCANTAB-5E plasmid and
the C595scFvGFP DNA insert.  The restriction digests for each vector were set up as
follows: -
Sfi I digest
10 x NEB 2 buffer          2.5µl
Sfi I (20,000 units/ml)    0.25µl
100 x BSA                      0.25µl
Plasmid DNA                 22.0µl
Not I digest
10 x NEB 2 buffer          2.5µl
Not I (10,000 units/ml)   0.5µl
100 x BSA                      0.25µl
Plasmid DNA                 21.75µl
Sfi I / Not I digest
10 x NEB 2 buffer          2.5µl
Not I (10,000 units/ml)   0.5µl
Sfi I (20,000 units/ml)    0.25µl
100 x BSA                      0.25µl
Plasmid DNA                 21.5µl
A control reaction was set up consisting of plasmid DNA, 100 x BSA and 10 x NEB 2
buffer to ensure that no contamination of the reagents with restriction enzyme had
occurred.  The restriction digests were heated for 3 hours at 37oC followed by heating
for 3 hours at 50oC to enable Not I and Sfi I enzymes repctively to both function.
Agarose gel electrophoresis was used to analyse the digests, and the required gel
fragments were excised from the gel.  An in-gel ligation was conducted as follows:
The excised slices of gel were placed in separate, labelled microfuge tubes.  The tubes
were heated to 70 oC for 15 minutes to melt the agarose.  Aliquots (5 µl each) of the
melted bands to be ligated were combined in a prewarmed ependorf tube (37 oC).  The
molar ratio of foreign DNA : plasmid vector was estimated to be approximately 2:1
(estimated from the relative fluorescence intensities of the desired bands (Sambrook,
et al. 1989)).  Two additional ligation reactions were set up in separate tubes as
controls; one containing the plasmid vector alone and the other containing only the
fragment of foreign DNA.  The three tubes were incubated for 10 minutes at 37 oC.
To each tube ice cold 2 x bacteriophage T4 DNA ligase mixture (10 µl) was added,
and mixed well with the contents of the tube before the gel hardened.  The reactions
were incubated at 16 oC for 16 hours.  The agarose in the ligation mixture was then
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remelted by heating to 70 oC for 15 minutes.  An aliquot (5=µl) of one of the ligation
mixtures was used to transform 100 µl of chemically competent E.coli strain TOP10
(Invitrogen BV, Groningen, The Netherlands) according to the manufacturers
instructions.  Transformed cells were plated out onto LB-agar plates containing
ampicillin (50 µg/ml).  The plates were incubated at 37 oC overnight.
A small sample of colonies were picked from the plate using a sterile pipette tip and
suspended in 20 µl of LB media.  Samples were analysed by PCR using the method
described in section (3.4.16.7) using primers S1 and S6 (Denton, et al. 1997).
Samples containing an insert of the desired size were then analysed by restriction
enzyme digestion (Sfi I, Bgl II and Not I) using the methods described in section
(3.4.16.10).  Positive clones were then sequenced.  The positive clone containing the
correct sequence was named pCANTAB-5E [C595scFvGFP]. A sample of the
bacteria containing the engineered plasmid were stored as a glycerol stock (10 % w/v
glycerol) at –70oC.
3.4.17 Protein expression
Plasmid pCANTAB-5E [C595scFvGFP] isolated as described in section (3.4.16.10.3)
was used to transform the nonsuppressor strain of E.coli. (strain HB2151) by
electroporation.  This strain recognizes the amber stop codon after the C595scFvGFP
gene insert, enabling the production of soluble fusion protein.  Electrocompetent
E.coli. (strain HB2151) were prepared as described in section (3.4.16.1).  The
transformed E.coli. were streaked onto a SOBAG-N plate and incubated overnight at
30 oC.
3.4.17.1 Expression in supernatant
An overnight culture of was prepared by transferring a colony from the SOBAG-N
plate prepared in section (3.4.17) to 5.0 ml of freshly prepared SB-AG medium and
incubated overnight at 30 oC with shaking at 250 rpm.  The overnight culture was then
added to 50.0 ml of freshly prepared SB-AG medium.  The culture was incubated for
one hour at 30 oC with shaking at 250rmp.  The culture was centrifuged at 1500 x g
for 20 minutes at 4 oC.  The supernatant was carefully removed from the sedimented
cells.  The cells were then resuspended in 50.0 ml of freshly prepared SB-AI medium
and incubated overnight at 30 oC with shaking at 250 rpm in baffled flasks.  The
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culture was divided into two centrifuge tubes and centrifuged at 1500 x g for 20
minutes at room temperature.  The supernatants were removed from both pellets and
transferred to a single clean glass container.  The supernatant was filtered through a
0.45 µM filter (Satorius, Gottingen, Germany) and stored at –20 oC.  One pellet was
retained for preparation of the periplasmic extract and the other pellet for preparation
of whole cell extract.
3.4.17.2 Affinity Purification of induced supernatant
The supernatant (~50 ml) was applied to a chromatography column consisting of
peptide APDTRPAPG linked to beaded agarose at a concentration of 1µmole peptide
per ml gel, as described in section (3.4.7.1).  After extensive washing of the column
with PBSA (100ml), a gradient elution was conducted using NaSCN (3M), as
described in section (3.4.7.2).  Fractions (2.5 ml) were collected and desalted using a
PD10 column (Amersham, Pharmacia, Biotech) containing Sephadex G25.
3.4.17.3 Trichloroacetic acid (TCA) precipitation of protein
The soluble antibody fractions were too dilute to visualise on western blot.  A TCA
precipitation step was conducted to establish if concentration of protein could be
achieved to enable visualisation on western blot.  Trichloroacetic acid (250 µl, 20%
w/v) was added to a microcentrifuge tube containing 250 µl of sample and mixed.
The mixture was incubated on ice for 15 minutes and centrifuged on a bench top
centrifuge for 15 minutes ar 12,000 rpm.  The supernatant was removed and the pellet
resuspended in 20 µl of water.  The sample was then used for electrophoresis as
described in section (3.4.8)
3.4.17.4 Periplasmic Extract
One of the pellets from (3.4.17.1) was resuspended in ice cold TES buffer (0.5 ml).
Ice-cold 1/5 x TES (0.75 ml) was added, and the mixture was vortexed.  The mixture
was incubated on ice for 30 minutes.  The contents were transferred to a
microcentrifuge tube (1.5 ml) and centrifuged at full speed for 10 minutes.  The
supernatant was carefully removed and place in a clean tube and stored at –20 oC.
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3.4.17.5 Whole Cell Extract
The second pellet from (3.4.17.1) was resuspended in PBS (0.5 ml) and boiled for 5
minutes.  The cell debris was pelleted as in (3.4.17.2) and the supernatant was
carefully transferred into a clean tube, and stored at –20 oC until use.
3.4.18 Western blot analysis
Periplasmic extract (20 µl) was mixed with 6X loading buffer (4 µl) (Novagen).  A
prestained molecular weight marker was run in parallel with the samples.  All samples
were heated to 99 oC for 5 minutes, cooled to room temperature and briefly spun.
Each sample was loaded onto an SDS-polyacrylamide gel and electrophoresed until
the dye contained in the loading buffer reached the bottom of the gel.
The proteins were transferred from the gel to a nitrocellulose membrane.  When the
transfer was complete, the membrane was incubated in Blocking Buffer (20.0 ml) for
1 hour at room temperature, in a closed container.  The anti-E Tag HRP (2.0 µl)
conjugate was diluted in blocking buffer (20.0 ml).  The blocking buffer was removed
from the blot and replaced with the diluted anti-E Tag HRP conjugate solution.  The
blot was incubated for one hour at room temperature with gentle agitation in a closed
container.  The diluted conjugate solution was removed from the blot.  The blot was
washed six times (2 minutes per wash) with an excess of wash buffer, and once with
distilled deionized water.  Excess water was drained from the blot, and the blot was
placed in freshly prepared 4-chloro-1-napthol substrate.  The blot was gently agitated
in a sealed container until a blue colour developed, indicated that a reaction had
occurred.  The blot was rinsed with deionized water to stop the reaction.
3.4.19 ELISA of Supernatant, Periplasmic Extract, Whole Cell Extract and
fractions from affinity purification of supernatant.
A Standard ELISA technique was conducted using the procedure described in section
2.4.12.  BSA-APDTRPAPG peptide conjugate was dried down in the wells of a
microtitre plate overnight.  The various products of the expression were incubated on
the plate.  The marker antibody in this case was HRP/Anti-E Tag conjugate
(Amersham Pharmacia Biotech).  ABTS was used as the revealing substrate.  Colour
development was measured using a Milenia Kinetic Analyser (Diagnostic Products
corporation, Llanberis, UK).
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3.4.20 Random mutagenesis of the C595-ScFv gene – analysis of a selection of
mutants.
The method employed consisted of a modified polymerase chain reaction  which was
used to produce random point mutations in the C595 ScFv gene.  The ScFv gene was
amplified using the polymerase chain reaction (PCR) under conditions that reduce the
fidelity of DNA synthesis by Thermus aquaticus (Taq) DNA polymerase.  The pool of
amplified DNA fragments containing the point mutations was then inserted into the
pCR 2.1-TOPO cloning vector to produce a library of random mutants.
3.4.20.1 Cloning of ScFv gene from pCANTAB-5E into pCR2.1 TOPO
The C595 scFv gene was cloned from the pCANTAB-5E using C595Sfi FOR and
C595 Not I REV primers as described in sections (2.4.16.7 – 2.4.16.9).
3.4.20.2  Mutagenic PCR reaction
The method of mutagenic PCR as described by Cadwell et al was employed (Cadwell
and Joyce 1994).  The protocol is derived from standard PCR conditions (Coen 1991),
using changes which enhance the mutation rate as follows: -
Standard PCR Mutagenic PCR
[MgCl2] 1.5 mM    7.0 mM   1
[MnCl2] -    0.5 mM  2
[dATP] 0.2 mM    0.2 mM
[dCTP] 0.2 mM     1.0 mM  3
[dGTP] 0.2 mM     0.2 mM
[dTTP] 0.2 mM    1.0 mM  3
Taq polymerase 2.5 U    5.0 U    4
Note: -
1.  Stabilize noncomplementary pairs.
2.  Diminish template specificity of the polymerase.
3.  Promote misincorporation.
4.  Promote chain extension beyond positions of base mismatch.
The mutagenic PCR reaction was set up alongside the normal PCR reaction as
follows: -
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Mutagenic PCR Normal PCR
10 x mutagenic buffer 10 µl 10 x PCR buffer 10 µl
10 x mutagenic dNTP mix 10 µl 10 x  dNTP mix 10 µl
C595 Sfi I FOR primer
  2 µl C595 Sfi I FOR primer 2 µl
C595 Not I REV primer
  2 µl C595 Not I REV primer 2 µl
Plasmid DNA
  2 µl Plasmid DNA 2 µl
DH2O 62 µl dH2O 72 µl
MnCl2* 10µl -
*
 MnCl2 added last to prevent formation of a precipitate that disrupts PCR
amplification.
The appropriate amount of Taq polymerase was added to each of the reactions (see
above), bringing the final volume to 100 µl.  The mixture was covered with mineral
oil.  The reactions were incubated for 30 cycles of 94oC for 1 min, 45oC for 1 min,
and 72oC for 1 min.
3.4.21 Evaluation of pSKGFP expression system
The vector pSK-GFPmut1 (Griep, vanTwisk et al. 1999) was supplied in lyophilised
form.  The vector was resuspended in TBE buffer and used to transform E.coli strain
XL1-Blue-MRF’ (Invitrogen.  Directions were carried out as written by the authors to
see if their results could be reproduced.
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4 Chapter 4 - Results.  Phage Display of Peptides.
4.1 Introduction
Chapter 1 described the various techniques that are available to purify antibodies from
crude biological feedstocks.  Affinity purification utilising synthetic peptides as
paratope-specific binding ligands was observed to be the method of choice.  Unlike
any of the other methods described, the use of this method to isolate antibodies from
crude feedstocks can yield antibodies of high and standardized immunoreactivity in a
single purification step (Price, et al. 1991; Murray, et al. 2000; Smith, et al. 2001).
Chapter 2 outlined the different library technologies that are currently available to
facilitate the discovery of paratope specific binding ligands.  This chapter focuses on
the use of one of these technologies – phage display.  In this chapter, a description and
analysis is given of the results obtained when the polyvalent T7 display library was
used to isolate a novel binding ligand for the anti-MUC1 murine monoclonal antibody
C595.
The process relies on the use of a technique known as “biopanning”.  Biopanning (or
affinity selection) is a procedure for the enrichment of molecules that bind to a given
target protein.  The target protein can be linked to a solid support (e.g. biotinylated
antigen can be linked to streptavidin coated magnetic beads) or the target protein can
be non-specifically absorbed onto a solid support (e.g. ELISA plate, immunotubes
…etc.).  The use of biotinylated target proteins offers advantages in terms of tailoring
the selection conditions to select for a desirable kinetic in the interaction (e.g. slow
off-rate).  Elution conditions can be tailored to select for desirable kinetic traits when
biopanning using proteins which are non-specifically adsorbed to solid supports.
Parameters such as the stringency of the washes can be varied, and so too can the
elution buffers.  Specific phage bind to the target protein, whilst non-specifically
binding phage are washed off.  Bound phage removed in the elution step can then be
quantified (e.g. plaque assay and sequencing of individual clones) and propagated for
repeated rounds of selection and enrichment.
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4.2 The T7Select415 phage display library
The T7 phage was described in section 2.3.1.1.  Peptides were encoded for by a
degenerate oligonucleotide insert, consisting of a randomized library of 9-residue
peptides flanked by cysteine residues (to impose a structural constraint on the C-
terminus of the displayed peptides (McConnell, et al. 1994).  The cysteine residues
were also flanked with serine residues, such that the N terminus of the peptide was
linked to the capsid head through a serine residue (see fig. 4.1).  The nine randomized
residues were incorporated into the insert using a sequential synthesis strategy for
each codon of NNK; where N is an equimolar mixture of the bases A, G, C and T; and
K is an equimolar mixture of the bases G and T only.  Using this method the number
of stop codons that can be coded for falls from three to one at each codon (see fig.
4.2).
The chemically synthesized single-stranded degenerate oligonucleotide insert was
converted into a clonable double-stranded DNA insert containing EcoRI and HindIII
restriction sites.  This was done by annealing a second short oligonucleotide
incorporating the HindIII restriction site, and using Taq polymerase to fill in the rest
of the strand.  Taq polymerase fills in complementary strand of degenerate oligo.  The
insert was digested using EcoRI and Hind III restriction enzymes and ligated into the
T7Select415-1b vector.  From the initial ligation reaction 1.4 x 108 independent clones
were obtained (Dr P. Tighe, University of Nottingham – personal communication).
Propagation of the library resulted in a lysate consisting of 4.36 x 1010 pfu/ml.  This is
equivalent to 311 copies of each individual clone per ml of lystate (4.36 x 1010 / 1.4 x
108 = 311).
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21271 5’21295 R1 FOR Primer
AAA GGT GAG GGT AAT GTC AAG GTT GCT AAG GAC AAC GTT ATC GGC CTG
T7 Select 415-1b Vector CGA TTC CTG TTG CAA TAG CCG GAC
3’ 21340
TTC ATG CAC CGC TCT GCG GTA GGT ACT GTT AAG CTG CGT GAC TTG GCT
AAG TAC GTG GCG AGA CGC CAT CCA TGA CAA TTC GAC GCA CTG AAC CGA
GGT ACT GTT AAG CTG CGT GAC TTG GC
5’ SEQ FOR Primer 3’
CTG GAG CGC GCT CGC CGT GCT AAC TTC CAA GCG GAC CAG ATT ATC GCT
GAC CTC GCG CGA GCG GCA CGA TTG AAG GTT CGC CTG GTC TAA TAG CTA
AAG TAC GCA ATG GGC CAC GGT GGT CTT CGC CCA GAA GCT GCA GGA GCT
TTC ATG CGT TAC CCG GTG CCA CCA GAA GCG GGT CTT CGA CGT CCT CGA
Ala Ala Gly Ala
EcoRI
GTC GTA TTC CAG TCA GGT GTG ATG CTC GGG GAT CCG AAT TCC TGC xxx
CAG CAT AAG GTC AGT CCA CAC TAC GAG CCC CTA GGC TTA AGC ACG xxx
Val Val Phe Gln Ser Gly Val Met Leu Gly Asp Pro Asn Ser Cys xxx
1
           Degenerate oligonucleotide insert Hind III
xxx xxx xxx xxx xxx xxx xxx xxx TGC TCT TGA AGC TTG CGG CCG CAC
xxx xxx xxx xxx xxx xxx xxx xxx ACG AGA ACT TCG AAC GCC GGC GTG
xxx xxx xxx xxx xxx xxx xxx xxx Cys Ser STOP
2 3 4 5 6 7 8 9
CAC TCG AGT AAC TAG TTA ACC CCT TGG GGC CTC TAA ACG GGT CTT GAG
GTG AGC TCA TTG ATC AAT TGG GGA ACC CCG GAG ATT TGC CCA GAA CTC
GGG TTT TTT GCT GAA AGG AGG AAC TAT ATG CGC TCA TAC GAT ATG AAC
CCC AAA AAA CGA CTT TCC TCC TTG ATA TAC GCG AGT ATG CTA TAC TTG
GTT GAG ACT GCC GCT GAG TTA TCA GCT GTG AAC GAC ATT CTG GCG TCT
CAA CTC TGA CGG CGA CTC AAT AGT CGA CAC TTG CTC TAA GAC CGC AGA
3’
21697
ATC GGT GAA CCT CCG GTA TCA ACG CGA AGG TGA CGC TAA CGC AGA TGC
TAG CCA CTT GGA GGC CAT AGT TGC
R2 Rev Primer 5’
21748 3’
AGC GAA CGC TCG GCG TAT TCT CAA CAA
xxx = NNK Where N is an equimolar mixture of A, G, C & T
K is an equimolar mixture of G and T
Figure 4.1: Cloning region of theT7Select415-1b vector.
A C G T
A AAG (K)
AAT (N)
ACG (T)
ACT (T)
AGG (R)
AGT (S)
ATG (M)
ATT (I)
C CAG (Q)
CAT (H)
CCG (P)
CCT (P)
CGG (R)
CGT (R)
CTG (L)
CTT (L)
G GAG (E)
GAT (D)
GCG (A)
GCT (A)
GGG (G)
GGT (G)
GTG (V)
GTT (V)
T TAG Stop
TAT (Y)
TCG (S)
TCT (C)
TGG (W)
TGT (C)
TTT (F)
TTG (L)
A R N D C Q E G H I L K M F P S T W Y V
GCG
GCT
AGG
CGG
CGT
AAT GAT TCT
TGT
CAG GAG GGG
GGT
CAT ATT CTG
CTT
TTG
AAG ATG TTT CCG
CCT
AGT
TCG
ACG
ACT
TGG TAT GTG
GTT
Figure 4.2: Illustration of the NN(K/T) strategy used to reduce the number of stop codons present in the degenerate oligonucleotide insert.  The
table shows that only the TAG stop codon is present.  Also shown is a table illustrating the relative frequencies of codons for each amino acid
using this strategy.
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4.3 Determination of initial phage library titer and stability of the
library
In order to calculate the volume of the phage library that was needed to give a large
enough representation of all the clones within the library, it was necessary to
determine the concentration of viable (infectious) phage within the sample.    Clarified
phage lysates are normally stable at 4oC, but a gradual decrease in phage titer is
usually observed [Tighe personal communication].  The change in the concentration
of infectious phage was monitored by conducting a second plaque assay - after the
clarified phage solution was stored at 4oC for two months.  The multiplicity
(theoretical number of indentical, independent phage clones per ml of lysate) of the
phage library was then calculated by using the following formula:-
Multiplicity               =                        Titer of amplified library
(independent clones/ml)               No of independent clones from  initial ligation
reaction
The plaque assays were conducted as described in chapter 3.
1/Dilution factor No Plaques No Plaques
(after 2 months)
106 >200 >200
107 27 15
108 2 0
109 0 0
1010 0 0
Titer (pfu/ml) 2.7 x 109 1.5 x 109
Multiplicity
(independent clones/ml)
19 10
Table 4.1: Results of phage plaque assays.  100µl of each phage dilution were added
to 250µl of E.coli (strain BL21) cells grown to OD600 = 1.0.  3.0 ml of top agarose
was added and the mixture poured onto LB agar plates.  Plaques were counted after
incubation overnight at 37oC.
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Note the reduction in the multiplicity of the library after 2 months of storage at 4oC.
The multiplicity has approximately halved.  To compensate for this the volume of
library screened would have to be doubled to ensure that the number of clones
screened remained consistent.
4.4 Analysis of passive adsorption of proteins on the surface of
NUNC immunotubes by ELISA method
An ELISA was performed to evaluate the adsorption of the two antibodies onto the
surface of NUNC immunotubes (using the protocol described in Chapter 3).  A 2.5-ml
volume of the serially diluted protein was dispensed (in triplicate) into the
immunotubes, which were then incubated at 37oC for 3 hours.  The two antibodies
were probed with Horseradish peroxidase conjugated rabbit-anti-mouse antibody.
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Figure 4.3: Passive adsorption of monoclonal antibody 4155 onto the surface of
NUNC immunotubes.  The antibody was diluted in PBS.  Rabbit anti-mouse
horseradish peroxidase conjugated antibody was used at a 1/1000 dilution.  ABTS
was used as the revealing substrate.
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Figure 4.4: Passive adsorption of mAb C595 onto the surface of NUNC
immunotubes. The antibody was diluted in PBS.  Rabbit anti-mouse horseradish
peroxidase conjugated antibody was used at a 1/1000 dilution.  ABTS was used as the
revealing substrate.
These results demonstrate the C595 and 4155 monoclonal antibodies are both
adsorbed at equivalent levels onto the NUNC immunotubes.
4.5 Removal of non-specifically binding phage.
In order to reduce the number of phage displaying peptides that bound non-
specifically to the adsorbed protein, an initial screen was conducted in which an
“irrelevant protein” was adsorbed to the immunotube.  After amplification, the eluted
phages were then used in the first round of biopanning against the desired target
molecule.
For the screen against mAb 4155, mAb C595 was used as the irrelevant protein;
likewise for the screen against mAb C595, mAb 4155 was used as the irrelevant
protein.
After each screen of the phage against the respective proteins, the titer of the eluted
phage was determined using the plaque assay described in chapter 4.
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Titration of phage eluate
MAb 4155 @ 10µg/ml mAb C595 @ 10µg/ml
2.1 x 105 pfu/ml 7.1 x 105 pfu/ml
Table 4.2: Titer of eluted phage from prescreen to remove non-specifically binding
phage.
4.6 Biopanning - Screening of library against 4155 mAb
Previous work has been published in which 4155 mAb was screened using a
filamentous phage display library displaying a library of random nonapeptides, each
peptide flanked with two cysteine residues in order to promote disulphide bond
formation resulting in constrained peptides (Murray, et al. 2001).  Here the same
antibody was used to screen the T7 phage displaying a cysteine constrained random
nonapeptide library.  The T7 phage differs in the presentation of peptides to that
observed with the filamentous phage used in the previous study (Murray, et al. 2001)
T7 phage lysate with an initial titer of 3.98 x 1010 pfu/ml was used in the screen.
4.6.1 Determination of the extent of enrichment that can be observed
Five rounds of enrichment were conducted, using the protocol described in chapter 3.
The titer of the eluted phage was measured by plaque assay, as described in chapter 3.
The results are presented in table 4.3.
Biopanning
round
[viable phage] in eluate
(pfu/ml)
φ1 2.6 x 105
φ2 5.8 x 105
φ3 2.4 x 104
φ4 3.7 x 105
φ5 5.0 x 105
Table 4.3: Results from the screening of Ab4155 (passively adsorbed to NUNC
immunotubes) with the phage library.
Chapter 4 - Results.  Phage Display of Peptides.
101
These results show that no significant level of enrichment of the phage titer occcurred
over the five successive rounds of biopanning.  The level of phage titer remained
constant at around 105 pfu/ml.  The biopanning (affinity selection) process did not
selectively enrich any phage clones displaying peptides which exhibited an increased
affinity for the antibody.
4.7 Screening of library against C595 mAb
A library consisting of single random hexapeptides encoded by, and expressed on the
surface of filamentous bacteriophage has previously been used to examine the fine
specificity of the C595 mAb (Laing, et al. 1995).  In this library the displayed peptide
was expressed as part of the gene III (pIII) protein.  The peptide was limited in
expression to approximately five molecules per virion.  The peptide was also non-
constrained.
In these experiments C595 mAb was screened using the T7 library displaying the
constrained nonapeptide library.  Approximately 415 copies of the peptide are
displayed on the virion.  First an experiment was conducted to see if any enrichment
of the phage library could be observed over five rounds of biopanning.
4.7.1 Determination of the extent of enrichment that can be observed
The results presented in table 4.5 and figure 4.6 show that a significant increase in the
titer of the eluted phage has occurred during the first four rounds of biopanning.  The
titer of the eluted phage declined slightly in the 5th round of biopanning.
Biopanning
round
[viable phage] in eluate
(pfu/ml)
φ1 4.2 x 104
φ2 6.0 x 105
φ3 1.1 x 106
φ4 2.2 x 107
φ5 1.7 x 107
Table 4.5: Results investigation into enrichment of phage.  Initial phage titer = 1.5 x
109 pfu/ml.
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Figure 4.6:  Graph illustrating the extent of enrichment observed over the five rounds
of biopanning.
Comparing these results to those obtained in section 4.6.1, it is clear that enrichment
of the phage library  is occurring in the first four rounds of biopanning.
4.7.2 Capture ELISA of phage populations from biopanning rounds
An ELISA was performed to confirm the results of the plaque assay conducted on the
amplified eluate from each round of biopanning (i.e that phage were being selectively
enriched for their ability to bind to mAb C595).  Antibody C595 was passively
adsorbed onto the wells of a microtitre plate, and used to capture phage from the
amplified phage lysate.  After washing captured phage were then probed with
bioinylated C595. antibody, utilising an avidin-horseradish peroxidase conjugate to
reveal the sandwiched phage particles (as described in chapter 3).
The results are presented in figure 4.4.  The amplified phage populations from rounds
1,2,3 and 4 gave positive signals on the ELISA.  The amplified phage population
lacking the degenerate insert and the naïve (unenriched) library were not able to form
a sandwich between the adsorbed antibody and the biotinylated antibody.
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Figure 4.4: Results of capture ELISA read at 405nm.  φ1 - φ4 are the amplified phage
populations from biopanning rounds 1 – 4 respectively.  (A) is the amplified phage
population lacking the degenerate oligonucleotide coding for the peptide library; and
(B) is the amplified naïve parent library.
This assay ascertained that the ELISA could be used to discriminate between binding
and non-binding phage particles.  The results of ELISA did not reflect the increase in
phage titer after each round of biopanning as seen from the plaque assay.  One
possible explanation for this is that the levels of phage used in the ELISA were
saturating the available binding sites of the adsorbed antibody.  The ELISA was
repeated with a serial dilution of the amplified phage lysate from each round of
biopanning.  The results from this experiment are presented in figure 4.5.
These results show that there is a large difference in the signal between the first three
rounds of biopanning, but there is an overlap in the signal between the third and
fourth rounds.  This result was not observed with the plaque assay, where the phage
titer was seen to reach a maximum in the fourth round of biopanning.  The ELISA
measures only the net binding ability of the phage particles from each respective
round of biopanning.  The plaque assay (by nature of the selection process used) also
measures the net binding ability of the phage particles in each round of biopanning;
but one must also take into account the selective growth pressures that may occur
during each round of phage propagation.  In each round of phage binding and
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propagation, not only are the best binders being selected for, but also the fittest phage
are being selected. Certain peptides displayed on the capsid head of the bacteriophage
may confer a specific growth advantage to a particular phage clone.  These phage
particles will also undergo enrichment at each round of propagation
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Figure 4.5: Titration of amplified phage from rounds 1 to 4 of biopanning.  Dotted
vertical line used as a reference point to compare the binding of the phage at a single
dilution.
4.7.3 Capture ELISA of phage clones from rounds one and four of screening.
Individual phage clones were isolated from the eluate of rounds one and four of the
biopanning.  The phage capture ELISA (as described in section 4.7.2.) was used to
compare the spectrum of reactivity of the clones sampled in round one with those
sampled from round four.  The results from rounds one and four are presented in
figures 4.6 and 4.7 respectively. Phage clones from round four display a more
prounounced activity in the assay (see figure 4.7); compared to a more even
ditrubution of activity (overall majority Vmax < 100 mOD/min) in the clones sampled
from round one of biopanning (see figure 4.6).
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Figure 4.6: Phage-capture ELISA of amplified clones (1) to (22) from the first round
of biopanning.  (A is phage lacking the degenerate oligonucleotide insert; B is no
phage)
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Figure 4.7: Phage-capture ELISA of randomly chosen amplified phage clones from
fourth round of biopanning.  A is phage lacking the degenerate oligonucleotide insert;
B is PBS only.
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It was decided that since the phage concentrations had not been normalised for each
clone, it would be misleading to try and associate binding ability in the capture assay
of individual clones with a particular sequence.  The purpose of the figure is to
demonstrate that enrichment of specific clones has occurred, compared to the naïve
library and the vector containing no degenerate insert.  Normalising for protein
concentration was attempted by determining protein concentration for each clone, but
this proved unsuccessful.  Another approach would be to conduct a plaque assay for
each clone, and normalise the assay by using the same concentration of phage for all
of the samples.  This is not a trivial task for a large number of clones, and was not
feasible in the time allocated for this work.
4.8 SPR analysis of selected phage clones
To add evidence to the ELISA data which demonstrated that phage clones were
capable of binding in a sandwich assay to mAb C595, surface plasmon resonsance
(SPR) analysis (using a BIAcore 2000 instrument) was conducted.  The aim of this
experiment was to demonstrate, in real time, a specific binding event occuring
between a phage particle displaying a peptide sequence containing an RXXP peptide
motif, and mAb C595.  Ethanolamine, mAb C595, mAb HMFG1, and anti- M13
antibody, were all immobilised using NHS/EDC coupling chemistry on the four
flowcells of a BIAcore sensor chip (As described in chapter 3).  The ethanolamine
was to be used as a measure of the background level for binding to the sensor surface.
The anti-M13 mAb was used as a control for non-specific binding of the phage
species to antibodies.  Figure 4.8 illustrates the immobilisation of the species in the
respective flowcells of the BIAcore 2000 instrument.
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Figure 4.8: Covalent linking of ethanolamine (pH 8.0) and three antibodies to the
channels of a carboxymethyl-dextran coated sensor chip using NHS-EDC coupling
chemistry.
The peptide APDTRAAPG was used to demonstrate the specific binding of the
RXXP motif to immobilised mAb C595.  The peptide is derived from the mucin
epitope peptide APDTRPAPG, with the 6th residue substituted with alanine.  Figure
4.9 illustrates the specific binding of the BSA-peptide conjugate, using peptide
APDTPAAPG.  Note the very low level of non-specific binding observed for the
anti-M13 antibody.  The background level of binding to the flowcell in which
ethanolamine was immobilised, was subtracted from each of the traces.  The level of
binding to mAb C595 was approximately 10x the level observed for the anti-M13
mAb.
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Figure 4.9: Binding of BSA-APDTRAAPG to C595 antibody covalently linked to
the surface of a biosensor chip (50µg/ml in acetate buffer pH 4.0), using NHS/EDC
coupling chemistry.  Showing low level of non-specific binding to anti-M13 antibody
linked under identical conditions.
Figure 4.10 illustrates the binding of a phage clone isolated from the fourth round in
the preliminary biopanning experiment.  The clone used was clone 4, displaying the
peptide YRTAPK form the initial biopanning experiment.  This clone was chosen
because of its simplicity, containing the RXXP motif flanked on either side by single
amino acid residues.  Here the HMFG1 mAb was used as a control for non-specific
binding, since this binds to the PDTR region of the mucin epitope peptide
APDTRPAPG.  Note the much slower on-rate and much slower off-rate compared to
the binding of the BSA – peptide conjugate presented in figure 4.9.
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Figure 4.10: Binding of phage clone YRTAPK and naïve phage library to C595
antibody covalently linked to the surface of a CMD sensor chip.  Antibody HMFG1
was used as a control.
The  size of the phage particles compared to the size of the BSA-peptide conjugate is
the most likely factor influencing the dramatic decrease in the observed on-rate.  The
polyvalency of the phage, meaning that rebinding is highly probable is one possible
explanation for the much-reduced off-rate.
4.9 PCR analysis of phage clones from round four of initial screen
Two primers (R1FOR  5’GCT AAG GAC AAC GTT ATC GGC CTG TTC ATG C3’
and R2REV  5’CGT TGA TAC CGG AGG TTC ACC GAT AGA CGC C3’) were
designed to allow PCR amplification of the region surrounding the degenerate
oligonucleotide insert.  A third primer was designed to anneal inside this PCR
amplification product  (SEQFOR 5’GGT ACT GTT AAG CTG CGT GAC TTG GC3’)
to enable direct sequencing of the PCR product (see fig. 1).  PCR reactions were
conducted as described in Chapter 3. Agarose gel electrophoresis was used to analyse
the PCR products to ascertain that only a single PCR product of the expected size was
present before sequencing.  An example of the analysis of the PCR products is
presented in figure 4.11.
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Figure 4.11: Agarose gels showing the results of a PCR conducted on 24 individual
phage clones recovered from the fourth round of biopanning, using primers R1 and
R2.
A positive band of 480 b.p. in size was expected from the PCR (see figure 4.1).
Figure 4.11 shows that all of the phage clones tested contain an insert in the region of
300 - 500 b.p. in size.  The last well in the gels contained a -ve control consisting of
PCR primers only, with no template present.  This indicated that all of the clones
sampled contained a degenerate oligonucleotide insert.
4.10 Sequencing of phage clones
Direct sequencing of the PCR products was conducted - as described in Chapter 3.
This enabled the elimination of any clones not containing an insert from the
sequencing reaction.  Two preliminary experiments in which only the fourth round of
phage were sequenced were first conducted.
4.10.1 Sequencing of clones from the fourth round of biopanning.
Table 4.7 illustrates the results of the first sequencing reactions conducted on the
fourth round of biopanning.  It can be ssen that two sets of consensus sequences
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emerged.  The first set of consensus sequences consisted of a set of RXXP motifs.
This motif was observed in the previous study using filamentous phage displaying
non-contrained hexa-peptides (Laing, et al. 1995), and has been observed in solid
phase peptide studies (Murray, et al. 2000).  The second set of consensus sequences
consisting of a set of RXP motifs had not been identified in any previous studies.
None of the sequences selected contained the full nine residues, or both of the
flanking cysteine residues.  Analysis of the sequence of the degenerate
oligonucleotide insert shows that the absence of the 5' cysteine residue in seven of the
sequences can be accounted for by five T-C transitions, one G-A transition and one
G-C transversion.  The absence of the 3' cysteine residue in 13/13 of the sequences is
the result of the TAG stop codon.  As illustrated in figure 4.2, this is the only stop
codon present in the NN(K/T) synthesis strategy.
The experiment was repeated, and the results of the sequence anlaysis are presented in
table 4.8.  The presence of the RXXP and RXP sequences is confirmed by the second
set of sequence analysis.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
1 RHAPRS CGC CAT GCG CCT CGG TCG TAG AGG GGT CTT GCT CTT GAA
2         CLRSSPNPR TGC TTA CGT AGT AGT CCT AAT CCT CGG TAG TGC TCT TGA
3     RGGRPVPSA CGC GGT GGT CGG CCT GTG CCG TCG GCG TAG TGC TCTTGA
4           YRTAPK TAC CGT ACG GCT CCG AAG TAG AGG GAG TTT GCT CTT GAA
5            SRPNPRQ TCC CGT CCG AAT CCG CGG CAG TAG CTG GAT TGC TCT TGA
6 CNSSVRKPV TGC AAT AGT TCG GTG CGG AAG CCG GTG TAG TGC TCT TGA
7       CSSRKPASL TGC AGT AGT CGG AAG CCT GCT AGT CTG TAG TGC TCT TGA
8              RGPGR CGC GGT CCA GGT CGG TAG CTT TGG GTT ATG TGC TCT TGA
9    CRSQRSPA TGC CGG TCT CAG CGT TCG CCT GCT TAG GAG TGC TCT TGA
10              RQPAR CGC CAG CCG GCG CGG TAG AGC TTT TAT AAT TGC TCT TGA
12 CNSSVRKPV TGC AAT AGT TCG GTG CGG AAG CCG GTG TAG  TGC TCT TGA
11 RYDHRSSK CGC TAT GAT CAT AGG TCT TCG AAG TAG GCG TGC TCT TGA
18 CATRGVAGR TGC GCT ACG CGT GGT GTT GCG GGG CGT TAG TGC TCT TGA
Table 4.7: Summary of results from round 4 of initial biopanning experiment.
Sequence data and displayed peptides for 13 randomly chosen phage clones.  The
sequencing data is arranged in three groups: the first group consisting of clones
displaying sequences containing the RXXP motif, the second group consisting of
sequences containing the RXP motif, and the third group displaying no consensus
motif.  Underlined nucleotide residues represent constant regions in the degenerate
oligonucleotide insert.  Individual residues in bold highlight mutations of the
nucleotides in the constant regions of the degenerate insert.  The stop codons (amber
TAG stop codon encoded in the degenerate library and opal stop codon TGA in the 3’
terminal constant region) are highlighted in italics.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
2          CRPAPQRLAKCS TGC CGT CCT GCT CCG CAG CGG TTG GCT AAG TGC TCT TGA
8       CARDKP TGC GCG AGG GAT AAG CCT TAG CGG AAG TGG TGC TCT TGA
17 CGRDRKAP TGC GGT CGG GAT CGG AAG GCT CCT TAG GGT TGC TCT TGA
20    CATRAIPTRDCS TGC GCG ACG CGG GCG ATT CCG ACG CGT GAT TGC TCT TGA
5 CDAKRRSPPVCS TGC GAT GCT AAG CGT AGG TCT CCG CCG GTG TGC TCT TGA
5 CDAKRRSPPVCS See above
6    CVTDRHPGDKCS TGC GTT ACT GAT AGG CAT CCG GGG GAT AAG TGC TCT TGA
10          CERGPARREHCS TGC GAG CGT GGG CCG GCG CGG CGG GAG CAT TGC TCT TGA
21     CRVTRLPACVCS TGC CGT GTG ACG AGG CTT CCG GCG TCT GTT TGC TCT TGA
22        STGRLPRM TCC ACG GGT AGG CTG CCT CGT ATG TAG AAG TGC TCT TGA
24         CMRGPESKERCS TGC ATG AGG GGT CCG GAG TCT AAG GAG CGG TGC TCT TGA
11 CLPANGRPAQSS TGC CTG CCT GCT AAT GGG CGG CCG GCG CAG TCC TCT TGA
12 CR TGC AGG TAG CGG GCT CGG ACT GCT CCT CGT GCT CTT  GAA
16 CRR TGC CGG CGT TAG ACG AGG ATT ATG AAG TAT TGC TCT TGA
19 CY TGC TAT TAG CGT CAG AAT AGG CTT ATG AGT TGC TCT TGA
3 C TGC TAG AGT GGG CCT GTT TGT GAG AGT ATG TGC TCT TGA
4 CV TGC GTG TAG TTG TGT GAG GGG TCG CGG AAG TGC TCT GAA
8 CRQGRGGC TGC AGG CAG GGT CGG GGC GGA TGC TGA CTT TTT GCT CTT GA
9 CVSDRRVRSHCS TGC GTT TCG GAT CGT CGG GTT CGT TCC CAT TGC TCT TGA
Table 4.8: Repeat of biopanning experiment.  Sequence and binding data from 18
randomly chosen phage clones from round 4 of biopanning.  See Table 4.6 for
description of table.
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Only one G-C transversion was present at the 5' end of the degenerate insert in the
second set of sequencing data, resulting in the mutation of the flanking cysteine
residue to a serine residue.  One G-C transversion was present at the 3' end of another
sequence, resulting in the mutation of the flanking cysteine residue to a serine residue.
8/19 of the sequences analysed consisted of a nonomer peptide flanked with the two
terminal cysteines. (G-C transversion).  One sequence contained a TGA stop codon,
but the sequence upstream of the stop codon was mutated, containing a 2 b.p.
insertion.  The remainder of the sequences contained TAG stop codons.
4.10.2 Sequence analysis of all four biopanning rounds
To gain more of an insight as to the source of these mutations, a third biopanning
experiment was conducted.  In this experiment, a random sample of individual phage
clones was selected from the eluate of each round of biopanning.  The sequences of
these clones were examined.  The results of the sequencing are presented tables 4.9 -
4.12.
In the first round of biopanning, a sequence containing the RXP motif was obtained
(clone 1).  This sequence contained no mutations at the 5' or 3' ends of the degenerate
insert, or any stop codons in the randomised region and so was flanked by terminal
cysteine residues.  No sequences containing the RXXP motif were obtained.  2/5 of
the sequences contained T-G and T-C transitions at the 5' terminal cysteine codon.  A
portion of the degenerate insert in clone 3 appeared to have been deleted at the 5' end.
The hyphens present in clone 4 represent residues containing an undeterminable
nucleotide (denoted N in the sequence).  No T-A or G-C transversions were observed.
In the sequence anlaysis of the clones obtained from the second round of biopanning,
one sequence containing the RXXP motif was obtained (Clone 1).  This sequence
contained the TAG stop codon prior to the 3' terminal cysteine codon, and so only an
eight-residue peptide was displayed.  All of the other sequences were also free from
any mutations.  Clones 2, 3 and 4 encoded for nine-residue peptides flanked by
terminal cycteine residues, but no consensus motifs could be observed.  The
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remaining clones (5-9) all contained the TAG stop codon prior to the 3' terminal stop
codon.  The peptides encoded varied in length from seven residues down to only the
5' terminal cysteine.  No consensus sequence was observed in these peptides.
In the sequence data from the clones obtained in the third round of biopanning, a
striking consensus sequence consisting of the residues RNREAPRGKICS emerged.
Of the sequences obtained in this round, 17/25 contained mutations in the codon for
the 5' terminal cysteine (compared to only 1/25 containing mutaions at the 3' terminal
cysteine). The mutation of the first cysteine residue to an arginine residue in the
consensus sequence RNREAPRGKICS is the result of a T-C transition.  8/25 of the
sequences consisted of the RNREAPRGICS sequence (clones 1-8).  2/25 sequences
(clones 9 and 10) contained the RXXP motif.  These contained mutations in the
codon for the 5' cysteine residue (T-C transition, and what appears to be the deletion
of a codon for clone 9; and a G-T transision in clone 10).  2/25 sequences (clones 11
and 12) contained the RXP motif.  Both of these clones were mutation free, and so the
flanking cysteine residues were present.  The remaining 13 sequences contained four
which were mutation free (clones 18, 20, 22 and 23), four clones appeared to have
portions of the degenerate insert deleted (clones 13-16).  The remainder consisted of a
G-C transversion (clone 17), a T-A transversion and a base deletion (clone 25).  Clone
24 contained a number of undeterminable nucleotides.
The frequency at which the RNREAPRGKICS peptide was detected dropped from
8/25 clones in the third round of biopanning, to 5/42 in the fourth round.  (Clone 5
contained a single undetermined nucleotide in the first amino acid residue; it is highly
probable that the undetermined nucleotide is Guanine, resulting in a CGC codon -
coding for arginine.  This can be asserted since the remaining 11 residues are identical
to those in clones 1-4).   Of the sequences obtained for the clones sampled in the
fourth round of biopanning, 7/42 contained mutations in the codon for the 5' flanking
cysteine residue; and 1/42 contained a mutation in the codon for the 3' flanking
cysteine residue.  The RXXP motif was present in 3/42 of the clones (clones 6-8)
sequenced in the fourth round of biopanning. The RXXP motif in all three of these
clones took the form RXAP.  Clone 6 contained the RPAP motif - the simple linear
peptide motif which is present in the mucin core variable number of tandem repeat
sequence (VNTR) PDTRPAPGSTAPPAHGVTSA (Gendler, et al. 1988), to which
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mAb C595 has been shown to bind(Price, et al. 1990).  Clone 7 contained a single G-
C transversion in the 5' terminal cyteine residue.  The RXP motif was present in 4/42
of the clones (clones 9-12).  Clones 10 and 11 were mutation free, but clones 9 and 12
contained T-C transitions in the codon for the 5' flanking cysteine residue.  Clone 13
consisted of a 9-mer peptide containing an RP motif.  Such a motif was also observed
in the second biopanning experiment (see table 4.8 - clone 11).  This sequence was
free of mutations and so was flanked by terminal cysteine residues.  Clones 14-17 and
20-22 all contained 9-mer peptides which were mutation free.  No consensus
sequence could be identified in these clones.  Clone 23 was also mutation free at the
terminal cysteine residues, but contained a number of undeterminable nucleotides.
Clone 18 contained a G-A transistion in the codon for the 5' terminal cysteine.  The
majority of the remaining peptides were mutation free, with the exceptions of clones
26 and 29 which contained mutations (T-C transitions) in the 5' and 3' terminal
cysteine residues respectively.  Notebly the 5' teminal cysteine residue in clone 42
contained a C-A transition and so encoded for the TGA stop codon.
A summary of the frequency and location of the mutations observed in each of the
four rounds of biopanning is presented in table 4.13.  Note that the vast majority of
the mutations that occur in the constant flanking cysteine residues, do so at the 5’
cysteine residue.  This cysteine is the one closest to the phage capsid proteins.  This
may have a bearing on the increased frequencey of mutations seen at this residue.
Peptide residues closest to the capsid proteins are likely to have the greatest influence
on the capsid protein rather than the 3’ terminal residues.  It is also interesting to note
that the frequency of these mutations in the codon of the 5’ cysteine residue peaks in
the third round and reduces in the fourth round.  This is coincidental with the
emergence of the RNREAPRGKICS peptide in the third round followed by a decline
in frequency at which this peptide was observed the fourth biopanning round.  This is
also coincidental with the peak of the phage capture ELISA signal after the third
round of biopanning (see figure 4.5).  It is important to note that this peptide does not
account for all of these mutations (8/25 different clones displayed the
RNREAPRGKICS peptide in round three of the biopanning, and 5/42 different
clones in round four).  Compare this to 17/25 and 8/42 clones respectively containing
mutations at the 5’ terminal cysteine residue.  These figures suggest that residues
close to the capsid head proteins are most vulnerable to mutation.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
1 CERGPGKSRSCS TGC GAG AGG GGT CCT GGG AAG TCG AGG TCT TGC TCT TGA
2 CGNRVSKAPK-S TGC GGG AAT CGT GTG AGT AAG GCA CCT AAG NGC TCT TGA
3 GRKVKCS GGG CGG AAG GTG AAG TGC TCT TGA
4 R-AA-MEKP-S CGC CNT GCG GCG GNT CNG ATG GAG AAA CCG NGC TCT TGA
5 RRAAVRMEKPCS CGC CGT GCG GCG GTT CGG ATG GAG AAG CCG TGC TCT TGA
Table 4.9: Round one biopanning sequence results.
Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
1 CSRVAPNRK TGC TCG AGG GTG GCT CCG AAT AGG AAG TAG TGC TCT -GA
2 CVKRTASGSGCS TGC GTT AAG CGT ACG GCT AGT GGT TCT GGT TGC TCT TGA
3 CSMRASGGPKCS TGC TCG ATG CGT GCG TCT GGG GGG CCG AAG TGC TCT TGA
4 CTVPVRPQQKCS TGC ACT GTT CCG GTG AGG CCG CAG CAG AAG TGC TCT TGA
5 CPATTHLG TGC CCT GCT ACT ACG CAT TTG GGG TAG ATG TGC TCT TGA
6 CHLAGT TGC CAT CTT GCG GGT ACT TAG TGG GTT CAG TGC TCT TGA
7 CEE TGC GAG GAG TAG CAT CTG CTG CCG GAT TCG TGC TCT TGA
8 C TGC TAG CAG TTT AAT TCT ACG TCT ACT AAG TGC TCT TGA
9 C TGC TAG TAT TGT TAG CTT AAT GCG CTT TTT TGC TCT TGA
Table 4.10: Round two biopanning sequence results.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
1 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
2 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
3 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
4 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
5 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
6 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
7 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
8 RNREAPRGKIC- CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
9     RRPPMTTASCS CGC CGG CCG CCT ATG ACG ACT GCG TCG TGC TCT TGA
10 FERIAPKGGNCS TTC GAG CGG ATT GCT CCG AAG GGT GGG AAT TGC TCT TGA
11 CSRGPAGRTVCS TGC TCT CGT GGG CCG GCT GGG CGG ACG GTG TGC TCT TGA
12   CRAPAGSKKMCS TGC AGG GCG CCG GCG GGG TCG AAG AAG ATG TGC TCT TGA
13 GKRMGVTRCS GGT AAG CGG ATG GGT GTG ACG CGT TGC TCT TGA
14 GKRMGVTRCS GGT AAG CGG ATG GGT GTG ACG CGT TGC TCT TGA
15 GRKVKCS GGG CGG AAG GTG AAG TGC TCT TGA
16 GRKVKCS GGG CGG AAG GTG AAG TGC TCT TGA
17 SLMQRASGRTCS TCC CTG ATG CAG AGG GCG AGC GGG CGT ACG TGC TCT TGA
18 CSKKGKNSLSKCS TGC TCT AAG AAG GGG AAT AGT TTG AGT AAG TGC TCT TGA
19 SAR-ERSKGKCS TCC GCG CGG CAN GAG AGG AGT AAG GGG AAG TGC TCT TGA
20 CM-S-TANGKCS TGC ATG ANT AGT ANG ACT GCG AAT GGT AAG TGC TCT TGA
21 SSVDKLAAALE AGC TCC GTC GAC AAG CTT GCG GCC GCA CTC GAG TAA
22 CLP-LLHF TGC TTG CCG CCN AAG AAA CAT TTT TAG AAT TGC TCT TGA
23 CVRTKKV TGC GTG CGG ACG AAG AAG GTC TAG ATG CGG TGC TCT TGA
24 C---P—RT-CS TGC TNT CGN GNG CCG NNT NGG CGG ACG GNN TGC TCT TGA
25 CD TGC GAT TAG CGG GCG TTC TTT AGG TGT CTT GCT CTT GAA
Table 4.11: Round three biopanning sequence results.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
1 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
2 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
3 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
4 RNREAPRGKICS CGC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
5 - NREAPRGKICS  CNC AAT CGG GAA GCG CCT AGG GGG AAG ATT TGC TCT TGA
6          CRPAPSAKVACS TGC AGG CCT GCG CCT TCT GCT AAG GTG GCT TGC TCT TGA
7         FERIAPKGGNCS TCC GAG CGG ATT GCT CCG AAG GGT GGG AAT TGC TCT TGA
8   CDSERTAPKSCS TGC GAT AGT GAG AGG ACG GCT CCT AAG TCG TGC TCT TGA
9 RQAGRKPVNNCS CGC CAG GCG GGA CGG AAG CCG GTG AAT AAT TGC TCT TGA
10        CSRGPAGRTVCS TGC TCT CGT GGG CCG GCT GGG CGG ACG GTG TGC TCT TGA
11     CSDRMPCEPSCS TGC AGT GAT CGT ATG CCT TGT GAG CCG AGT TGC TCT TGA
12             RRPSR CGC CGG CCTC AGT CGT TAG ATT GCG AGG CTG TGC TCT TGA
13  CGNSLKSRPDCS TGC GGT AAT TCT CTT AAG TCG CGT CCG GAT TGC TCT TGA
Table 4.12: Results from round four of biopanning.  This table shows the four groups
of consensus sequences isolated.
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Clone Displayed peptide 5’   Nucleotide sequence of degenerate insert   3’
14 CGNGRGERDTCS TGC GGG AAT GGG AGG GGT GAG CGG GAT ACG TGC TCT TGA
15 CGAEIKTGARCS TGC GGT GCG GAG ATT AAG ACT GGT GCC CGG TGC TCT TGA
16 CSNKYTTKSQCS TGC TCT AAT AAG TAT ACT ACG AAG TCT CAG TGC TCT TGA
17 CGNRVSKAPKCS TGC GGG AAT CGT GTG AGT AAG GCA CCT AAG TGC TCT TGA
18 YGRMSKATGSCS TAC GGG AGG ATG TCG AAG GCG ACG GGG TCG TGC TCT TGA
19 AGVKQLKRACS GCC GGC GTG AAG CAG CTT AAG CGG GCG TGC TCT TGA
20 CYEANKASKACS TGC TAT GAG GCG AAT AAG GCG TCT AAG GCG TGC TCT TGA
21 CVSSGAKRQCS TGC GTT TCT TCG GGG GCG AAG GCG AGG CAG TGC TCT TGA
22 CPSNRSSQEDCS TGC CCT TCT AAT CGG AGT TCT CAG GAG GAT TGC TCT TGA
23 CAKRGM-R-ICS TGC GCG AAG CGT GGT ATG TAN CGT NCT ATT TGC TCT TGA
24 CGLACG TGC GGT CTG GCG TGT GGG TAG ACT GCG CTT TGC TCT TGA
25 CGRT-EP TGC GGG AGG ACG TAN GAG CCT TAG CAT ATT TGC TCT TGA
26 RN-GSA CGC AAT CNG GGA AGC GCC TAG GGG GAA GAT TTG CTC TTG….
27 CVEA TGC GTG GAG GCT TAG TAG TAT ATG ATT TAG TGC TCT TGA
28 CVEA TGC GTG GAG GCT TAG TAG TAT ATG ATT TAG TGC TCT TGA
29 CVE- TGC GTG GAG GCN TAG TAG CAT ATG ATT TAC CGC NCT TGA
30 CVRS TGC GTG CGG TCT TAG CTT GTT CTG TCT ATG TGC TCT AGA
31 CRTR TGC CGT ACT CGG TAG GCG GAG CGG AGG CCG TGC TCT TGA
32 CISPA TGC ATT TCG CCT GCT TAG GGG TGG CAG TTT TGC TCT TGA
33 CRD TGC CGG GAT TAG CAT TCT GCG TAT AAT TTG TGC TCT TGA
34 CRS TGC CGG AGT TAG GCT ACG TAG CGT AGT CAT TGC TCT NGA
35 CEE TGC GAG GAG TAG CAT CTG CTG CCG GAT TGC TCT TGA
36 CA TGC GCG TAG CAG CGT TCT TTG AAT CTT CAG TGC TCT TGA
37 CS TGC TCT TAA ATT CGG CTG TAG AAG CGT GCT TGC TCT TGA
38 CS TGC AGT TAG CAG AGT CCG CTG ACG GGT GCT TGC TCT TGA
39 CV TGC GTT TAG TGG GAT ATG AGG CCG TCT TGT GCT CTT ……
40 CV TGC GTT TAG TGG GAT ATG AGG CCG TCT TGT GCT CTT GA
41 C TGC TAG GCT GAC GTA GTG GAC TGA TCG TTG CTC TTG AA
42 No peptide displayed TGA CGG CAG GTT ATT ATT TGT AGG CAG TCT TGC TCT TGA
Table 4.12 continued: Results from round four of biopanning showing sequences
from this round of biopanning that did not fall into any of these consensus sequences.
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Biopanning round 5' Cysteine mutations 3' Cysteine mutations
Round 1 2/5 0/5
Round 2 0/5 0/5
Round 3 17/25 1/25
Round 4 8/42 1/42
Table 4.13: Summary of the mutation frequency observed at the 5' and 3' flanking
cysteine residues through all four rounds of biopanning.
4.11 Summary
Phage display was used to discover novel peptide sequences that bind to the
therapeutic monoclonal antibody C595.  A number of biopanning experiments were
conducted using the anti-MUC1 mAb C595 and the anti-steroid hormone mAb 4155
as the target receptor.  No enrichment of titer of eluted phage was observed when
mAb 4155 was used as the target receptor.  A 500-fold level of enrichment was
observed when mAb C595 was used as the target receptor.
Analysis of phage populations from each of the four rounds of biopanning revealed
that affinity-based enrichment was occuring, with eluted phage recovered from each
round producing a much larger signal in a phage capture ELISA compared with naïve
library and bacteriophage with no degenerate oligonucleotide insert.  Using Surface
Plasmon Resonance (SPR), the real-time binding of a phage clone displaying the
RXXP motif, to immobilised mAb C595 was demonstrated.
Sequence analysis of phage clones revealed the emergence of two novel consensus
motifs: RXXP and RXP.  A possible third consensus motif of RP also emerged, but
the two clones displaying peptides containing this motif were from separate
experiments.  A predominant peptide sequence of RNREAPRGKICS emerged in
one experiment, with highest frequency in the third round of biopanning, reducing in
the fourth round of biopanning.  Sequence analysis of the phage clones from all
rounds of biopanning, also revealed the extent of mutation occuring in the constant
regions flanking the degenerate oligonucleotide insert.  The majority of mutations
were found to have occurred in the third round of biopanning, at the 5’ flanking
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cysteine residue.  This residue is closest to the capsid head of the phage particle.  Only
two mutations were detected at the 3’ terminal cysteine residue.
The peak of mutation frequency at the 5’ terminal cysteine residue was coincidental
with the emergence of the RNREAPRGKICS peptide sequence displayed on the
selected phage in round 3.  The phage capture ELISA also demonstrated a peak at the
third round of biopanning.
From these experiments, it could not be determined whether the RNREAPRGKICS
peptide was purely the result of affinity selection.  As the first cysteine residue was
mutated to arginine the clone could be the result of selection for growth advantage,
rather than binding ability.
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5 Chapter 5 - Results.  Analysis of peptides derived from phage
display.
5.1 Introduction
The presence of the peptide RNREAPRGKICS which emerged as the predominant
sequence at the peak of phage enrichment in the last chapter merited further study.
The fully conserved nature of all the residues in this peptide (compared to the residues
flanking the RXXP and RXP consensus sequences) was striking.  From the
experiments conducted in chapter 4, it could not be determined whether the
RNREAPRGKICS peptide was selected for affinity, or whether the mutation of the
5’ terminal cysteine had conferred a growth advantage to this particular phage clone.
This chapter describes the experiments that were conducted to try and answer this
question.
In this chapter a comparison of affinity constants and structual content is made
between the phage derived peptide RNREAPRGKICS and the MUC1 derived mucin
core peptide APDTRPAPG (containing the native epitope RPAP).  Two control
peptides were also used: APDTRPEAPG (used as a control peptide for a possible
REAP mimotope) and APDTRPAPGC (used as a control for potential peptide
dimerisation).
Standard ELISA techniques were first used to establish the relative antigenicity of the
phage-derived peptide, compared to the mucin core peptide.
A sepharose bead assay was then conducted to determine if the phage derived peptide
would function as an affinity ligand, and to establish the relative antigenicity
compared to the mucin core peptide in this different environment.  Peptide affinity
chromatography was then used to examine the point at which any retained antibody
eluted along a gradient elution profile.  It has been postulated that gradient elution
using a chaotropic agent can be used as a means of confirming relative affinities from
fluorescence quenching (Murray, et al. 1998).
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Fluorescence quenching immunoassay was then used to test the above hypothesis
with regard to the phage derived peptide and mucin core peptide.
Conformational analysis was then conducted on the peptides APDTRPAPG,
APDTREAPG and RNREAPRGKICS using circular dichroism techniques.
Previous studies have demonstrated that the synthetic peptide representing the natural
antigen of C595 (APDTRPAPG) exists in a PII helical conformation, and that this
conformation is stabilised in cryogenic studies and with increased glycosylation
(Murray, et al. 1998),(Spencer, et al. 1999).
Surface Plasmon Resonance (SPR) was then used to conduct an in-depth analysis of
the kinetic parameters involved in the interaction between mAb C595 and the mucin
core peptide APDTRPAPG immobilised onto the surface of a biosensor chip.  The
use of SPR enables a more complex analysis of the interaction, since unlike FQ, on
and off rates can be examined, enabling the fitting of more complex models to the
data set.  A comparison will be made between the data obtained in the FQ
experiments with the data obtained in the SPR experiments.
5.2 ELISA of BSA – peptide conjugates
There are a number of examples where peptides derived from phage-display libraries
lose their ability bind to the target antibody when synthesised and are no longer part
of the phage.  Examples include the phage-derived low affinity mimic of a
discontinous epitope of glucoseoxidase (gluox) (Meloen et al. 2000), which only
bound anti-gluox antibody when part of the phage; and the phage-derived mimic of a
steroid hormone (Murray, et al. 2000), which only weakly bound to the anti-steroid
antibody.
In order to ascertain whether the phage derived peptide RNREAPRGKICS could
bind mAb C595 in the absence of phage, the phage-derived peptides, and mucin core
peptide were conjugated to BSA using the method described in chapter 3.  The BSA-
peptide conjugates were then serially diluted, and the ability of mAb C595 to bind to
the conjugates was determined using a standard ELISA as described in chapter 3.
Figure 5.1 shows the results of this ELISA.  The phage-derived peptide
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(RNREAPRGKICS) formed an insoluble pink precipitate when conjugated to BSA.
The precipitate is probably the result of conjugation through N-terminus amine and
the amine side-chain of lysine.  From the data presented in figure 5.1, it appears that
the precipitation observed in the conjugation reaction has resulted in less of the
peptide RNREAPRGKICS (in the form of the BSA conjugate) binding to the
microtitre plate – compared to the BSA conjugate containing the mucin epitope
peptide (APDTRPAPG).
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Figure 5.1: ELISA of BSA – peptide conjugates dried down onto the wells of a
microtire plate at various concentrations.
As a result of the precipitation observed during the synthesis of the BSA –
RNREAPRGKICS peptide conjugate, it is not possible to make a direct comparison
between the two peptides using this method.
5.3 Sepharose bead assay
The phage-derived peptide RNREAPRGKICS and the mucin core peptide
APDTRPAPG were coupled to cyanogen bromide activated Sepharose 4B as
described in chapter 3. A sepharose bead assay was conducted as described in chapter
3.  A control assay was run in parallel, to establish the level of binding of the marker
antibody to the peptides linked to the beads.  In the control assay, only marker
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antibody (rabbit anti-mouse IgG peroxidase conjugate) was added to the beads.  The
results are presents in figure 5.2.
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Figure 5.2: Sepharose bead assay comparing the mucin core peptide (APDTRPAPG)
with the phage derived peptide (RNREAPRGKICS).
From the results presented in figure 5.2, it appears that the average level of binding of
mAb C595 to the phage-derived peptide is greater than the level of binding observed
for the mucin core peptide.  These results indicate that the phage clones displaying the
RNREAPRGKICS peptide may have been selected on the basis of affinity.
However it is not possible to conclude whether phage displaying the
RNREAPRGKICS clone emerged as a result of affinity selection, or selection as a
result of growth advantage conferred to the phage clones by displaying this peptide.
These results demonstrate that the phage derived peptide is able to bind mAb C595 in
the absence of the phage.
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5.4 Peptide Affinity Purification of antibody from solution
The use of immobilised ligands to analyse macromolecular interactions, particularly
using analytical affinity chromatography techniques has been much documented
(Chaiken, et al. 1992; Chaiken, et al. 1996).  Here the technique will be used to
compare the properties of peptide affinity matrices prepared using the phage derived
peptide and the mucin core peptide.  Peptide affinity matrices were also prepared
using the APDTRPAPGC and APDTREAPG control peptides.  The relative
performance of the phage-derived and mucin core epitope peptide matrices will also
be assessed by their abilities to purify antibody from hybridoma feedstock.
5.4.1 Peptide Affinity Purification using the phage derived peptide and the
mucin core peptide.
The phage-derived peptide RNREAPRGKICS was linked to cyanogen-bromide
activated sepharose 4B at a ratio of 1µmole of peptide per ml of swollen gel, as
described in chapter 2.  The mucin core peptide APDTRPAPG was also linked to
sepharose 4B at an equivalent ratio, as were the two control peptides APDTRPAPGC
and APDTREAPG.  Antibody (mAb C595 at 15µg/ml) was loaded onto the
respective columns under standard conditions of sample loading (0.3 ml/min), column
size (2.0 ml swollen gel volume), ligand density (1 µmol/ml gel) and elution (3M
NaSCN).
Figure 5.3 presents the results of the gradient elution of mAb C595 from the
RNREAPRGKICS and APDTRPAPG peptide affinity matrices.  Chromatograms
demonstrating the elution of mAb C595 from the affinity matrices containing the
peptides APDTREAPG and APDTRPAPGC are omitted for clarity.  The elution
profiles from the APDTREAPG and APDTRPAPGC were identical in shape and
size to the elution profile of the APDTRPAPG matrix (figure 5.3).  Note the sharp
symmetrical peak for the antibody eluted from the RNREAPRGKICS peptide
matrix.  The maximum of this peak appears before the maximum of the peak for the
elution of antibody from the APDTRPAPG peptide matrix.  The elution of antibody
bound to the RNREAPRGKICS matrix occurs lower down in the gradient elution
than antibody eluted from the APDTRPAPG peptide matrix using 3M NaSCN.
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Eluted fractions were collected and the total mass of protein was determined
spectrophotometrically at 280nm by applying the Beer-Lambert Law (assuming an
extinction coefficient of 14.3 for IgG), for each of the matrices.  These results are
presented in table 5.1.
5.4.2 Purification of C595 antibody from hybridoma supernatant.
To directly compare the mucin core epitope peptide and phage-derived peptide as
peptide affinity ligands, mAb C595 was purified from 100 ml of clarified hybridoma
supernatant (200 ml sample divided into two) using the APDTRPAPG and
RNREAPRGKICS affinty matrices.  Antibody was loaded onto the two columns
under standard conditions (as described in chapter 3), and a step elution of the loaded
antibody was conducted for each of the matrices.  Eluted fractions were collected and
the total mass of protein was determined spectrophotometrically at 280nm by
applying the Beer-Lambert Law for each of the matrices.  The results of this
experiment are presented in figure 5.4 and table 5.1.  There is very little difference
between the two chromatograms for the step elution profile.
From the results of the protein determinations for the two sets of experiments
presented in table 5.1, it can be seen that the amount of antibody recovered from both
the phage-derived affinity matrix and the mucin-derived affinity matrix is almost
identical, recovering 65% of protein.  However, the results showing antibody recovery
from the same sample of hybridoma supernatant are quite different.  Less protein is
recovered when the phage-peptide affinity matrix was used compared to the mucin-
peptide affinity matrix (0.78 and 1.01 mg respectively).
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Figure 5.3:  Gradient elution of the phage and mucin core peptide-Sepharose affinity matrices following column loading with 100 ml C595
antibody at 15µg/ml in PBS.
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Figure 5.4: Step elution of the phage and mucin-core peptide-Sepharose affinity matrices following column loading with 100ml of   clarified
C595 hybridoma supernatant.
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Expt Matrix
(Seph 4B)
Sample type Sample
volume (ml)
Elution method Total Protein (mg) in each
2.5 ml fraction
Total (mg) Mean Vmax
(mOD/min) of F1
F1 F2 F3
1 Mucin
peptide
Ab in PBSA
(15µg ml-1)
100 0-3M Gradient over
20ml of NaSCN
0.35 0.47 0.16 0.98 -
2 Phage
peptide
Ab in PBSA
(15µg ml-1)
100 0-3 M Gradient over
20ml of NaSCN
0.70 0.25 0.04 0.99 -
3 Mucin
peptide
*Hybridoma
supernatant
100 Step to 1M NaSCN 0.85 0.16 - 1.01 15.47
4 Phage
peptide
*Hybridoma
supernatant
100 Step to 1M NaSCN 0.68 0.10 - 0.78 24.45
Table 5.1: Comparison of the performance of the mucin core peptide column (APDTRPAPG) and the phage derived peptide column
(RNREAPRGKICS).
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5.4.2.1 Immunoreactivity of purified antibody
A standard ELISA was conducted on the recovered protein fractions from the phage
and mucin peptide affinity matrices (as described in chapter 3).  BSA-peptide
conjugate (using peptide APDTRPAPG) was adsorbed to the wells of a microtitre
plate.  The level of binding observed for the combined fractions from the elution of
the Phage peptide affinity matrix was compared with the combined fractions from the
elutions of the Mucin peptide affinity matrix.  These were compared with a sample of
the original hybridoma supernatant, prior to circulation around the columns.  The
pass-samples from the phage and mucin peptide columns were also compared in the
assay.  The results are presented in figure 5.5.
0 5 10 15 20 25 30
Phage Peptide
Mucin Peptide
Feedstock
Phage column pass
Mucin column pass
mean Vmax (mOD/min)
0.78 mg
1.01 mg
Figure 5.5: Mass in bars is the protein content of each fraction determined
spectrophotometrically at 280nm by applying the Beer-Lambert Law and assuming an
extinction coefficient for IgG of 14.3
From the results presented in figure 5.5, it appears that even though less total protein
was recovered from the phage-derived peptide affinity matrix, it had a higher specific
activity than the protein recovered from the mucin-core epitope peptide matrix.
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The activity of the antibody eluted from the phage peptide affinity matrix was greater
than that of the antibody eluted from the mucin peptide affinity matrix, as tested by
ELISA (see figure 5.5).
The mucin derived peptide and the phage derived peptide affinity matrices
demonstrated a 6-fold and 9.4-fold concentration of antibody from the clarified
hybridoma supernatant respectively- with respect to the activity of the purified
antibody in ELISA (see figure 5.5).
5.4.2.2 SDS-PAGE analysis of purified antibody.
The purity of the affinity purified antibodies recovered from the hybidoma
supernatant using the phage-derived peptide affinity matrix and the mucin core
peptide affinity matrix was analysed using SDS-PAGE as described in chapter 3.  The
results are presented in figure 5.6.
1    2
50kD
24kD
Figure 5.6: SDS-PAGE gel of purified antibody, conducted using 12.5% w/v
homogeneous acrylamide as described in section 3.4.8. Samples were boiled in
loading buffer containing β-mercaptoethanol for 5 min before gel loading.  Lane 1
contains the antibody recovered from the purification of hybridoma supernatant using
the phage-derived pepitde (RNREAPRGKICS) affinity matrix.  Lane 2 contains the
antibody recovered from the purification of hybridoma supernatant using the mucin-
core peptide (APDTRPAPG) affinity matrix.  50kD and 24 kD represent the
approximate size of the bands corresponding to C595 heavy and light chains
repectively.
Chapter 5 - Results.  Analysis of peptides derived from phage display.
134
As can be seen in the gel in figure 5.6 the purity of the antibody purified using the
phage-derived peptide affinity matrix appears to be identical to the purity of the
antibody purified using the mucin-core peptide affinity matrix.
5.5 Fluorescence Quenching (FQ) analysis of peptides.
The aromatic amino acid residues present in proteins exhibit a natural fluorescence.
The aromatic amino acid tryptophan exhibits the greatest fluorescence, with excitation
and emission maxima at approximately 295nm and 350nm respectively.  The position
of the emission maximum is highly dependent upon the local enviornment of the
trytophan residue (e.g. 320nm for internal residues c.f. 360nm for solvent exposed
residues).  This dependence on the local enviroment of the tryptophan residue can be
used to monitor a specific binding event.  Thus if a tryptophan residue is exposed in
the binding pocket of an antibody, upon binding of a ligand, the intensity of the
emitted radiation will be reduced.  This technique is known as fluorescence
quenching, and can be used to measure the equilibrium association constant for
antibody-ligand interations.  FQ has been successfully used in the past to determine
equilibrium association constants for interactions involving mAb C595 and MUC1
related peptides (Missailidis, et al. 1997; Spencer, et al. 1999).
The interaction of the synthetic peptides APDTRPAPG, APDTRPAPGC,
APDTREAPG, and RNREAPRGKICS with antibody C595 were measured and
expressed as an equilibrium association constant (KA) using the technique of
fluorescence quenching.  Experimental binding curves were obtained by plotting the
changes in fluorescence of the antibody emission versus the antigen concentration at
each titration step (figure 5.7).  The experimental data was then fitted to a
mathematical equation describing the binding (Missailidis, et al. 1997; Spencer, et al.
1999) (see chapter 3), allowing the calculation of the equilibrium association
constants for the above interactions.  The equilibrium association constants for the
peptides are presented in table 5.2.
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Figure 5.7: Binding of the APDTRPAPG, APDTRPAPGC, APDTREAPG and
RNREAPRGKICS peptides to mAb C595.  Changes in the natural fluorescence of
the antibody were plotted versus peptide concentration to calculate the equilibrium
association constants for formation of the antibody-antigen complexes.
Peptide Association constant (M-1)
APDTRPAPG 0.15 x 106
APDTRPAPGC 0.21 x 106
APDTREAPG 0.40 x 106
RNREAPRGKICS 0.75 x 106
Table 5.2: Affinity of C595 antibody for MUC1-related peptides and the phage
derived peptide.  The values shown in the table are calculated from the experimental
data (in triplicate) using the method described in chapter 3.  The precision of these
values = + 0.01 x 106 M.
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The peptides in the study all showed a significant affinity towards the C595 antibody,
as expected from the results of the chromatographic and ELISA studies.  The phage
derived peptide RNREAPRGKICS was shown to have the highest affinity for the
antibody (KA=0.75 x 106 M-1), followed by the substituted peptide APDTREAPG
(KA=0.40 x 106 M-1), the natural antigenic peptide with the cysteine residue at the C-
terminus APDTRPAPGC (KA=0.21 x 106 M-1) and the natural antigenic peptide
APDTRPAPG (KA=0.16 x 106 M-1).
5.6 Circular Dichroism (CD) analysis of peptides.
Circular Dichroism is a spectroscopic technique for analysing the global secondary
conformation of a protein or peptide.  The CD of proteins or peptides is primarily the
CD of the amide chromophore; secondary structure as measured by CD examines
amide-amide interactions.  The technique relies on the difference in the absorption of
left and right circularly polarised light (which varies according to the secondary
structure of the protein and the wavelength of the light).  If a peptide has a secondary
conformation then decreasing the temperature of its solvent will stabilise the
conformation of the solute.  Peptides APDTRPAPG, APDTREAPG, and
RNREAPRGKICS were studied at temperatures of 4 oC and 20 oC.  The results are
shown in figure 5.9.
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The CD spectra of peptides APDTRPAPG, APDTRPAPGC, APDTREAPG and
RNREAPRGKICS at room temperature (Figure 5.9) indicated that the peptides did
not adopt an highly ordered structure, but there was a distinct trend of a preferred left-
handed extended polyproline II helix (PII conformation) (Campbell and Sykes 1993).
All the peptides in the study presented positive bands at 217-225 nm and negative
bands at 195-200 nm.  The presence and intensity of the positive band at 217-225 nm
and the negative band at 195-200 nm confirms the population of a PII conformation
(Dalcol, et al. 1996).  The intensity of the positive band is directly proportional to the
stability of the PII helix.  It has previously been demonstrated that peptide
APDTRPAPG exists in a PII helical conformation, which is stabilised in cryogenic
studies and with increased glycosylation (Murray, et al. 1998), (Spencer, et al. 1999).
All three peptides have demonstrated an increase in the intensity of the positive band
at 217-225 nm with decrease in temperature.
There is a profound correlation between the structural content of the peptides, and
their binding ability.
The C595 antibody has previously been studied by CD and its denaturation with
temperature and pH variation has been reported (Spencer, et al. 1999).  The melting
profile of the C595 antibody was re-evaluated, and the possible stabilising effect of
the binding of peptides containing the natural epitope (APDTRPAPG and
APDRPAPGC) or the phage display derived sequences (RNREAPRGKICS and
APDTREAPG) to the antibodies binding pocket was investigated.  When the
antibody was subjected to thermal denaturation the clear melting profile previously
reported (Spencer, et al. 1999) emerged, with melting transitions at 61 and 68oC.
Addition of the peptides APDTRPAPG, APDRPAPGC, APDTREAPG and
RNREAPRGKICS did not have any stabilising effect on the antibody melting
profile.  This is not unexpected as these short peptides are occupying necessarily only
one binding site.  The binding of a single peptide per binding pocket would not seem
to have any effect on the disulphide bonds stabilising the antibody’s molecular
structure.  The antibody was shown to have two melting transitions as previously
determined (Spencer, et al. 1999), in which case two Tm values were determined
(Tm1, Tm2). Similar, two-melting transitions were obtained from the peptide bound
antibody.
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5.7 Kinetic analysis of the interaction between C595 antibody and
the mucin core peptide APDTRPAPG using surface plasmon
resonance.
Surface Plasmon Resonance (SPR) measurements were conducted using a BIAcore
biosensor.  Its configuration involves the interaction of soluble macromolecules in a
flow cell with ligands (or receptors) immobilised on the dextran coating of a gold
chip.  The interaction is measured directly as an increase in refractive index, a change
directly related to an increase of molecular mass on the chip.
Measurements conducted using an immobilised ligand are more likely to reflect the
affinity constants observed in an affinity chromatography situation, than
measurements taken in free solution in the FQ assay.
The purpose of these experiments was to determine the affinity constants for the
interaction of the mucin core peptide APDTRPAPG and mAb C595, and compare
the data obtained with the results obtained from the FQ experiments.
5.7.1 Optimisation of peptide APDTRPAPG immobilisation on the surface of a
Pioneer CMD sensor chip.
The accurate measurement of the kinetics of biomolecular interactions using
biosensor kinetic techniques requires data not limited by the effect of immobilisation
of the ligand.  High ligand immobilisation levels can lead to poor fitting of binding
models to the data set.  Factors that cause poor fitting include:
Mass transport limitation - the binding of ligate flowing over the sensor surface to
the immobilised ligand requires the efficient delivery of ligate to all of the ligand
sites.  If delivery of ligate is slower than the specific binding, the measured kinetics
(association rate constant - ka) will be limited by this mass transport effect.
Rebinding of ligate  - the dissociation rate constant kd should be independent of
ligate concentration.  If a high concentration of ligand is present then the probability
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of the ligate molecules rebinding to the surface on dissociation will be high, thus
giving an incorrect representation of the value of kd.
Steric hindrance within the CMD matrix – the binding of ligate to a particular site
may prevent binding of other ligate molecules to an adjacent site.  At low ligand
loadings it has been demonstrated that the association rate constant is significantly
higher than at higher loadings of the ligand (Edwards 1999).
Thus it is absolutely necessary to achieve a low concentration of peptide immobilised
on the surface of the biosensor chip because of the above, and also because of
crowding, avidity and aggregation effects (see section 3.4.14.1).
Initial experiments were conducted using a BIAcore CM5 CMD chip.  However it
proved impossible to reduce binding levels of the peptide to the activated matrix to
the required level using techniques described in section (3.4.14.1).  A Pioneer Sensor
chip F1 was used as this provided the same functionality as Sensor Chip CM5, but has
a shorter dextran matrix.  It was thought that the shorter dextran matrix would also
limit mass transport and rebinding effects.  Due to the shorter matrix the
immobilization yield is typically around 30% of that obtained on Sensor Chip CM5
under comparable conditions (BIAcore 1997).
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Figure 5.10: Optimization of peptide immobilisation on the surface of a pioneer L1
CMD sensor-chip.  Repeat injections of peptide APDTRAPAPG (1mM) in HBS
were injected into the four flowcells over the activated sensor-chip at volumes of 50,
40, 35 and 30 µL, at a flow rate of 5 µL/min.  Remaining activated carboxyl groups
were blocked with ethanolamine.  Monoclonal antibody C595 was then passed over
the four flowcells (3.0 µM) to visualize levels of binding.
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5.7.2 Kinetic analysis of the interaction between immobilised mucin core
peptide APDTRPAPG (ligand) and C595 mAb (ligate)
Model ka (M-1s-1) kd (s-1) KA (M-1) χ2
Langmuir 8.24 x 103 2.18 x 10-3 3.78 x 106 5.38
Langmuir* 8.27 x 103 2.42 x 10-3 3.41 x 106 4.15
Langmuir* + mass-
transfer
8.29 x 103 2.41 x 10-3 3.43 x 106 4.15
Table 5.3: Kinetic rate constants derived from Global Analysis of the monoclonal
antibody C595 – mucin core peptide APDTRPAPG Biosensor data, using the
Langmuir model and the Langmuir model with mass transfer model.  * 2.0 µM
concentration of C595 monoclonal antibody was omitted from the global analysis (see
below).
Analysis of the individual values of ka and kd for each of the concentrations of the
antibody used, indicated that the dissociation rate constant (which is independent of
concentration of analyte) for the 2.0 µM concentration of C595 monoclonal antibody
did not correlate with the other observed values.
[C595 mAb] (µM) ka kd χ2
3.0 9.10 x 103 2.76 x 10-3 10.800
2.5 9.48 x 103 2.27 x 10-3 2.600
2.0 1.01 x 104 1.36 x 10-3 1.950
1.5 8.60 x 103 2.79 x 10-3 2.130
1.0 1.15 x 104 2.36 x 10-3 1.380
0.5 1.58 x 104 2.45 x 10-3 0.898
Table 5.4: Results of local fitting of the Langmuir model individually to each
antibody concentration.
In further analysis of the data the experimental results derived from the 2.0 µM
concentration of monoclonal antibody C595 were excluded.
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Figure 5.11: Corrected sensorgram overlays for the C595 monoclonal antibody-
mucin peptide interaction.  Repeat injections of C595 monoclonal antibody at 3.0, 2.5,
1.5, 1.0 and 0.5 µM.  The data collection rate was set to high.  The extended red lines
represent the best global fits to the Langmuir model using BIAevaluation software
version 3.0.2.
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Figure 5.12: Residual plot for the global fit of the experimental versus modeled
sensor data.  Showing random scatter of points about the median line.
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Model ka1
(1/Ms)
ka2
(1/s)
kd1
(1/s)
kd2
(1/s)
KA (M-1) χ2
2-state 1.01 x 104 5.12 x 10-3 7.68 x 10-3 3.21 x 10-6 2.1 x 109 2.83
Parallel 1.15 x 104 114 3.08 x 10-3 2.24 x 10-6 (1) 3.73 x 106
(2) 5.10 x 107
3.43
Bivalent 3.8 x 103 2.86 x 10-5 2.96 x 10-3 4.94 x 10-6 - 4.01
Table 5.5: Kinetic rate constants derived from Global Analysis of the monoclonal
antibody C595 – mucin core peptide APDTRPAPG Biosensor data using more
complex models.
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Figure 5.13: Initial binding responses for monoclonal antibody C595 injected at
different flow rates over the peptide surface.  A 1.0 µM concentration of antibody was
injected over the peptide surface as a flow rate of 10 (A), 30 (B) and 90 (C) µL/min.
The initial binding responses indicate that mass-transport is not a limiting factor in the
measurement of the kinetics of the interaction between the peptide and antibody at the
surface of the sensor chip.  This supported the global fitting data for the Langmuir
model (1:1) interaction and the Langmuir model with mass transport, which did not
indicate that mass transport of antibody to the peptide was a significant factor.
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Global analysis of the data obtained indicated that the model which most accurately
described the data set was the two-state (conformational change) model.  It should be
noted that conformational changes in ligand or complex do not normally give a
response because the detection systems of optical biosensors is mass based and a
conformational change does not produce any change in mass in and of itself.  The
affect is indirect, as formation of the second species will alter the equilibrium between
the bound and free forms and so change the mass on the sensor surface.
A + B  =  AB  =  AB*
However the significance of this result should not be overestimated, since all of the
models fitted had very small values of χ2 and so all are equally as applicable.  From
these result a value for KA ~ 3 x 106 M-1 appears likely.
5.8 Summary and Discussion
The phage-derived peptide RNREAPRGKICS and the mucin core peptide
APDTRPAPG were conjugated to BSA, and the level of binding of C595 after
equilibrium was reached compared.  A significantly lower level of binding was
observed for the phage-derived peptide conjugate compared with the mucin-core
peptide conjugate.  When the same peptides were linked to beaded agarose, the
average level of binding of mAb C595 was greater for the phage-derived peptide than
the mucin-core peptide.  A possible explanation for this difference was the
precipitation of the phage-derived peptide on conjugation to BSA.  It was
demonstrated that the phage-derived peptide could still bind mAb C595 in the absence
of phage.
Affinity chromatography was performed using the phage-derived peptide
RNREAPRGKICS linked to beaded agarose and compared with affinity matrices
using:  (i) the mucin-core peptide APDTRPAPG; (ii) the mucin-core peptide with a
terminal cysteine residue (to control for dimerisation) APDTRPAPGC, and (iii) the
mucin-core peptide with a glutamic substitution (to control for binding being
enhanced by the REAP mimotope alone) APDTREAPG.  NaSCN gradient elution
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profiles of columns loaded with mAb C595 were compared.  The elution profiles from
the APDTREAPG and APDTRPAPGC matrices were identical in shape and size to
the elution profile of the APDTRPAPG matrix.  The maximum of the peaks in the
elution of mAb C595 from the APDTREAPG and APDTRPAPG were directly in
line in the gradient elution profile.  The maximum of the peak from the elution of
mAb C595 from the APDTRPAPGC matrix was further up the NaSCN gradient than
any of the other maxima, this has previously been attributed to dimerisation of the
peptide leading to an increased affinity (A.  Murray, University of Nottingham –
personal communication).  The elution profile for the phage-derived peptide affinity
matrix exhibited a sharp symetrical peak, compared to the more broad, unsymmetrical
peaks observed for the other peptide affinity matrices.
Antibody purified from hybridoma supernatant using the phage-derived peptide
affinity matrix, exhibited a higher specific reactivity than antibody purified from
hybridoma supernatant using the mucin-core peptide affinity matrix.  SDS-PAGE
analysis of the purified antibody from both matrices demonstrated that the antibodies
were effectively purified from hybridoma supernatant, and contained no impurities.
Affinity determination using fluorescence quenching analysis and structural analysis
using circular dichroism, of the phage-derived peptide RNREAPRGKICS, the
mucin-core peptide APDTRPAPG, and the related control peptides APDTRPAPGC
and APDTREAPG revealed a profound correlation between structual content of the
peptides and their relative equilibrium association constants.  The peptides showed a
structural content and equilibrium association constant in the following order:
RNREAPRGKICS > APDTREAPG > APDTRPAPGC > APDTRPAPG
These results were in agreement with the relative performances of the phage-derived
peptide affinity matrix and the mucin-core peptide affinity matrix (i.e. Antibody
recovered from the phage-derived peptide affinity matrix exhibited higher specific
reactivity than antibody reovered from the mucin-core peptide affinity matrix).
Analysis of the interaction of mAb C595 with immobilised mucin-core peptide
APDTRPAPG using a BIAcore biosensor gave an equilibrium association constant
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approximately 20x the value observed in the solution phase FQ assay.  This can be
attributed to the reduction in entropy of the immobilised peptide compared to the
solution-phase peptide.  This increased equilibrium association constant is likely to be
reflected in the real value observed on the peptide affinity matrix.  Thus the FQ assay
can be used to give relative affinities of the repective ligands, but the actual
eqilibrium constants on the column are likely to be higher as a result of the reduction
in entropy of the immobilised peptide compared to the solution-phase peptide.
The results of the gradient elution of antibody from the RNREAPRGKICS peptide
affinity matrix are in contrast to several authors who have suggested that tolerance to
thiocyanate elution is proportional to the strength of the antigen-antibody interaction.
Examples of the disruption of antigen-antibody interactions using thiocyanate elution
in ELISA based techniques to determine relative affinities of interaction have
previously been published (Pullen, et al. 1986; Macdonald, et al. 1988; Ferreira and
Katzin 1995).  This relationship has also previously been used as an empirical
measure of the affinity of the interaction between an immobilised antigen or ligand
and the antibody by eluted a loaded chromatography columnwith thiocyanate
(Murray, et al. 1997; Murray, et al. 1998; Murray, et al. 2000).  Other chaotropic
solvents have been employed to fractionate polyclonal antibodies (Narhi, et al. 1997).
Here too, the authors note that “…tighter binding pAbs would require increasingly
more denaturing solvents to elute them”.  However  Murray, et al. (2000) comment
on the relatively low concentration of NaSCN required to elute antibody from an
affinity column, even though the yield of antibody recovered was high.
These results suggest affinity selection played a part in the selection of the phage-
derived peptide RNREAPRGKICS in the four rounds of biopanning.  The fact that
all of the nucleotides were identical for all of the phage clones displaying the
RNREAPRGKICS peptide, does not prove that these clones were selected as a result
of a particular growth advantage conferred to the phage as a result of the mutation of
the 5’ terminal cysteine residue.  Measurements of the initial phage titer indicated that
311 copies of each clone would be displayed per ml of phage lysate.  A 2.5 ml aliquot
of phage lysate was used in the biopanning process, which equates to 777 copies of
each phage clone.  It is conceivable that a single clone that had acquired a point
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mutation could be propagated in the amplification stages of the propagation process
and be selected for enhanced affinity.
The equilibrium association constant for the interaction of mAb C595 with the MUC1
related peptide CPAHGVTSAPDTRPAPGSTAP has been determined using a
BIAcore biosensor (Karanikas, et al. 1998).  The value (KA= 5.6 x 106 M-1) is of the
same order of magnitude as the value obtained in the interaction of the mucin core
peptide APDTRPAPG (3.41 X 106 M-1) using the Langmuir model of binding.  The
author does not describe any optimisation process for immobilising the ligand onto
the sensor chip.  The only information given regarding the immobilisation process is
the chemistry used (NHS/EDC).  The larger value is likely to be the result of
immobilising too great a quantity of peptide onto the sensor chip, the result being that
re-binding of antibody can occur, reducing the value measured for kd, resulting in a
higher value for KA.  Only one antibody concentration was used to determine the
affinity constant in the published data.
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6 Chapter 6 - Results.  Mimotope peptides cross- reactive with an
anti-steroid hormone antibody.
6.1 Introduction
Chapter two of this thesis described the approaches available for the discovery of
novel peptide mimotopes using synthetic and biological libraries.  Chapters four and
five described the use of a phage display library to discover novel peptide mimotopes
cross- reactive with antibodies to protein antigens, characterisation of the synthetic
peptides derived from the phage display library, and their application in the affinity
purification of monoclonal antibodies from supernatant.  A number of examples exist
in the literature, of synthetic phage-derived peptide mimotopes which (i) only bind
very weakly to the target antibody (Murray, et al. 2000), or (ii) the synthetic versions
of the phage peptide does not bind at all to the target antibody (Meloen et al, 2000).
Both of these examples have used small synthetic libraries to systematically optimise
the phage-derived peptide in order to create a peptide that can be used for the
paratope-specific affinity purification of the target antibody.
This chapter outlines the systematic optimisation process used in the first example
(Murray, et al. 2000), and describes an approach to improve the signal to noise ratio
in peptide arrays in order to reduce the number of candidate peptides for optimisation.
An empirical analysis of the equilibrium constants of the interaction between the
phage-derived peptide, the optimised peptide and the target antibody was conducted
in an attempt to rationalise the optimisation process.  An inhibition ELISA was
conducted to obtain proof that the optimised and phage-derived peptides were binding
specifically to the paratope of the antibody.   A competition ELISA was created to
determine if the optimised mimotope could be used in an assay to measure free E-3-G
concentration in solution.  Surface Plasmon Resonance was used to measure the
kinetics of the interaction between the optimised peptide and the antibody, and the
effect of temperature on the interaction was also investigated.  Part of the work within
this chapter contributed to a publication (Murray, et al. 2001) and served as an
example in a patent application (Badley, et al 2001).
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The second example above (Meloen et al, 2000) describes the optimisation, using
small peptide arrays, of a phage-derived, low affinity lead sequence (which only
bound antibody when part of the phage) reactive with an antibody directed against a
discontinuous epitope of glucoseoxidase.  The systematic optimisation protocols were
not described.  Publications described as forthcoming in the article, which were to
describe the optimisation process, have yet to be published since they from part of a
patent application (R.H. Meloen – personal communication).  The Kd of the original
phage sequence ASLQGMDT was improved by a factor of 105 in the optimised
synthetic sequence GCAPDPFKQGVDTCG that bound anti-glucoseoxidase
antibody in the absence of phage.  As can be seen the optimised sequence contains
only two pairs of residues which were adjacent in the phage sequence (QG and DT).
The optimised sequence is elongated compared to the phage sequence, which
presumably gives rise to a better mimic of the discontinuous epitope.
The approach outlined in this chapter differs from the process outlined by Meloen et
al. (2000), in the way the peptide libraries were constructed, and that the antibody is
raised against a non-proteinaceous target.  Thus the target ligand can neither be
described as a continuous or discontinuous epitope.  Scott (Scott, 1992) stated that
phage-based epitope libraries can be used to select peptide mimics for non-peptide
binding ligates (i.e. a non-proteinaceous target).  As outlined in chapter 1, a number of
peptide mimics have been discovered for non-proteinaceous targets, including DNA,
biotin and carbohydrate moieties, but none had previously been reported for steroid
hormones.
As described in chapter 1, monoclonal antibody 4155 is an anti-steroid antibody,
which was raised against E-3-G, a metabolite of the steroid hormone estradiol.
Section 1.5.3.4 described how mAb 4155 is purified using a competitive elution
approach - after the antibody binds to estrone immobilised on an affinity column, the
higher affinity analogue – estradiol 3-(beta-D-glucuronide) is then used to desorb the
bound antibody from the affinity matrix.  The antibody in the estradiol 3-(beta-D-
glucouronide) – antibody complex can then go on to react with the higher affinity
parent ligand E-3-G (to which the antibody was raised).  This paratope-specific
method of purification, whilst ensuring that purified antibody is fully immunoreactive
Chapter 6 - Results.  Mimotope peptides cross- reactive with an anti-steroid hormone
antibody.
151
is far from ideal since it requires the use of equivalent quantities of E-3-G for each
quantity of antibody purified.  If a more facile paratope-specific interaction could be
employed in the purification process, bound antibody could be eluted by employing
an elution buffer  which perturbs the antibody-ligand interaction, and the need to use a
competing ligand to elute bound antibody would be eliminated.  The elimination of
the need to use a competing ligand in the purification process would provide a
substantial saving in the cost of manufacture of purified mAb 4155.
Peptide mimotope affinity purification offers a solution, necessitating the discovery of
a peptide mimotope ligand that is cross-reactive with an antibody raised against a
non-peptide ligand.  Peptide mimotopes of an analyte are also a valuable tool for the
development of biosensors utilising mimotope-recombinant antibody constructs such
as those described in the biosensor in section 1.1.3.
6.2 Optimisation of peptide mimotope ligands from lead sequences
obtained from a phage display library
The overall strategy for the refinement of peptide mimotope ligands from lead
sequences obtained from a phage display library as outlined in (Murray, et al. 2001) is
illustrated in figure 6.1.  The following describes each of these stages in the
application of this process in the refinement of peptide mimotopes cross-reactive with
the anti-E-3-G 4155 mAb.
6.2.1 Lead sequence identification
(Conducted by S. Williams, Unilever Research, Sharnbrook, UK)
A cysteine constrained, multivalent peptide library displaying random nonapeptides
flanked at each end by cysteine residues fused to the major coat protein pVIII of f1
bacteriophage (Felici 1991) was used to screen for binders to mAb 4155 by affinity
selection.  The random insert was synthesised using an equimolar mixture of all four
nucleotides at each codon.  (This has the disadvantage that all three-stop codons are
coded for compared to only two in the NNK strategy – see chapter 4).  Screening was
conducted using Nunc Immunotubes, and bound phage were eluted using 0.1M HCl,
pH 2.2 adjusted with glycine containing 1 mg/ml ovalbumin.  Three rounds of
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biopanning were conducted.  ELISA and DNA sequencing were used to identify the
sequences of peptides displayed on phage which bound above background level on
ELISA.  The following three peptides were identified:
AAERGLFED
TAWTYVLGP
TSWAYVLGP
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Figure 6.1: Strategy for the selection of peptide mimotopes from a phage display
library, and the affinity maturation of these peptide mimotopes for application as a
peptide mimotope affinity ligand.
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6.2.2 Identification of the minimum binding unit
(Conducted by Dr A.  Murray, University of Nottingham, UK)
The three lead sequences were then produced by solid phase peptide synthesis.
Sequences TAWTYVLGP and TSWAYVLGP were found to be insoluble in aqueous
solvent, and so investigation of these sequences ceased.  Immobilisation of the
synthetic peptide AAERGLFED onto cyanogen bromide activated Sepharose 4B,
when used as an affinity matrix, failed to purify mAb from supernatant spiked with
mAb 4155.
Three sets of peptides (based on the AAERGLFED lead sequence) were then
synthesized on the heads of polypropylene pins (Geysen, et al. 1987).  The array of
pins were arranged in a plastic holder in the format of a 96-well microtitre plate,
enabling ELISA to be conducted on the heads of the pins by inserting the array  into a
microtitre plate containing the ELISA reagents.  The three sets consisted of: -
(i) The phage derived mimotope sequence AAERGLFED truncated from the N
terminus, producing the peptides
AAERGLFED
AERGLFED
ERGLFED
RGLFED
GLFED
LFED
FED
ED
(ii) The phage derived mimotope sequence AAERGLFED truncated from the C
terminus, producing the peptides
AAERGLFED
AAERGLFE
AAERGLF
AAERGL
AAERG
AAER
AAE
AA
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The aim of these two libraries was to identify the core binding regions of the
sequence.
(iii)  In the third library, each of the residues in the phage derived peptide mimotope
sequence AAERGLFED were replaced with alanine (or glycine if alanine already
existed at that position)
GAERGLFED
AGERGLFED
AAARGLFED
AAEAGLFED
AAERALFED
AAEAGAFED
AAERALAED
AAERGAFAD
AAERGLFEA
The aim of this library was to assess the contribution of each residue in the sequence
to the binding event.
ELISA conducted on these peptide arrays demonstrated that a minimum binding unit
from the first two truncated libraries was identified as FED (Badley, et al. 2001).
Since the alanine substitution library showed a gradual decrease in binding levels
when each of the residues from the glycine onwards were replaced, the minimum
binding unit was identified as the sequence GLFED (Murray, et al. 2001).
Replacement of the phenylalanine residue was found to lead in a 75% reduction in
antibody binding.
6.2.3 Affinity maturation of the minimum binding unit
A Replacement Net (RNET) analysis (as described in section 3.2.2) of the tetra
peptide LFED was conducted, producing a set of 80 peptides with sequences GXFED,
GLXED, GLFXD and GLFEX where X is each of the 20 naturally occurring amino
acids, and two unrelated control peptides RPAPG and MPAPG.  The results are
presented in figure 6.2.  Note that in this experiment the range of binding ability of
peptides across each of the arrays is not particularly well defined, with little difference
between the majority of the peptides in a particular array.  i.e. These results
demonstrate a low signal to noise ratio across the array.  All of the peptide arrays
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demonstrated levels of antibody binding above the level observed for the two
unrelated control peptides, apart from the GLXED array – where phenylalinine was
replaced.  In the GLXED array, the majority of peptides demonstrate binding levels
equal to or below that of the control peptides.
In order to improve the signal to noise ratio, a variation on the RNET assay was
conducted.  In this variation each of the duplicate peptides (synthesized in duplicate in
the pin array) were incubated with a different mixture.  The first pin was incubated
with a pre-equilibrated mixture consisting of mAb 4155 and 10,000 x concentration of
E-3-G, and the second pin was incubated with an equivalent amount of mAb 4155
only.  (Several experiments were conducted to determine this concentration of E3G at
which the optimum signal to noise ratio was achieved). -
Pi
n 
1 75 µl mAb 4155 @ 10 µg/ml
+
75 µl E-3-G @ 3.33 µM
Pi
n 
2
150 µl mAb 4155 @ 5 µg/ml
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Figure 6.2: Results of an experiment demonstrating differential binding of mAb 4155
to an RNET array of peptides derived based on the GLFED minimum binding unit.
(A) GXFED RNET; (B) GLXED RNET; (C) GLFXD RNET; (D) GLFEX RNET;
(E) unrelated control peptides.  X represents the 20 naturally occurring (L) amino
acids.  Peptides tethered to pins via their C-terminus.
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Figure 6.3: Results of an experiment demonstrating differential blocking of binding
of mAb 4155 to an array of RNET peptides based on the phage derived GLFED
minimum binding unit, using E3G.  Percentages correspond to the fraction of
antibodies binding to the peptide in the presence of E3G divided by the antibodies
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binding to the peptide in the absence of E3G.  (A) GXFED RNET; (B) GLXED
RNET; (C) GLFXD RNET; (D) GLFEX RNET and (E) unrelated control peptides.
X represents the 20 naturally occurring (L) amino acids.
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Figure 6.4: Average values for blocking of binding across the RNET for each of the
GXXXX substituted peptides of the phage derived GLFED minimum binding unit.
Error bars indicate the standard deviation of values across each substitution sequence.
Note that the average level of binding is lowest in the array in which the
phenylalanine residue was replaced.
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Using this approach the signal to noise was much improved compared to measuring
the binding of antibodies to the array (see figures 6.2 and 6.3). A background
measurement of secondary antibody binding to the pins was conducted prior to the
experiment and subtracted from the values obtained in these experiments to correct
for non-specific binding of the secondary antibody to the pins.
Results were expressed as a percentage of the OD405 nm of pin 1 divided by OD405 nm
of pin 2.  Low percentage values indicate a large difference of OD405 nm between pin
1 and pin 2 exists (i.e. OD405 nm (pin 1) << OD405 nm (pin 2)).  This would suggest
that the peptide mimotope immobilised on the pin is a poor mimic of E-3-G, and so
the peptide on the pin is unable to compete mAb 4155 from the mAb 4155-E-3-G
complex.  High values indicate only a small difference of OD405 nm between pin 1
and pin 2 exists (i.e. OD405 nm (pin 1) ~ OD405 nm (pin 2).  This would suggest that
the peptide mimotope immobilised on the pin is a good mimic of E-3-G, and so the
peptide on the pin is able to compete mAb 4155 from the mAb 4155-E-3-G complex.
Comparing the results of the RNET assay in fig 6.2 with the results of this RNET
assay incorporating a displacement component (fig 6.3) a significant reduction in the
background level of binding is observed.  The non-specific binding of antibody to the
pins is in effect cancelled out, and only the ability of each mimotope to compete mAb
4155 from the E-3-G – mAb 4155 complex is reported.  The use of the E-3-G-mAb
4155 complex significantly reduces the level of background binding observed.
A control experiment was conducted using another array of peptides based on the
sequence RXXX using mAb C595 (recognises RXXP epitope).  The experiment was
conducted in the same format as with the GLFED based RNET, to establish if E-3-G
reduces the binding of an irrelevant antibody to other peptide ligands. Little variation
across the array was observed, with the majority of peptides totally unperturbed by the
presence of E-3-G.  This provides evidence that the blocking of binding of mAb 4155
to the GLFED based RNET is a specific reaction for the paratope of the mAb 4155,
and is not the result of non-specific interactions between the antibody and E-3-G.
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The results of the analysis suggested that in the GLFED lead sequence phenylalanine
was a critical contact or anchor residue; leucine could only be replaced by other large
hydrophobic residues (indicative of the side chain of this amino acid contributing to
the binding event); and the glutamate and aspartate residues tolerated a larger number
of substitutions, suggesting less of a contribution to the binding event from these
residues.  See figures 6.3 and 6.4.
All of the previous observations lead to the focussing on the residues at positions 4
and 5 for affinity maturation. Substitution of amino acid residues at positions 4 and 5
of the lead sequence GLFED with aromatic or hydrophobic residues increased
binding of the antibody to the peptide.  Cysteine, tryptophan, and tyrosine were
observed to give the highest levels of binding.  Cysteine substituted mimotopes
GLFEC and GLFCD were discounted for further study because of the potential for
dimerisation.  This left peptides GLFWD, GLFEW, GLFEY and GLFYD, which
were synthesised and tested as affinity ligands.  Significant peaks of eluted material
were observed for the peptides GLFWD and GLFEW, but were found to be
contaminated with non-antibody species (Dr A. Murray, University of Nottingham,
personal communication).  Elution from the affinity matrices containing peptides
GLFYD and GLFEY respectively yielded small peaks corresponding to ~5%
recovery of antibody from the spiked feedstock.
This was not in agreement with the binding studies conducted on the surface of the
pins and the results of the ELISA where the mimotopes were able to compete with
estrone in binding the antibody.  Peptides were tethered to the pins via their C-termini,
whereas peptides were bound to the CNBr activated Sepharose via their N-termini.
Both N- and C- termini of the peptides were free in the ELISA competition assay.
Thus presentation of the peptide mimotope to the antibody is an important factor in
governing the peptide mimotopes success as an affinity matrix.
6.2.4 Establishing the correct presentation in the desired application
Synthesis of the peptide GLFYD in reverse using (D) amino acids (DYFLG) instead
of the naturally occurring (L) amino acids, upon immobilisation to CNBr activated
Sepharose 4B, enabled the side chains of the amino acids to be presented to the
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antibody in the same orientation as the (L) amino acid residues in the mimotope
tethered to the pins via the C- terminus.  A similar example is given by (Guichard, et
al. 1994) “Antigenic mimicry of natural L-peptides with retro-inverso-
peptidomimetics”.  Recovery of 98% of the spiked mAb 4155 from tissue culture
supernatant was achieved using the retro-inverso mimotope peptide (Murray, et al.
2001) – see figure 6.5.
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Figure 6.5:  Gradient elution of the anti- E-3-G antibody (4155) from  a peptide-Sepharose affinity matrices following column loading with 100
ml mAb 4155.  The affinity matured mimotope (d) DYFLG was linked to the CNBr activated affinity matrix via the amino-terminus. Antibody
at 15µg/ml in PBS.
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6.3 Rationalisation of the process involved in the optimisation of
peptide mimotope ligands from lead sequences obtained from a
phage display library
The optimisation of peptide mimotope ligands from mimotope sequences derived
from a phage display library has proved to be a successful strategy for the isolation of
paratope-specific binding ligands capable of functioning as affinity ligands for the
purification of monoclonal antibodies from feedstocks (Meloen et al,2000) (Murray,
et al. 2001).  A number of experiments were conducted to investigate the differences
observed between the binding properties of the phage-derived peptide and the
optimised peptide isolated using the process described in section 6.2.
6.3.1 An ELISA to estimate relative values of the equilibrium association
constant (KA)
As described in chapter 1, the current purification process for mAb 4155 involves the
competitive elution of the antibody bound to an affinity matrix using estrone as the
immobilised affinity ligand.  This is a high affinity interaction, since 4155 mAb is not
easily eluted from the matrix, and can only be removed using the higher affinity
estradiol 3-(beta-D-glucuronide). An ELISA was conducted to establish the time
taken for the reaction of mAb 4155 with a number of different ligands to reach
equilibrium, and thus enable a qualitative assessment of the relative values of KA for
the interaction of each ligand with the antibody.  BSA- conjugates of estrone, the
phage derived lead peptide AAERGLFED and the optimised peptide (d)DYFLG
were immobilised onto the wells of an ELISA plate. The mAb4155 was added to the
wells of the plates for a range of incubation periods.  Standard ELISA procedure were
then conducted as described in chapter 3 to determine the level of antibody binding
for each incubation period.
First an ELISA was conducted to examine the reaction between mAb 4155 and
estrone.  Estrone was conjugated to BSA as described in Chapter 3, and the resulting
conjugate dried down onto the wells of an ELISA plate.  mAb 4155 was incubated at
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10µg/ml for varying incubation periods, in triplicate in the wells of the ELISA plate.
The results are presented in figure 6.6.
The results presented in figure 6.6 demonstrate that the reaction between mAb 4155
and the BSA-estrone conjugate reaches equilibrium in a time period of approximately
10 minutes. i.e. the amount of antibody accumulating on the conjugate reaches a
steady state, such that the amount of antibody binding equals the amount of  antibody
un-binding.  Thus the curve reaches a plateau.
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Figure 6.6: Results of an experiment to measure the empirical reaction rate of mAb
4155 to BSA- estrone conjugate.  mAb 4155 @ 10 µg/ml; conjugate dried onto
ELISA plate @ 10 µg/ml of BSA.
An identical experiment was conducted with the same concentrations of reagents,
using the phage derived peptide AAERGLFED, and the optimised mimotope
(d)DYFLG conjugated to BSA.  The results are presented in figure 6.7.  It can be
seen that amount of antibody binding is greater than in figure 6.6.  This probably
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results from the two different chemistries used to create the estrone and the peptide
conjugates.  From this experiment it is clear that the rate at which the reactions reach
equilibrium is slower than for the estrone conjugate.  The reactions involving the
peptide conjugates do not plateau, as was the case in figure 6.6 with the reaction of
mAb 4155 and the estrone conjugate.
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Figure 6.7: Results of an experiment to measure the empirical reaction rate of mAb
4155 to BSA- phage derived peptide mimotope conjugate, and BSA-affinity matured
mimotope peptide adsorbed onto a single ELISA plate.  mAb 4155 @ 10 µg/ml;
conjugates dried onto ELISA plate @ 10 µg/ml of peptide.
From these experiments a simple deduction can be made about the relative values of
the equilibrium association rate constant for each of the reactions.  The equilibrium
association rate constant (KA) for the reaction A + B = AB is defined as: -
[AB]
[A] [B]
______KA =
= ka / kd
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KA thus has units of M-1.
From the results presented in figure 6.7, assuming equivalent levels of peptide
conjugation, and equivalent levels of conjugate immobilisation on the ELISA plates,
it can be asserted that the equilibrium association constant (KA) for the reaction
between the optimised peptide (d)DYFLG is greater than the equilibrium association
constant (KA) for the reaction between the phage-derived lead sequence
AAERGLFED.
When considering the two types of structure: the flexible peptide, and the rigid steroid
structure, it is logical to assume that the on-rate (kon) will be the dominant factor
influencing the values observed for KA.  The peptides are able to adopt a much more
flexible structure than the more rigid steroid molecule, and so the on-rate for the
peptides is likely to be slower than the steroid molecule since the peptide is able to
exist in many conformations.
Using this assumption that the on-rate is the dominant factor in these antibody –
ligand interactions, then the results presented in figure 6.6 suggest that the equilibrium
association constant (KA) for the interaction of mAb 4155 with the BSA-estrone
conjugate is larger than the values of KA observed for the BSA-peptide conjugates,
since the signal reaches a plateau in a short time period (compared with the time taken
for the signal to reach a plateau in the experiments involving the peptide conjugates).
The concentration of antibody is in excess of the concentration of binding sites in all
of the experiments, and so can be assumed  to be constant, for all of the experiments.
Thus the value of KA decreases in the following order: -
Estrone > optimised mimotope (d)DYFLG > phage derived mimotope
AAERGLFED
The equilibrium association constant for the interaction between mAb 4155 and the
target antigen E-3-G has been determined to be 1 x 1010 M-1 (Dr A. Badley, Unilever
Research – personal communication).  The cross-reactivity of the related steroids
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estrone was also measured, and determined to be 0.1 % with respect to E-3-G.  An
approximate estimate of the affinity of mAb 4155 to estrone can be made (0.1 % of 1
x 1010 = 1 x 107 M-1).
6.3.2 Inhibition ELISA’s
The properties of the phage-derived peptide mimotope AAERGLFED and the
optimised peptide mimotope GLFYD free in solution were investigated in an
inhibition ELISA.  The BSA-estrone conjugate used in section 6.3.1 was dried down
onto the surface of a microtitre plate and an inhibition assay conducted as described in
Chapter 3.  The ability of the peptides to inhibit the binding of mAb 4155 to the BSA-
estrone conjugate was tested.  An unrelated peptide (KSKAGVC) was used as a
negative control.  The results are presented in figure 6.8.  From the results it can be
seen that the control peptide did not inhibit binding of mAb 4155 to the BSA-estrone
at any of the concentrations used.   Two completely different inhibition profiles
resulted from the inhibition of antibody binding using the phage-derived peptide
mimotope and the optimised mimotope.  The phage-derived peptide only inhibited
binding over a relatively small concentration range (3.0 mM to 1.0 mM) compared to
the optimised mimotope peptide, which inhibited antibody binding over a much larger
concentration range (3.0 mM to 0.03 nM).
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Figure 6.8: Results of an experiment to demonstrate inhibition of binding of mAb
4155 to a BSA-estrone conjugate using the phage-derived peptide AAERGLFED and
the affinity-matured mimotope peptide GLFYD in solution.  An irrelevant peptide
KSKAGVC was employed as a negative control.
This is in agreement with the difference observed in the equilibrium association
constants observed in section 6.3.1.  This can be explained as follows: consider case
(1) and (2) below: -
(1) A + B AB Large KA
(2) A + B AB Small KA
B represents the antibody and A represents the peptide.  The concentration of B can
be considered constant in both cases, with only the concentration of peptide varying in
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each case. Equation (1) applies to the interaction of the optimised peptide GLFYD
with mAb 4155.  The reaction is less dependent upon the concentration of the peptide
(A) than (2) where the reaction is more dependent upon the concentration of peptide
AAERGLFED.  This difference of concentration dependence (i.e. the difference in
the KA values) is reflected in the inhibition assay.  Peptide (d)DYFLG showed a
similar profile to peptide GLFYD.  The fact that these mimotope peptides are able to
inhibit the binding of the antibody to estrone, is strong evidence that these peptides
are binding specifically to the paratope of the antibodies.
6.3.2.1 The use of a peptide mimotope in an inhibition ELISA to measure E-3-
G.
As well as being useful as paratope-specific binding ligands for the purification of
monoclonal antibodies, peptide mimotopes can be used as diagnostic reagents.  An
example of the use of synthetic peptides in an assay is the use of a synthetic peptide in
a preclinical test for prion diseases (Scrapie) (Schreuder et al, 1996).  Synthetic
peptides are employed in such assays since they offer a number of advantages
compared to the native protein with respect to production, storage and safety.  A
review of the use of synthetic peptides for diagnostic use is given by (Meloen, et al,
1997).   There is very little published data on the use of peptide mimotopes reactive
with antibodies raised against non-proteinaceous analytes such as E-3-G as is
described here.
Using the optimised mimotope reactive with mAb 4155, a competitive ELISA assay
was developed to measure the concentration of E-3-G in solution.  The results of this
assay for a range of concentrations of E-3-G are shown in figure 6.9, alongside an
equivalent assay using the target antigen.  Inhibition of binding of mAb 4155 to a
BSA conjugate of the affinity-matured, phage derived peptide (d) DYLFG using E-3-
G in solution was compared to the inhibition of binding of mAb 4155 to an E-3-G
ovalbumin conjugate.  The results have been normalised over the mean Vmax to
directly compare the two inhibition curves.
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Figure 6.9: A comparison of results from competition ELISA’s to measure free
concentration of E-3-G in solution, using an ovalbumin-E3G conjugate, and a BSA-
affinity matured peptide mimotope conjugate.  Note Vmax values were normalised to
aid comparison.
The results presented in figure 6.9 demonstrates that the optimised mimotope peptide
(d) DYFLG can be used to create an assay for the determination of the concentration
of E-3-G in solution.  From these results, it is clear that the range of concentrations of
E-3-G that could be quantified using the optimised peptide conjugate is much smaller
(1 x 10-9 M to 3 x 10-9 M) - compared to the range quantifiable when using the E3G-
ovalbumin conjugate (3 x 10-10 M to 3 x 10-7 M).  However the switch from maximum
inhibition to minimum inhibition as the concentration of E-3-G is increased, occurs
over a much smaller range for the optimised mimotope peptide, compared to the
gradual decrease in inhibition observed using the E-3-G-ovalbumin conjugate.  This
could be advantageous in a situation requiring the rapid detection of a particular
analyte (e.g. a toxin), where a fast, definite “yes/no” answer is required.  Detection of
such a change would be much easier to detect and would be more sensitive than if the
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E-3-G-ovalbumin conjugate had been used.  The improved response exhibited by the
optimised mimotope peptide would be useful in systems reliant on an electrical
transducer to detect the signal, such as the biosensor utilising mimotope peptides
outlined in Chapter 1, figure 1.1.  This switch from maximum inhibition to minimum
inhibition would circumvent problems of extracting a change in signal over the
background noise which would be present when monitoring only small changes of
inhibition using curves with a profile similar to that observed when using the E-3-G-
ovalbumin conjugate.  This work was used as an example in patent application
(Badley et al, 2002).
The assay was repeated using a BSA conjugate of the phage-derived lead sequence
AAERGLFED in place of the E-3-G ovalbumin conjugate.  The results of this
experiment are presented in figure 6.10.  These results show that the range of the
assay for the determination of E-3-G using the phage-derived lead sequence is at
lower concentrations than when the optimised mimotope peptide is used.
All of these properties can be attributed by the differences in the equilibrium
association constant (KA) observed in section 6.3.1.  The equilibrium association
constant (KA) is the reciprocal of the equilibrium dissociation constant (KD).  Thus
from the experiments conducted in section 6.3.1, it would be expected that the
equilibrium dissociation constants for the species used in the competition assays
would decrease in the following order: -
BSA-AAERGLFED > BSA-(d)DYFLG > Ovalbumin-E-3-G
In the competition assay, mAb 4155 was pre-incubated on the ELISA plates on which
the conjugates were immobilised, before washing and then adding the solutions
containing the various concentrations of E-3-G.  The E-3-G in solution most easily
competed antibody from the BSA-AAERGLFED conjugate. The interaction between
the antibody and the conjugate exhibits the highest KD out of the three conjugates, and
so the antibody-antigen complex can be expected to be the most dissociated and thus
antibody is most easily competed from this conjugate.  The same reasoning can be
applied to explain why the range concentrations of E-3-G detectable using the BSA-
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(d)DYFLG  conjugate in the assay was higher.  The reason for the much larger range
of concentrations determinable in the assay using the ovalbumin-E-3-G conjugate
results from the similarity of the KD values for the interaction of mAb 4155 with E-3-
G free in solution and E-3-G conjugated to ovalbumin.  The difference in the KD for
these two interactions would not be expected to be significantly different (the
interaction of mAb 4155 with immobilised E-3-G might be expected to exhibit a
slightly higher on-rate and thus lower KD than the interaction between antibody E-3-G
in free solution).
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Figure 6.10: A comparison of the results from a competition ELISA to measure the
free concentration of E-3-G in solution, using the phage-derived mimotope peptide
AAERGLFED and the optimised peptide (d) DYFLG.
By utilising the differences in the equilibrium constants in such competition assays it
would be possible to tailor an assay for a particular situation.
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e.g. (1)  High sensitivity, but small dynamic range
or   (2)  Low sensitivity, but large dynamic range.
(1) and (2) can be considered to be the two extremes.  Case (1) would be poor for the
quantitative measurement of a particular analyte, but good for rapid qualitative
measurements.  Conversely, case (2) would be good for quantitative measurements,
but poor for rapid qualitative measurements.  It may be possible to use a combination
of such mimotopes in a single assay to broaden the range of an assay utilising peptide
mimotopes.
6.3.3 Determination of rate constants in the interaction of the affinity-matured,
phage derived peptide (d) DYLFG and mAb 4155
It was observed in section 6.3.1 using an empirical ELISA approach, that the time
taken for the reaction between the refined mimotope peptide sequence (d)DYFLG
and mAb 4155 to approach equilibrium was much longer than the time taken for the
interaction between mAb 4155 and estrone to reach a state of equilibrium.  Several
different methods were explored to quantify the kinetic parameters in the reaction
between mAb 4155 and the peptide mimotope (d)DYFLG and these are described
below.
6.3.3.1 Fluorescence quenching
Fluorescence quenching was attempted using the mimotope peptides, but a quenching
of fluorescence could not be observed.  This is probably a result of the aromatic
amino acid residues present in the mimotope peptides, masking any quenching effect.
6.3.3.2 Surface Plasmon Resonance (SPR)
Initial experiments focussed on the direct immobilisation of the optimised mimotope
peptide onto a BIAcore sensor chip, however the binding of antibody to these chips
was unable to be detected.  A BSA conjugate of the optimised mimotope peptide was
immobilised on the BIAcore sensor chip, and antibody binding to the conjugates was
detected.  As described in chapter 5, the accurate measurement of the kinetics of
antibody-antigen interactions requires data not limited by the method of ligand
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immobilisation.  Although BSA-conjugates are not ideal for the determination of the
kinetics of antibody-ligand interactions (since it is difficult to control the ligand
density in the BSA-conjugates), they can be used to gain information about the
kinetics of the interaction.  As in chapter 5, the response observed on antibody
binding of the conjugate was limited to less than 100 RU at saturation to reduce
crowding, avidity and aggregation effects.
SPR was conducted using the BSA-mimotope peptide conjugate, and mAb 4155.
Two different configurations were employed to test the validity of the results
obtained.  The kinetics of the interaction of antibody with immobilised BSA-peptide
conjugate were measured.  The configuration was then reversed with antibody
immobilised onto the sensor chip and the kinetics of the interaction of the BSA-
peptide conjugate in solution binding to the antibody were measured.  The results of
these experiments are presented in figure 6.11 and 6.12.  A simple Langmuir model of
binding was used to fit curves to the experimental data using global analysis.  The rate
constants derived from these fitted curves are presented in table 6.12.
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 Figure 6.11: SPR analysis of the interaction between immobilised peptide conjugate
BSA- (D) DYFLG and antibody 4155 at 25 oC.  Antibody 4155 at 500 nM, 200 nM,
100nM and 50 nM from top down.  A background signal consisting of the interaction
of antibody with a flowcell derivatised with ethanolamine was subtracted from each
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of the curves.  BSA- peptide conjugate immobilised using NHS/EDC coupling
chemistry.  HEPES buffer, flow rate of  1.0 ml/min.  Red lines are model data, black
lines are experimental data.
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Figure 6.12: SPR analysis of the interaction between immobilised antibody 4155 and
peptide conjugate BSA-(D)DYFLG at 4 oC. BSA-(D)DYFLG peptide conjugate at
500 nM, 200 nM, 100 nM and 50 nM peptide (assuming [peptide in conjugate] = 2.5
mg peptide per ml of undiluted conjugate solution). A background signal consisting of
the interaction of antibody with a flowcell derivatised with ethanolamine was
subtracted from each of the curves.  HEPES buffer, flow rate of  1.0 ml/min.  Red
lines are model data, black lines are experimental data.
Species Immobilised ka (1/Ms) kd (1/s) KA (1/M) χ2
BSA – (D) DYFLG 6.06 x 104 1.40 x 10-4 4.34 x 108 0.235
Antibody 4155 6.95 x 104 1.12 x 10-4 6.19 x 108 0.329
Table 6.1: Comparing kinetic constants derived from the SPR analysis of the
interaction between peptide conjugate BSA- (D)DYFLG and antibody 4155.  The
interaction of antibody in solution (ligate) with peptide conjugate immobilised
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(ligand) is compared to the interaction of peptide conjugate in solution (ligate) and
antibody immobilised (ligand).
The results presented in table 6.1 demonstrate a close agreement between the kinetic
constants obtained from both orientations studied (immobilised BSA-peptide
conjugate and immobilised antibody).  The χ2 values for the global fitting of the
Langmuir association model indicate that a good fit has been achieved.  However,
from the data presented in figures 6.11 and 6.12 it can be seen that at higher levels of
antibody concentration (for the interaction with immobilised BSA-peptide conjugate),
and higher levels of BSA-peptide conjugate (for the interaction with immobilised
antibody), differences start to occur between the model data and experimental data.
This deviation at higher concentrations of solution-phase reagent is probably the
result of mass-transport limiting effects as outlined in chapter 5.  The dissociation
phase of the modal data appears to be in good agreement with the experimental data,
indicating that rebinding of antibody (immobilised BSA-peptide conjugate) or
rebinding of BSA-peptide conjugate (immobilised antibody) is not a significant
factor.
6.3.3.3 Analysis of the effect of temperature on the reaction rate using SPR
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 Figure 6.13: Analysis of the temperature dependence of the interaction between
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immobilised 4155 antibody and BSA-(D)DYFLG peptide conjugate in solution.
Temperatures from top down are 30o C, 20o C, 15o C and 10o C.  Example of
sensorgrams used to investigate the variation in association rate constant and
dissociation rate constant to peptide conjugate solution at the various temperatures.
Here 500 mM peptide conjugate solution is being used.  The dispersion spikes around
the 180-s timepoint indicate the start of the dissociation phase.
Temp ka kd KA χ2
10o C 2.40 x 104 5.50 x 10-4 4.36 x 107 0.0836
15o C 3.07 x 104 5.07 x 10-4 6.06 x 107 0.0812
20o C 3.27 x 104 4.29 x 10-4 7.61 x 107 0.0750
30o C 4.23 x 104 2.08 x 10-4 2.07 x 108 0.1710
Table 6.2: Rate constants determined from SPR experiment, looking at the effect of
temperature on the interaction between BSA-(D)DYFLG in solution and antibody
4155 immobilised on the surface of CMD BIACORE sensor chip.
From the results presented in table 6.2, it can be seen that in the temperature range
investigated, increasing the temperature leads to a gradual increase in the association
rate constant (ka), and a gradual decrease in the dissociation rate constant (kd);
resulting in an overall increase in the equilibrium association rate constant with
increase in temperature.  The increase in the association rate constant with increase in
temperature could be explained by the peptide adopting a high-energy preferential
binding structure with greater frequency with increased temperature.  The decrease in
the dissociation rate constant with increase in temperature may suggest that the
antibody can bind to a number of conformations of the peptide, but the higher energy
conformation has a reduced off-rate, and as the temperature is increased the
population of peptides adopting this more favourable structure increases.  It was
found that the hydrophobic phenylalanine and leucine residues are critical in the mAb
4155 – peptide interaction, another reason for the changes observed in the rate
constants could be the result of water molecules being eliminated more effectively
from hydrophilic regions around the binding pocket.
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6.4 Summary and Discussion
In the example given by Meloen, et al. (2000), the affinity of a weak-binding phage-
displayed mimotope peptide for a monoclonal antibody (anti-glucoseoxidase) was
enhanced through a process of optimisation using small synthetic peptide libraries to
produce a higher affinity ligand capable of functioning as an affinity ligand for use in
the paratope-specific purification of monoclonal antibodies.  In this chapter it has
been demonstrated that a similar process applied to a weak-binding mimotope peptide
reactive with a monoclonal antibody raised against a non-proteinaceous target
molecule, can be used to produce a small peptide exhibiting enhanced affinity, which
can be used as a paratope-specific affinity ligand for the purification of monoclonal
antibodies.
The results presented in this chapter have demonstrated an improved method for
screening small synthetic libraries for paratope specific binding ligands, using a
competitive approach to measure the binding abilities of peptides across an RNET
array.  This approach succeeded in reducing the level of noise in the assay, as a result
of non-specific binding interactions.
An empirical analysis of the equilibrium association constants for the interactions of
the phage-derived mimotope peptide, the optimised peptide and estrone, demonstrated
that the optimisation process had resulted in a peptide displaying an increased
equilibrium association constant over the phage-derived mimotope peptide.  The
results from an inhibition ELISA were in agreement with the results from the previous
assay to determine the relative KA values for the peptides.  The results of the
inhibition ELISA also demonstrated that the phage-derived mimotope peptide and the
optimised peptide bound specifically to the paratope of mAb 4155 – the anti-E-3-G
antibody.
It was demonstrated that the optimised peptide mimotope could be used in an assay to
determine the concentration of free E-3-G in solution.  Furthermore it was
demonstrated that such an assay employing the optimised peptide mimotope was
more sensitive to changes in E-3-G concentration than an assay employing an E-3-G
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ovalbumin conjugate.  This increased sensitivity was explained by the different
equilibrium constants observed for the interaction of the peptide mimotope and E-3-
G.
Fluorescence quenching could not be conducted using mAb 4155, since the peptide
mimotopes contained aromatic amino acid residues essential for binding, masking any
observable quenching effects.
The interaction of mAb 4155 with a BSA-conjugate of the optimised peptide
mimotope ((d) DYFLG) was conducted using Surface Plasmon Resonance.  An
equilibrium association rate constant (KA) of order of magnitude 108 M-1. Was
obtained for the interaction.  The effect of temperature on the interaction was also
investigated.  Increasing the temperature in the range 10oC to 30oC was found to lead
to an increase in the on-rate (kon), and a decrease in the off-rate (koff), resulting in an
increase in the equilibrium association rate constant (KA) with increase in
temperature.  This could be the result of the peptide adopting a more favourable high-
energy conformation at the higher temperatures, or the more effective elimination of
water from hydrophilic regions around the binding pocket.
The ability to produce a peptide ligand that is capable of purifying monoclonal
antibodies raised against a non-proteinaceous analyte is a significant achievement.
No other examples of using a peptide ligand to purify monoclonal antibodies using
peptide mimotope affinity chromatography have been found in the research literature
at the time of writing.  The advantages of using paratope-specific peptide mimotope
affinity chromatography for the purification of antibodies from biological feedstocks
were outlined in chapter 1.  The use the peptide ligand in place of estrone (which has
previously been used as an affinity ligand for the purification of mAb 4155), means
that use of a competitive elution procedure in the purification protocol (see section
1.5.3.4) can be eliminated.  The use of a peptide ligand in place of estrone also has
advantages in terms of the cost of matrix production, and simplification of the ligand
immobilisation chemistry.  The use of (d) amino acid residues in place of the naturally
occurring (l) amino acid residues should also improve the stability of the peptide to
proteolysis in biological feedstocks.
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Peptide mimotopes could also provide valuable reagents for use in biosensors which
measure non-protein analytes, offering advantages in terms of stability,
reproducibility, and the ability to fine-tune the antibody recognition process for a
particular assay requirement (e.g. qualitative or quantitative assays).
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7 Chapter 7 - Results.  Towards the production of a scFv-GFP
fusion protein.
7.1 Introduction
Chapter 2 of this thesis outlined the different technologies that are currently available
for the selection or screening of protein libraries.  It was noted that the interrogation
of such libraries using selection methodologies proved more powerful than screening
methodologies.  The amount of sequence space that can be surveyed using selection
methodologies is greatest; and the cumulative combinatorial effects observed after
successive rounds of selection leads to a faster evolution of protein structure than
could ever be achieved in a screen-based approach.
The aim of the work presented in this chapter was to construct a library of randomly
mutated C595scFv clones fused to GFP and displayed on the surface of
bacteriophage.  This would then allow the use of a more effective selection method -
fluorescent activated cell sorting (FACS) (see section 7.1.5).  Selection of scFv clones
which demonstrate a higher specific affinity to MUC1 antigens expressed in their
natural environment on tumour cell lines could prove more effective than selection
based on synthetic peptides or on the isolated antigen.  This would potentially enable
the development of a scFv demonstrating a higher specific in vivo reactivity to tumour
cells over normal cells.  The scFv-GFP fusion could also be useful in its own right as
a tumour marker.
7.1.1 Affinity maturation of antibodies
In vivo, antibodies are derived by selection from large repertoires of antigen-binding
sites displayed on the surface population of B-cells. Active antibody genes are
initially formed from unmodified germline gene segments.  The limited number of
these segments in the genome places a ceiling on the number of different antibody
structures in the naïve repertoire.  Each B-cell assembles and expresses on the surface
a single antibody species and encounter with antigen leads to the selection of those B-
cells of the repertoire with binding activities (the B-cell is effectively a package which
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links the genotype and phenotype of the antibody).  The rearranged V-genes,
encoding the heavy and light chain variable domains responsible for binding to
antigen are created by a combinatorial assembly of V-gene elements (heavy chain
VH, D and JH; light chain Vλ and Jλ, or Vκ and Jκ) during lymphocyte development.
Binding of antigen and help from T-cells triggers differentiation of the B-cell to
plasma cells and production of soluble antibody.  All of this occurs in the primary
immune response, when the B-cell population is first exposed to the antigen.
Antibodies produced in the primary response are likely to bind to the antigen with low
affinity as a result of imperfect chemical complimentarity to the immunising antigen.
Enhancement of the combining-site geometries in the progeny of the originally
activated B cell occurs by the combined action of somatic mutation and selection
(Foote and Eisen 1995).
In the mouse, there are approximately 2.5 x 108 B-cells displaying a large repertoire
of approximately 107 antigen binding sites.  Each antigen binding site is selected from
this large repertoire of structures and, typically, the antigen binding affinities are in
the range 105 to 107 M-1 (Hawkins, et al. 1993).  These affinities can be improved by
random mutation, by which variants are created with an estimated mutation rate of 10-
3
 to 10-4 point mutations per base pair per generation.  Those with higher affinity of
binding are selected on further immunisation with antigen – the secondary immune
response.  This in vivo “affinity maturation” process often leads to improvements in
affinity of five- to tenfold (Hawkins, et al. 1993).
It is possible that a rare antibody gene with germ-line sequences could generate an
antibody with optimum chemical complimentarity to the antigen, thus demonstrating
optimal antigen-binding properties without enhancement by somatic mutation and
selection.  The affinity of such an antibody has been termed static since the
occurrence of somatic mutations would probably be neutral or deleterious, causing the
elimination of cells making the sequence, or the cells may not be selectively simulated
to produce the sequence (Foote and Eisen 1995).
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The use of scFv molecules for tumour targetting offers potential advantages compared
to using whole antibodies.  IgG are large molecules (150 kDa) which diffuse slowly
into tumours and are slowly cleared from the circulation, resulting in poor
tumour:normal organ ratios.  Smaller single-chain antigody fragments (scFv, 25 kDa),
which are potentially less immunogenic than whole antibodies, penetrate tumours
better than IgG and are cleared more rapidly from the circulation.  The use of such
engineered molecules also facilitates protein-engineering techniques.  The scFv
molecule is monovalent and is thus unable to exhibit higher apparent affinity due to
avidity as is observed with the bivalent IgG molecule.  Significant tumour retention
beyond 24 h will require a dissociation rate constant (kd) less than 10-4s-1 (t1/2 = 1.8 h).
Antibodies typically have rapid association rate constants (kon>105 M-1s-1), requiring
Kd <10-9 M.  An “affinity ceiling” exists for antibodies produced during normal
immune responses (Foote and Eisen 1995).  This is as a result of limits on the
maximum on and off rates occurring in antibody-antigen interactions produced in the
immune response.  The on-rate constant has a maximum of 105-106 M-1s-1 controlled
by the diffusion coefficients of the reactant molecules, and has been verified
experimentally (Raman, et al. 1992).  The off-rate constant has been suggested to be
fixed at 10-3 – 10-4 s-1, since antibodies with slower off rates would not be selected in
vivo (Foote and Eisen 1995).  Thus Kd <10-9 M is rarely observed in antibodies
derived from a murine immune response (Schier, et al. 1996).
The sensitivity of an assay using monoclonal antibodies and their derivatives is
ultimately linked to the affinity of the antibody for the analyte.
7.1.2 Selection of high affinity antibodies in vitro
The arrival of phage display and other display technologies as outlined in Chapter 2
allows the manipulation of selection conditions in vitro.  This can enable the isolation
of higher affinity antibody species such as scFv, which may not be obtained by in vivo
antibody production methods.  An example of this was published by Hawkins, et al.
(1992).  Here the use of excess biotinylated antigen was used to select for higher
affinity scFv molecules from a library of mutants created by error-prone PCR.  A
four-fold increase in affinity over the parent molecule was obtained.  The
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disadvantage with this method is that the antigen is not in the natural environment,
which may lead to the antigen exhibiting a different structure to that seen in vivo.
FACS can potentially overcome this by using whole cells instead of the biotinylated
antigen.
7.1.3 Anti-MUC1 scFv construction
The construction and characterisation of the anti-MUC1 scFv as used in this work is
described in detail by (Denton, et al. 1997).  Briefly the procedure consisted of first
isolating mRNA from hybridoma cells expressing whole monoclonal C595 antibody.
Hybridoma mRNA was then used as the template to construct C595 scFv using the
Recombinant Phage Antibody System (RPAS; Pharmacia, Uppsala, Sweden).  First a
cDNA library was produced from mRNA through reverse transcription with random
(N6) primers.  VH and VL specific oligonucleotide primers were used to amplify
separate VH and VL chain encoding regions from the cDNA library.  Purified VH and
VL encoding DNA were spliced together by PCR using primers to introduce a linking
sequence between the two segments and unique Sfi I/Not I restriction sites at 5’ and
3’ ends respectively, enabling directional cloning into the digested pCANTAB 5E
vector.  The system was then used to express C595 scFv in bacterial supernatant.  A
single immunoreactive clone was selected which bound to the synthetic peptide
APDTRPAPG containing the RPAP epitope recognised by C595 mAb.  Sequence
analysis of the scFv demonstrated that the majority of the scFv representing the
variable regions were homologous with those of the parent antibody, except for five
conservative changes outside the CDR regions of the antibody.
7.1.4 Green fluorescent protein (GFP)
Antibodies conjugated to the fluorochromes such as fluorescein isothiocyanate (FITC)
have been used extensively for immunofluorescence techniques (REFS).  The use of
such chemically conjugated fluorochromes can lead to partial or complete loss of
antigen binding ability as a result of conjugation with residues (e.g. lysine) in the
antigen-binding site.  FITC is also very sensitive to photobleaching by illumination.
GFP isolated from the jellyfish Aequorea victoria emits intrinsic intense and stable
green fluorescence without any cofactors and exhibits less photobleaching than
fluorescein (Arai, et al. 1998). Genetic fusions between antibodies and GFP encoding
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genes circumvent the problems associated with chemical conjugation, giving a 1:1
ratio between antibody and fluorochrome.  The intensity of fluorescence and stability
of GFP has thus resulted in it’s use in fluoroimmunoassays in vitro (Aoki, et al. 1996;
Arai, et al. 1998) (see section 7.1.4 also).  GFP mutants exhibiting enhanced
fluorescence and/or altered excitation/emission wavelengths have been developed.
These have been extensively reviewed (Kendal and Badminton 1998).  Briefly these
include red-shifted variants (enhanced green fluorescent protein - EGFP), blue-shifted
variants (enhanced blue fluorescent protein – EBFP), an enhanced cyan variant and an
enhanced yellow variant.
7.1.5 Published examples of scFv-GFP fusion proteins
There are several examples of scFv-GFP fusion proteins, details of which were
published during the period of research undertaken in this thesis.  Interestingly not all
of the authors are aware of previous publications.
The first to describe a fusion between a scFv and GFP was by (Wang 1999), this is a
conference abstract describing fusion proteins between a single-chain antibody and
several photoproteins (aequorin, obelin and GFP).  These were used for assay
development in the detection of Salmonella antigen, with a detection limit for
Salmonella antigen of 2 ppm.  All retained luminescent activity of the native
photoproteins, as well as the binding affinity of the scFv to the antigen.  A decrease in
luminescence was observed and it was postulated that this could be due to a
conformational change of the fusion proteins upon binding to the antigen.
The next publication describing a scFv-GFP fusion invented the term “Fluobody” to
describe such fusion proteins (Griep, et al. 1999).  No reference is made to the
previous publication and the paper states that “genetic fusion between antibody and
GFP encoding genes would be ideal”, suggesting the authors were unaware of the
earlier example.  The paper describes the expression of two N-terminal fusions of
different scFv fragments (both directed against the lipospolysaccharide of the
bacterium Ralstonia solanacearum) to a red-shifted GFP.  A vector utilising a
tetracycline promoter (inducible with anhydrotetracycline) and a CAT-signal peptide
was used to direct expression of the fusion protein to the periplasm.  A His-tag was
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added to the C-terminus of the GFP protein to facilitate purification of fluorescent and
active expressed protein, at a yield of ~101 µg per liter of bacterial culture.
A different approach was taken in the next paper published.  Instead of labeling the
whole scFv molecule, antibody variable domains were fused with green fluorescent
protein variants, enabling the phenomena of fluorescence resonance energy transfer
(FRET) to be utilised in an homogeneous immunoassay (Arai, et al. 2000).  The work
was based on previous work creating an “open sandwich ELISA”.  Conventional
sandwich ELISA techniques require the presence of at least two epitopes, and usually
have a long measurement time as a result of the consecutive binding and washing
steps.  The open sandwich ELISA exploits the reassociation of the generally weak
VH-VL complex by a bridging antigen.  Using immobilised VL and enzyme tagged VH
fragments, antigen was measured at concentrations <10ng/ml in  a shorter time period
than the conventional sandwich immunoassay (Suzuki, et al. 1999).
The FRET variation of this technique utilised fusions of GFP derivatives with
VH and VL fragments of anti-hen egg lysozyme (HEL) antibody.  Gene fusions were
constructed and expression in the periplasm attempted.  This proved unsuccessful, and
a cytoplasmic expression system utilising a thioredoxin (Trx)-fusion expression
vector was attempted.  This approach proved successful and functional Trx-VH-EBFP
and Trx-VL-EGFP fusion proteins were purified from the cytoplasm at 3mg per liter
of culture.  The addition of antigen (HEL) to a mixture of Trx-VH-EBFP and Trx-VL-
EGFP induced heterodimerization of the two, accompanied by FRET from the EBFP
to the EGFP domains tethered with VH and VL domains respectively.  The authors
state that to their knowledge this was the first report of antibody fragment-GFP
variant fusion expressed in E. coli.
Schwallbach et al (Schwalbach, et al. 2000) describe the production of large amounts
of Fluorescent Single-Chain Antibody Fragments in the cytoplasm of E.coli.  scFv-
GFP fusion protein production was monitored by analysing the GFP fluorescence of
transformed cells under UV illumination.  Several different combinations of
promoters (lac and arabinose) and leader sequences (pel B) were tested.  The highest
levels of fluorescence were observed with expression under the control of an
arabinose promoter and no pel B leader sequence.  The GFP chromophore was found
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not to form in the cytoplasm.   Fusion protein was directed to the cytoplasm of the cell
(no disulphide bridges in the scFv), and only about 1% of the molecules were able to
bind antigen and exhibit fluorescence.  It was reported that yields of scFv-GFP fusion
proteins were highly dependent on the scFv sequence.  When a different scFv
molecule which had been adapted to cytoplasmic expression was used in place of the
previous scFv in the same vector, large amounts of functional fluorescent antibody
fragments were produced (~15mg/litre).   The authors state that to their knowledge
this was the first report of producing metabolically GFP-tagged scFvs and their
application to direct immunoassays.
(Casey, et al. 2000) describe the production of Green Fluorescent Antibodies and their
use as novel in vitro tools.  The scFvGFP fusion protein was expressed in the
periplasm of E.coli.  The authors claim this as being the first report to describe a
EGFP fusion protein that can be expressed in the periplasm of bacterial cells, to form
a functional chimera that can be used in vitro.   The scFv was specific for hepatitis B
surface antigen.  Both N and C terminal fusions of EGFP with the scFv were
constructed.  A pel B leader sequence was used to direct expression of the fusion
proteins to the periplasm, and constructs in which the pel B leader was absent were
also used to direct protein expression to the cytoplasm.  N-terminal fusions (i.e
EGFP-scFv) were demonstrated to be active and to demonstrate fluorescence.  Only a
small amount of the C-terminal scFv-EGFP periplasmic fusion protein was reported
to have been detected, indicating that this fusion was not as stable as the N-terminal
EGFP-scFv fusion.  In addition there was no evidence of full-length fusion proteins
for the cytoplasmic constructs.  The remainder of experiments in the study were
carried out using the full-length N-terminal EGFP-scFv.  A yield of ~200 µg per litre
of bacterial supernatant was reported for the N-terminal EGFP-scFv fusion protein.
7.1.6 Fluorescence activated cell sorting and affinity maturation
Fluorescence activated cell sorting (FACS) offers an effective alternative to screening
by solid support capture and elution (see chapter 4).  FACS instrumentation is
commonly used for the detection and isolation of rare cells in clinical medicine. The
following are examples where FACS has been used to screen libraries.
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- The screening of a library of short synthetic peptides immobilised on beads for high-
affinity peptide ligands (Needels, et al. 1993).
- The quantitative isolation of high affinity proteins from libraries displayed on the
surface of microorganisms (Francisco and Georgiou 1994).
- The isolation of red-shifted excitation mutants of GFP with a 20- to 35- fold increase
in fluorescence intensity has also been demonstrated (Cormack, et al. 1996).
- Affinity maturation of scFv molecules displayed on E.coli. has been demonstrated
using FACS (Daugherty, et al. 1998).
Like phage display, FACS offers the potential for the isolation of rare clones from a
very large excess of non or weakly binding background proteins, but offers the
advantage of using soluble hapten, eliminating artefacts due to binding to solid
surfaces.  The whole selection system using FACS can be considered as a totally
soluble selection system where neither the ligand nor ligand binding protein are
immobilised onto a solid support.  Both ligand and ligand binding protein are more
likely to retain structures associated with their natural chemical environment.  The
work presented in this chapter sought to use the advantage of a totally “solubilised”
selection system to screen tumour cells expressing tumour-related mucin which bound
with high affinity to a C595 scFv mutant protein.
This work can be divided into five stages:-
Stage 1:  Production of C595 scFv-GFP gene fusion containing the required
 restriction sites.
Stage 2: Ligation of scFv-GFP fusion into pCANTAB 5E.
Stage 3: Expression and purification of scFv-GFP fusion protein.
Stage 4: Creation of a library of C595 scFv mutants – optimisation of mutagenesis
  conditions.
Stage 5: Selection of mutant – GFP fusions using FACS.
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7.2 Strategy for the production of a scFv-GFP gene fusion
Figure 7.1 outlines the strategy which was finally used for the production of the scFv-
GFP gene fusion for ligation into the digested pCANTAB 5E vector.
Initially it was planned to amplify the C595 scFv and GFP genes from the respective
plasmids by PCR using the primers described in section 7.3, and after purification of
the PCR products, carry out a ligation reaction with the scFv and GFP fragments.  The
success of this ligation reaction was confirmed by PCR of the ligation reaction using
C595 SfiI FOR and GFP NotI REV primers (see figure 7.2).
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Sfi I / Bgl II
double digestion
Bgl II / Not I
double digestion
Ligation of two
digested fragments
PCR of scFv-GFP fusion,
followed by TOPO-TA cloning.
Figure 7.1: Strategy for the production of the scFv-GFP gene fusion.  A Sfi I/Not I
double disgest was conducted on the resulting vector and the gene fusion was ligated
into Sfi I/Not I digested pCANTAB 5E vector.
Not I
Bgl IIpCR 2.1 TOPO pCR 2.1 TOPO
Hind III / Bgl II
double digestion
Hind III / Bgl II
double digestion
Hind III Hind III
PCR using C595Sfi I FOR and GFP Not I REV
TOPO TA cloning of PCR product
Hind III
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Figure 7.2: Ligation of C595 scFv to GFP confirmed by PCR, showing bands
~1500bp for two different ligation reactions – (A) ligation using 1/10 dilution of scFv
PCR product + neat GFP PCR product; (B) ligation using 1/30 dilution of scFv and
neat GFP PCR product.  (C)  Sfi I / Not I digestion of pCANTAB 5E containing C595
scFv, showing the size of scFv gene in relation to the PCR product of the ligation
reaction.
Experiments to ligate the purified (ethanol/chloroform extraction and gel purification
methods both tried) and SfiI/NotI digested PCR product of the scFv-GFP ligation
reaction into SfiI/NotI digested pCANTAB 5E were unsuccessful.  Very few colonies
grew after transformation with the ligation reaction, and analysis of the plasmids of
the colonies that did grow always only contained the C595 scFv gene (Situated
between the Sfi I and Not I restriction sites of the pCANTAB 5E vector).
It was decided to clone the PCR products into a TOPO-TA cloning vector so that the
PCR products could be sequenced to confirm only the required mutations had
occurred in the amplified sequences before proceeding to the next stage.  Cloning of
the amplified genes into the cloning vectors also enabled (by agarose gel
electrophoresis) the verification that a successful restriction digest had occurred, when
the scFv-GFP fragment was cut out of the vector.
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A restriction digest was then conducted on the TOPO vectors containing the scFv and
GFP genes with the required mutations introduced.  The digested scFv and GFP
fragments were purified by agarose gel electrophoresis, and an "in-gel" ligation
conducted (as described in chapter 3).  The ligated fragment was amplified by PCR
and cloned into a TOPO cloning vector to confirm the sequence and to enable the
confirmation of the integrity of the restriction sites by agarose gel electrophoresis of
the products of a Sfi I / Not I restriction digest.
A sample of the original vector from which the C595 scFv gene was amplified was
used as the source of pCANTAB 5E vector.  Use of this vector containing the scFv
gene enabled the verification that the scFv gene had been “cut out” of the vector in the
restriction digest.
7.3 Mutagenic Primer design
A novel Bgl II restriction site was introduced at the 3’ end of the scFv gene, and at the
5’ end of the GFP gene.  The scFv and GFP genes were designed to be linked by the
unique Bgl II site at the centre of the scFv-GFP gene fusion, to enable later
manipulations when the mutated scFv library was constructed.  The Bgl II restriction
site is a unique restriction site (i.e. not present anywhere in the pCANTAB 5E
plasmid, or anywhere else in the scFv and GFP genes) enabling the insertion of
mutated scFv genes into Sfi I / Bgl II digested pCANTAB 5E plasmid containing the
scFvGFP gene fusion.  A novel Not I restriction site was also introduced at the 3’ end
of the GFP gene to enable ligation of the final gene fusion into pCANTAB 5E.
To facilitate the introduction of these novel restriction sites, primers were designed
using Amplify 1.2.  The program contains an algorithm which determines a
theoretical figure for the stability of match,  which is expressed as a percentage.  It is
desirable to have a Stability of match that is not too low or non-specific annealing of
the primer could occur at sites other than those intended, leading to unexpected PCR
products.
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1 5’CCTTTCTATGCGGCCCAGCCGGCCATGGCCCAGG3 87%
2 5’CCGGCGCACCTGCAGATCTCCGTTTCAGCTCCAGC3’ 68%
3 5`CGACAAGGTGAGGAGATCTACCATGGCTAGCAAAGGAGAAGAAC3 63%
4 5`GCGCGCGGTGAGCACCGGAACGGCACTGGTCGCGGCCGCATCCATGCCATGTGTAATC3’ 60%
Table 7.1: Stability of match for primers used to create scFv-GFP gene fusion.
C595 SfiI For, (2) C595 Bgl II Rev; (3) GFP Bgl II For and (4) GFP Not I Rev.
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C595 Sfi I For primer  
5’CCTTTCTATGCGGCCCAGCCGGCCATGGCCCAGG3`
                              I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
3’GGAAATCAACAAGGAAAGATACGCCGGGTCGGCCGGTACCGGGTCCAGGTT5’ pCANTAB-5E
C595 Bgl II Rev primer  
5’GGACCAAGCTGGAGCTGAAACGGGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGA3` pCANTAB-5E
                   I I I I I I I I I I I I I I I I     I  I I I I I I I I I I I I I
3`CGACCTCGACTTTGCCTCTAGACGTCCACGCGGCC5`
GFP Bgl II For primer  
5`CGACAAGGTGAGGAGATCTACCATGGCTAGCAAAGGAGAAGAAC3
              I I I I I I I I I I I I I I   I   I I I I I I I I I I I I I I I I I I I I I I I I I
3`ATTATGCTGTTCCACTCCTTGATTTGGTACCGATCGTTTCCTCTTCTTGAAAAG5` pTRACER-GFP
GFP Not I Rev primer  
5`TGCTGGGATTACACATGGCATGGATGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACCGCGCGCGACGTC3` pTRACER-GFP
                I I I I I I I I I I I I I I I I I I I I I       I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
3`CTAATGTGTACCGTACCTACGCCGGCGCTGGTCACGGCAAGGCCACGAGTGGCGCGCG5’
Figure 7.3:  PCR primers used to isolate c595 scFv and GFP genes from the pCANTAB-5E and pTRACER-GFP vectors.  Note C595Bgl II
Rev, GFP Bgl II Rev  and GFP Not I Rev primers were used to introduce novel restriction sites into the amplified genes.
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7.4 Amplification of C595 scFv and GFP genes with concurrent
introduction of unique restriction sites
The polymerase chain reaction (PCR) was used to introduce unique Bgl II restriction
sites at the 3’ end of the scFv gene and the 5’ end of the GFP gene; and a unique Not I
site at the 3’ end of the GFP gene.
7.4.1 Initial plasmid preparation
Before the scFv and GFP genes could be amplified from the pCANTAB 5E and the
pTRACER plasmids, a pure sample of plasmid had to be prepared.  This was done as
described in Chapter 3 of this thesis.
Figure 7.4: Gel of plasmid preparation of C595 scFv in pCANTAB 5E and GFP in
pTRACER.
The two bands indicate the presence of circular and supercoiled plasmid.
7.4.2 Polymerase Chain reaction to amplify C595 scFv and GFP
To isolate the C595 scFv and GFP genes and introduce the mutations outlined in
section 7.3, a Polymerase Chain Reaction (PCR) was performed using the primers
outlined in section 7.3.  The amplified fragments should be approximately 750 bp in
size.  The DNA from the PCR was run on an agarose gel to confirm the correction
portion of DNA had been amplified from the plasmids.
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      A         B
Figure 7.5: Agarose gel of PCR products confirming the amplification of C595 scFv
and GFP genes from plasmids pCANTAB 5E and pTRACER respectively.  (A)
demonstrates optimisation of the number of PCR cycles for the amplification of the
C595 scFv gene and (B) demonstrates the optimisation of the number of PCR cycles
for the amplification of the GFP gene.  Negative control PCR reactions (run in lanes
marked -ve) consisted of reactions excluding the target DNA (i.e. the respective
plasmids).
From these results it can be seen that 5 cycles of PCR amplification gives the most
distinctly defined PCR products for the scFv and GFP genes.  Also from this gel, it is
clear that the PCR reaction produced reaction products of the expected size.  The
bands in the lanes where the PCR product for the 5-cycle amplification was run were
excised and used in the TOPO-TA cloning reaction.
7.4.3 TOPO-TA cloning of PCR products
In order to confirm that the required mutations outlined in section 7.3 were introduced
in the PCR reaction, and to ensure the integrity of the introduced restriction sites,
PCR product from both reactions was cloned into respective TOPO-TA cloning
vectors (pCR 2.1), as described in chapter 3.  The plasmids were used to transform
E.coli TOP10F cells (Ultracomp Competant Cells, Invitrogen).  After overnight
incubation with the transformation mix, white colonies were picked from the
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LB/Ampicillin agar plates and suspended in 10µl of LB media.  1µl of the suspended
cells was used in a PCR as in the previous section.  The remainder of each suspended
colony mix was used to inoculate 5ml samples of LB/Ampicillin, which were
incubated overnight at 37oC with shaking at 200rpm.
Figure 7.6: Agarose gel of PCR products obtained from PCR of the TOPO-TA
cloning reactions.  PCR was conducted as described in Chapter 3 using the primers
C595 Sfi I For and C595 Bgl II Rev (lanes 1-10 for TOPO clones expected to contain
the scFv PCR product)  and GFP Bgl II For and GFP Not I Rev; (lanes 11,12,13 and
14 for TOPO clones expected to contain the GFP PCR product); in the lane marked
+ve the results of a PCR conducted using C595 Sfi I For and C595 Bgl II Rev using
pCANTAB 5E (C595 scFv) as the template DNA were used; in the lane marked –ve a
PCR was conducted using all primers but no DNA template, a pick from an area of
the plate containing no colonies was used.
Sequence analysis of the clones showed that the required mutations were successful
and the unique restriction sites were introduced.  Sfi I/Bgl II and Bgl II/Not I
restriction digests also confirmed the integrity of the restriction sites.
7.5 Production of scFv-GFP gene fusion
After the sequence and integrity of the restriction sites in the scFv and GFP PCR
products had been demonstrated, the next step was to ligate the two genes at the Bgl II
restriction site.
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7.5.1 Restriction digests of pCR 2.1 vectors containing the C595 scFv and GFP
mutated PCR products
A Hind III / Bgl II restriction digest was conducted on the clones isolated in section
7.4 to create scFv and GFP fragments with a Bgl II site at the 3’ and 5’ ends
respectively.
Figure 7.7: Hind III / Bgl II double restriction digests on TOPO clones isolated in
section 7.4.  The lane marked M contains molecular weight markers (2000,1500,1000,
750, 500, 300, 150 and 50 base pairs respectively from top to bottom of the gel).
Lanes marked 5-14 contain digested TOPO vector thought to contain scFv genes.
Lanes marked 15-19 contain digested TOPO vector thought to contain GFP genes.
The pCR 2.1 vector itself contains one unique Bgl II restriction site, when the PCR
products containing a Bgl II restriction site are introduced, the vector contains two
Bgl II restriction sites.  The PCR product can be cloned into the pCR 2.1 vector in two
different directions.  Digestion of the plasmids with Hind III and Bgl II should yield
three bands of the following size:
Orientation TOPO (scFv) TOPO (GFP)
Forward 2874
984
792
2874
1717
74
Reverse 2874
1698
78
2874
980
811
Restriction digests in lanes labelled 5, 6, 7, 11, 12,13 and 14 contain two very clear
bands, one >2000 bp, the second between 2000 and 1500 bp, and a third very faint
band (not clearly visible on the scanned gel) between 50 and 150 bp.  This is
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consistent with a reverse orientation of the scFv PCR product.  The very faint band at
78 bp could be explained by the reduced amount of DNA available for the ethidium
bromide to intercalate compared to the much larger fragments.  The bands in the lanes
marked 8 and 9 are not consistent with either of the orientations.  The bands in the
lane marked 10 (>2000 bp, ~1000 bp and ~750 bp) are consistent with the forward
orientation of the PCR product.  For the GFP TOPO clones, the bands in the lanes
marked 15,16, 17 and 18 are not consistent with either of the orientations; the bands
in the lane marked 19 (>2000 bp, ~1000 bp and ~750 bp) are consistent with the
forward orientation of the PCR product.
7.5.2 Ligation of C595 scFv fragment to GFP fragment
The scFv and GFP fragments isolated in section 7.5.1 were ligated in gel as described
in Chapter 2. (R141)
Figure 7.8: PCR on a sample of the ligation reaction showing the prescence of the
band ~1500 bp, indicating a successful ligation reaction.
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7.5.3 TOPO TA cloning of the PCR product of the ligation reaction
Figure 7.9: Restriction digests of a number of pCR 2.1 (scFv-GFP) clones (R145
lanes 1-5 and 16-17; R146 lanes 6-10 and 18-19; and R147 lanes 11-15).  A sample of
the PCR product for the ligation reaction was used as a marker (~1500 bp) in lanes 5,
10 and 15.  Lanes marked 1,6 and 11 contain uncut plasmid.  Lanes marked 2,7 and
12 contain plasmid digested with Sfi I restriction enzyme only.  Lanes marked 3, 8
and 13 contain plasmid digested with Not I restriction enzyme only. Lanes marked 4,
9 and 14 contain plasmid digested simultaneously in a double digest with Sfi I and
Not I restriction enzymes.  Lanes marked 16 and 18 contain undigested plasmid; and
lanes marked 17 and 19 contain plasmid digested with the restriction enzyme Bgl II.
The pCR 2.1 TOPO vector contains one unique Not I restriction site.  When the scFv-
GFP fusion is cloned into the vector two Not I restriction sites are present.  Depending
on the orientation of the cloned scFv-GFP fragment in the vector, Not I restriction
digests yield the following sized fragments:
Orientation Fragment sizes (bp)
Sfi I Not I Sfi I / Not I
Forward ~3900 ~3700
~170
~2300
~1300
~173
Reverse ~3900 ~2400
~1500
~2400
~1442
~73
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(Figures in italics represent the band which contains the scFv-GFP gene fusion).
From this analysis it can be seen that TOPO clones R145 and R146 contain the scFv-
GFP gene in the reverse orientation, and the scFv-GFP gene fusion is located in the
band ~1400 bp in the Sfi I / Not I double digest.  TOPO clone R147 contains the
scFv-GFP gene in the forward orientation and the scFv-GFP gene is located in the
band ~ 1300 bp.    It was decided not to use the TOPO clone containing the scFv-GFP
fusion in the forward orientation since the Not I restriction sites were relatively close
(~100 bp between), and it was not easy to determine whether both Not I sites were
cleaved (band ~ 173 not clearly visible).  The presence of only a two bands when a
restriction digest using Bgl II was conducted on TOPO clones R145 and R146 is
indicative of both the Bgl II site in the cloned gene and the Bgl II site in the pCR 2.1
vector being active (The pCR 2.1 vector contains a unique Bgl II restriction site).
Hence it can be said that the Bgl II restriction site joining the scFv and GFP genes is
fully functional.  Sequence analysis of the clone R145 using M13 forward and reverse
primers confirmed the presence of the engineered restriction sites and the integrity of
the scFv and GFP genes (see appendix 1).
7.6 Ligation of scFv-GFP gene fusion into pCANTAB-5E
7.6.1 The pCANTAB 5E vector
The pCANTAB vector is part of the Recombinant Phage Antibody System (RPAS,
Amersham Pharmacia Biotech).  The RPAS kit is designed to provide a tool for the
synthesis of phage-displayed and soluble recombinant antibodies.  A detailed
description and critical appraisal of this system is given by (Krammer 1998).
Antibody fragments can be expressed as a fusion with fd gene 3 protein and displayed
on the tips of M13 phage.  Once antigen positive clones are isolated, the phage can
then be used to infect a nonsuppressor strain of E.coli to produce soluble antibody
fragments.  The crucial components of the vector are summarised below: -
An antibiotic resistance gene, Amp R enables selection of bacteria which contain the
pCANTAB 5E plasmid.  Amp R encodes for the protein β-lactamase, which degrades
the antibiotic ampicillin.
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A cloning region, scFv genes are cloned in-between the Sfi I / Not I restriction sites.
An inducible LacZ promoter (pLac) regulates transcription of the scFv gene.  The
binding of the transcription inhibition protein, Lac I, to a sequence immediately
downstream of the promoter prevents transcription of the scFv gene, preventing
inhibition of the growth of cells transformed with pCANTAB 5E containing a scFv
gene insert.  When a sufficient cell density is obtained, the addition of IPTG to the
cells inhibits binding of Lac I, enabling gene transcription to proceed.
A signal peptide is encoded prior to the Sfi I restriction site.  This signal peptide
allows the expressed protein to be transported from the cytoplasm to the periplasmic
space of the bacteria cells, allowing leaching of expressed protein into the supernatant
for simplified purification.  The signal peptide is cleaved off in this process.
An E-tag peptide (see chapter 2) is coded for in the sequence immediately
downstream of the Not I restriction site, enabling detection of the expressed protein
using anti-E-tag antibody, or purification using anti-E-tag antibody.
An amber stop codon is placed between the cloned gene, and the fd gene 3 protein.
This enables the vector to be used in conjunction with different strains of E.coli to
produce both phage-displayed recombinant antibody fragments and soluble
antibodies.  For example E.coli TG1 cells produce a suppressor tRNA which allows
read-through (suppression) of the amber stop codon.  In E.coli TG1 cells,  suppression
of the amber stop codon is only about 20% efficient and so soluble antibodies will be
produced as well as phage-displayed antibodies.  However, when E.coli HB2151
cells, (which is a nonsuppressor strain) are transformed with pCANTAB 5E, the
amber stop codon halts protein translation and only soluble antibody fragments are
produced (no scFv-gene 3 fusions are produced).
7.6.2 Preparation of pCANTAB 5E vector for ligation
As described in section 7.6.1, in pCANTAB 5E, the scFv gene is directionally
inserted between the Sfi I and Not I restriction sites.  In order to ligate the scFv-GFP
gene fusion into the pCANTAB 5E vector, a restriction digest was conducted on the
Sfi I and Not I restriction sites to enable cloning of the Sfi I / Not I digested scFv-GFP
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fragment into this region.  pCANTAB 5E vector is provided by the manufacturer
already in Sfi I / Not I digested form.  It was felt that Sfi I / Not I digestion of an
existing sample of pCANTAB 5E vector containing the C595 scFv gene alone would
yield a fresher sample of plasmid digest, leading to a lower vector background (i.e.
Cells transformed with self-ligated vector).  The success of the digest would also be
evident form the appearance of the scFv gene in the digested product when analysed
using agarose gel electrophoresis.
Figure 7.10: Agarose gel of restriction enzyme digest pCANTAB 5E vector
containing C595 scFv gene.  Note the clear presence of the scFv gene (marked with
arrow) after the “double-digestion” with both Sfi I and Not I restriction enzymes.
Note the presence of the three forms of DNA (supercoiled, linearised and negatively
supercoiled) in the lane containing the circular uncut plasmid, compared to only the
linearised form of plasmid in the remaining lanes.
7.6.3 Preparation of scFv-GFP gene fusion for ligation
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Figure 7.11: Agarose gel of the gel purification of the scFv-GFP gene fusion from
two separate TOPO clones in lanes marked A (Clone R145)  and B (Clone R146).  A
double restriction digest using Sfi I and Not I restriction enzymes was used to cleave
the scFv-GFP gene from the TOPO vector.
From the agarose gel it is clear that a single band ~ 1500 bp was isolated, the size
expected for the scFv-GFP gene fusion.
7.6.4 Ligation of scFv-GFP gene fusion into pCANTAB-5E
The ligation mix was used to transform chemically competent E.coli TOP10 cells
(Invitrogen).  0.5 µl of the ligation mixture was added to 50µl of the chemically
competent cells, and transformed as per the manufacturers instructions.  The
transformation mix was then spread onto LB-agar plates containing 100 µg/ml
ampicillin and incubated overnight at 37oC.  Approximately 50 colonies were
observed to have grown.  Colony picks were taken from ten colonies and suspended
in 10 µl of LB media.  PCR was used to verify whether the ligation reaction had been
successful for each colony (1 µl of the suspended cell mixture was used in the PCR
reaction). C595 Sfi I For and GFP Not I Rev primers were used in the PCR reaction.
The remainder of the cell suspension was used to inoculate 5 ml of LB media
containing ampicillin at 100 µg/ml, and grown overnight at 37oC with agitation at
200rpm.
Figure 7.12: Agarose gel of PCR reaction products of colony picks from colonies
transformed with pCANTAB 5E – scFv-GFP ligation reaction, using PCR primers
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C595 Sfi I For and GFP Not I Rev.  The negative control consisted of a PCR reaction
conducted on a pick from the plate, but where no colonies were present.  The positive
control consisted of a PCR conducted on a diluted sample of the ligation reaction.
The very faint band in the negative control could be the result of carry-over from lane
10.  However the results of three other picks from the plate where no colonies could
be seen (lanes 12-14) suggest that this is not an ideal negative control, since a very
faint band is observed in lane 12, suggesting colonies were present even though they
were no clearly visible.
From this gel it appears that the scFv-GFP gene fusion is present in the ten colonies
tested.
Plasmid was isolated from four of the overnight samples inoculated with the colony
picks.  Restriction digests were conducted to demonstrate the presence of the scFv-
GFP gene sized fragment on digestion with Sfi I and Not I restriction enzymes.
Figure 7.13: Agarose gel electrophoresis of restriction digests of pCANTAB-5E
clones R229/21, R229/22, R229/23 and R229/24 containing the scFv-GFP gene
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fusion.  Arrows indicate scFv-GFP gene fragment (~1500 b.p.) which has been cut out
of the plasmid using a double digest.
The PCR and the restriction digest analysis demonstrate that the ligation reaction was
successful and the scFv-GFP gene fusion was ligated into the digested pCANTAB 5E
vector.
7.7 Expression of scFv-GFP fusion protein using pCANTAB-5E
Details of the important components of the pCANTAB-5E vector were described in
section 7.6.1.  The presence of the amber stop codon between the cloned scFv gene
and the fd gene 3 enable the expression of the cloned gene.  If expression is conducted
in E.coli HB2151 cells (a nonsuppressor strain of E.coli),  transformed with
pCANTAB 5E containing the cloned gene, the amber stop codon halts protein
translation and soluble cloned gene product is expressed.
It was decided to experiment with the production of soluble scFv-GFP fusion protein
from the newly synthesised plasmid before attempting phage display of the construct.
The rationale being that if scFv-GFP fusion proteins could not be expressed in their
own right, display on the surface of phage was probably unlikely to be successful.
7.7.1 Small scale expression experiment
Electrocompetent E.coli HB2151 cells were produced as outlined in chapter 3.  50 µl
of cells were electroporated with 5 µl of the plasmid clone R229/21 (see figure 7.13),
pCANTAB 5E containing the C595scFv-GFP gene fusion.
Electroporation details  pCANTAB 5E (scFv-GFP)
High Voltage: 2500 v
Capacitance: 25 µF
Shunt: 201 Ω
Pulse: 5 ms
50 ml size , induction conditions.
After electroporation, 1ml of SOC medium was added, and the mixture was agitated
at 37oC for one hour.  10 µl, and 50=µl of the cells were then spread onto LB-agar
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plates containing ampicillin (100 µg/ml).  After overnight incubation a dense carpet of
cream-coloured colonies was observed, individual colonies just visible on the plate
with 10=µl of media spread.  Six colonies were picked (consisting of three large
colonies ~3mm diameter (1, 5 and 6) and three smaller colonies (2,3 and 4)), and
suspended in 10 µl of LB media.  1 µl was used in PCR reactions using primers C595
Sfi I For and GFP Not I Rev to determine if the scFv-GFP gene was present in the
transformed colonies, and the remainder was grown up overnight in LB media
containing ampicillin (100 µg/ml) at 37oC with agitation at 400 rpm.   A pick from the
plate in an area where no colony was present was also used in the PCR, and a second
negative control consisting of a PCR with no source of template DNA.  A positive
control was used which consisted of a sample of the TOPO vector containing the
scFv-GFP gene fusion.
Figure 7.14: Agarose gel of the six colony picks from the plate containing E.coli
HB2151 cells transformed with pCANTAB 5E containing the scFv-GFP gene fusion.
Lanes 1, 2, 3, 4 and 5 all show bands equal in size to the positive control ~ 1500 bp.
Lane 6 contains a smear all down the lane.  Lane 7 has no bands around ~1500 bp.
Lane 8 contains a band ~1500 consistent with the scFv-GFP gene present in the
TOPO clone.
Clearly from the agarose gel in figure 7.14, it appears that the transformation reaction
was successful, and that five of the six colonies picked contain the pCANTAB 5E
(scFv-GFP) plasmid.  Glycerol stocks of the five positive colonies were made as
outlined in chapter 3.
Chapter 7 - Results.  Towards the production of a scFv-GFP fusion protein.
211
Soluble antibody production was then tested using the procedure outlined in chapter
3.  The supernatant from the induction process was used in section 7.7.2, after ELISA
using immobilised BSA-APDTRPAPG, anti-E-tag antibody- HRP conjugate failed to
give any signal above backgound.
A periplasmic extraction was conducted on the clones as outlined in chapter 3.
ELISA failed to show any signal above background for any of the clones using
immobilised BSA-APDTRAPG and anti-E-tag antibody failed to give any signal
above background.
A whole cell extraction was also conducted on the clones as outlined in chapter 3.
Here too ELISA failed to show any signal above background for any of the clones
using immobilised BSA-APDTRAPG and anti-E-tag antibody-HRP conjugate failed
to give any signal above background.  This was expected, the fusion protein was
unlikely to be stable in the reducing environment of the cytoplasm.
7.7.2 Affinity purification of protein from the supernatant of a small-scale
expression experiment
Affinity purification has shown to be the method of choice for the purification and
concentration of antibodies and their derivatives.  It was decided to employ affinity
chromatography of the supernatant from the soluble protein expression experiments to
see if any functional expressed protein could be concentrated and purified using
affinity chromatography.  50 ml supernatant from clone 1 was loaded onto an affinity
column consisting of 2 ml of sepharose 4B with peptide APDTRAPAPG covalently
linked (see chapter 5), and an elution consisting of a 0-100% gradient of 3M NaSCN
over 20 ml was conducted.  The eluted fractions were collected in 2.5 ml aliquots and
de-salted using PD10 columns (Amersham Pharmacia Biotech).  The resulting
fractions were assayed by ELISA.  The ELISA consisted of BSA-APDTRAPG
conjugate adsorbed to the wells of a microtitre plate.  A normal ELISA protocol was
conducted as described in chapter 3.  The same procedure was conducted for E.coli
cells transformed with pCANTAB 5E containing the C595 scFv gene alone.  Anti-E-
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tag antibody was used to detect and bound species.  The results of the ELISA are
presented in figure 7.15.
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Figure  7.15:  Results from ELISA conducted on the de-salted fractions from the
affinity purification of small scale protein expression experiments (50ml) of E.coli
HB2151 cells transformed with pCANTAB 5E containing the C595 scFv-GFP gene
fusion (R245/1); and pCANTAB 5E containing only the C595 scFv gene (R245/6).
Numbers 1-10 represent the 2.5 ml de-salted fractions which were collected from the
affinity column during the elution with the 3M NaSCN gradient.  BG represents the
background signal with PBS in place of the purified fraction.  Detection of bound
species was conducted using anti - E-tag HRP conjugate (Amersham Pharmacia
biotech), using ABTS as the revealing substrate (using the method described in
chapter 3 of this thesis).
It can be seen from figure 7.15 that signal observed for fraction eight of the affinity
purification is above the background signal for both cells transformed with
pCANTAB 5E containing the scFv-GFP gene fusion, and cells transformed with
pCANTAB 5E containing the C595 scFv gene alone.  This suggests that functional
scFv protein was produced from both of the clones  (this is in the region where whole
antibody would also be eluted from the column).
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No green fluorescence was observable from colonies transformed with the pCANTAB
5E containing the scFv-GFP gene fusion. TCA precipitation of protein from the
purified fractions  did not reveal the prescence of protein by ELISA or western blot
analysis.
7.8 Production of a library of mutated C595 scFv genes
It was stated in the introduction to this chapter that when an organism is exposed to a
foreign antigen, a process of in vivo affinity maturation and selection occurs
producing antibodies with an improved affinity for the antigen, enabling the organism
to recognise non-self from self.  It has been postulated that this in vivo affinity
maturation process has a natural "affinity ceiling" (Foote and Eisen 1995) limiting the
typical maximum affinity observed for such antibodies.  Also, as was outlined in the
introduction, there are a number of publications which have used in vitro
methodologies to produce antibody species with affinities above this "affinity
ceiling".  The aim of the next stage of work was to use in vitro methods to produce
more stringent selection criteria so that the natural limit of this "affinity ceiling" could
be exceeded.
7.8.1 Mutagenesis of C595 scFv
The first step involved in the production of a library of C595 scFv mutants was the
optimisation of the mutagenesis protocol.  It was desired to achieve a mutation rate
that produced a library containing multiple mutations in the scFv gene, since such
multiple mutations are more likely to lead to complex combinatorial changes in the
structure of the expressed protein.  As described in chapter 2 of this thesis, the power
of selection techniques lies in the enrichment of rare clones exhibiting enhanced
activities as a result of these combinatorial effects.  The PCR-based mutagenesis was
conducted as described in chapter 3 of this thesis.
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Figure 7.16: An agarose gel comparing the reaction products of a PCR amplification
of the C595 scFv gene conducted using normal non-mutagenic conditions (Lane A),
with a PCR reaction using mutagenic buffer conditions (Lane B).  Negative controls
were also run alongside the PCR reactions, in which the template DNA (pCANTAB
5E plasmid containing C595 scFv gene) was omitted.  Reaction conditions were as
described in chapter 3, 30 PCR cycles were used.
From the agarose gel in figure 7.x it can be seen that both of the PCR reactions
produce bands ~750 bp, and a second fainter band ~1500 bp (see section 7.4.2).  The
main band at ~750 appears more diffuse for the mutagenic PCR than for the non-
mutagenic PCR.
The PCR was repeated for the mutagenic PCR reaction using only 5 amplification
cycles (as in section 7.4.2).
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Figure 7.17: Agarose gel of PCR product under mutagenic conditions, employing
only 5 amplification cycles.  The lane marked A contains the product of the PCR
reaction, and the lane marked B contains the products of the negative control reaction,
consisting of a PCR in which the template DNA (pCANTAB 5E containing scFv) was
omitted.
From the agarose gel it appears that 5 cycles of PCR under mutageneic reaction
conditions produce a DNA fragment of the expected size.
The PCR product was excised from the agarose gel and cloned into the pCR 2.1
vector in the TOPO-TA cloning system.  This enables individual clones to be isolated
– i.e. only one piece of mutated DNA will be present in the plasmid of a transformed
cell, enabling sequencing of the particular PCR fragment.  E.coli. TOP10 cells were
transformed with the pCR 2.1 plasmid containing the library of mutated scFv genes.
The transformed cells were plated out onto LB plates containing ampicillin.  29
colony picks were taken from the plate and suspended in 10 µl of LB media. 1 µl of
the sample was used in a PCR using M13 For and M13 Rev primers.  A negative
control consisted of a PCR on a pick from an area of the plate in which no colonies
were present.
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Figure 7.18: PCR analysis of a number of error-prone PCR clones showing the
majority have inserts corresponding to the size of the scFv amplification product.
Colony numbers 1, 2, 4, 5, 6 and 7 were grown up overnight in 5 ml of LB media
containing 100 µg/ml at 37oC with agitation at 250 rpm.  Plasmid preps for each of
the clones were prepared as described in chapter 3.
7.8.2 Sequence analysis of C595 scFv mutants
Figure 7.19 illustrates where the mutations occurred in the error-prone PCR clones.  It
can be seen that the mutations consist of a mixture of transversions (C-G) and
transitions (T–C or T–G).
An average mutation rate of 16.5 mutations per scFv gene was obtained.
Figure 7.19: Over page, illustrating the position and frequency of mutations in six
selected scFv genes.
scFv CTT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG GTC CAA CTG CAG CAG TCA GGG GGA GGC TTA GTG CAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA GCC
MUT1                                                                                                                          C                                                                      A                    A                                C                   A
MUT2                                                                                                                                                G                                    A        C
MUT4                                                                                                                                                G                                                                             C                                                                    A
MUT5                                                                                                                                                G                A
MUT6                                                                                                                                                                                                 C                                   T                                                            A
MUT7
TCT GGA TTC ACT TTC AGT AGC TAT GGC ATG TCT TGG GTT GCG CAG ACT CCA GAC AAG AGG CTG GAG TTG GTC GCA ACC ATT AAT AGT AAT GGT GGT AGC ACC TAT TAT
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                                                                                                 A
                                                                                                                                                                                                                                    T                                                A
                                                                                                                                                       A
TAC CAG CAG AAG TCA GGC ACC TCC CCC AAA AGA TGG ATT TAT GAC ACA TCC AAA CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT GGG TCT GGG ACC TCT TAC
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                                                                                                                             G
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7.9  Summary and Discussion
The advantages associated with the use of genetically engineered antibody fragments
(scFv) for use in cancer therapy were outlined.  These advanatages included better
tumour penetration, rapid clearance from the circulation resulting in enhanced
tumour: normal organ ratios, and the fact that such species are potentially less
immunogenic than whole antibodies.  However the key disadvantage described, was
the decrease in retention time compared to whole antibodies as a result of the loss of
the avidity effect which is present in the whole antibody.
The existence of an “affinity ceiling” was described for antibodies produced during a
normal immune response.  It was stated that the use of scFv fragments for cancer
therapy, which were derived from such an immune response, would require
significant improvements in their affinity for the target antigen to be of clinical use.
An example was given of the use of an in vitro method to enhance the affinity of a
scFv for an antigen outside its natural environment.
This chapter described a novel method of isolating high affinity scFv clones reactive
with tumour cells, by creating a scFv-GFP gene fusion which could be used in a
phage display system.  Selection of high-affinity binding clones from this library
using FACS could enable the selection of scFv clones exhibiting a higher specific in
vivo reactivity to tumour cells over normal cells.  A scFv-GFP gene fusion was
created and inserted into the pCANTAB-5E phagemid vector.  A method was
developed utilising error-prone PCR to introduce mutations into the scFv gene at an
average rate of 16.5 mutations per gene (n=6).  Small-scale expression experiments
were conducted to determine whether it was possible to express soluble fusion
protein.  Significant levels of protein expression could not be detected using
conventional ELISA techniques.  Peptide epitope affinity chromatography was then
used in an attempt to concentrate any expressed proteins which may have been
present.  Analysis of eluted fractions by ELISA, demonstrated a small peak above
background, in identical fractions, for pCANTAB-5E clones containing (i) the C595
scFv gene alone and (ii) the scFv-GFP gene fusion.  Protein could not be observed
using agarose gel electrophoresis, after TCA precipitation of the fractions giving a
signal above background.
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The very low level of protein detected for both the scFv and the scFv-GFP gene
fusion suggest that the low expression levels observed may not be the result of fusing
scFv to the GFP.  Levels of scFv expression have been detected in the past using this
system at a rather low concentration of  ~80 µg/ml (Denton, et al. 1997).  However
the production of soluble scFv using this system has proven to be highly problematic
and unreliable (G Denton – Personal communication).  Current strategies for the
expression of soluble C595 scFv include the use of a pET expression vector utilising a
more tightly controlled T7 RNA polymerase promoter in place of the rather “leaky”
lac promoter.  Protein expression in the pCANTAB-5E vector, under the regulation of
the lac promoter, can occur (especially at higher temperatures) prior to induction with
IPTG (see section 7.6.1).  Such protein expression may be deleterious to cell growth
and will thus result in a much-reduced yield of protein when the culture is induced, as
a result of cell death.  This is one possible explanation for the low yields of protein
observed for both the scFv and the scFv-GFP gene fusion.  The absence of expressed
protein in the periplasmic and whole-cell extracts for clones containing the scFv and
the scFv-GFP gene fusion add further support to this hypothosis.  The use of other
expression systems should be considered to find the optimum conditions for
expression.  R. Griep (Griep, et al. 1999) describe the use of a tetracyline promoter
which can be induced at much lower temperatures (16oC) to produce scFv-GFP fusion
proteins.  Other expression systems could be considered for the production of the
C595 scFv-GFP fusion protein such as insect cells of in other eukaryotic expression
systems in which the folding and secretion of proteins is guided by more adequate
chaperone proteins.
It is of note that peptide epitope affinity chromatography can be used as a tool for the
determination of cloned gene expression at very low levels - as was demonstrated in
this chapter.  As outlined in chapter 1, and the results presented in chpaters 5 and 6,
epitope affinity chromatography offers the advantage of concentrating antibodies
from feedstocks.  The results presented in this chapter further emphasise the great
utility of peptide epitope affinity chromatography as an analytical tool as well as a
method of purification.
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8 Chapter 8 - General Discussion and Future Work.
8.1 Introduction
Peptide epitope / peptide mimotope affinity chromatography was described as the
method of choice in chapter 1, for the purification of monoclonal antibodies
exhibiting high purity, high specific activity, and homogeneity from biological
feedstocks.  The major obstacle in the application of this technique for the purification
of monoclonal antibodies, and the reason why this technique has not found more
widespread use, was thought to be the extra work involved in tailoring specific
affinity ligands for each monoclonal antibody to be purified.  The extra effort
involved may be thought unnecessary when one considers all of the other antibody
purification techniques which are available and are described in chapter 1.  However,
none of the other techniques offer the unique advantages of paratope specific
purification, which have been described and demonstrated in this thesis.
Chapter 2 described the various techniques available for the regulation of peptide
epitope – antibody interactions.  Polyvalent phage display using a T7 phage display
system was chosen as a display system because it was thought this system could most
closely simulate the presentation of ligands to the antibody in an affinity matrix
The results from chapter 4 and 5 demonstrated that it is possible to discover a novel
peptide mimotope affinity ligand using phage display that functions as a more
effective paratope-specific affinity ligand than the parent linear epitope sequence. It
was demonstrated that using relatively simple selection procedures, it is possible to
isolate phage displaying peptides, which when chemically synthesized exhibit higher
affinity for the target antibody than the synthetic natural epitope sequence.  Chapter 7
demonstrated the application of peptide epitope chromatography for the concentration
of a novel scFvGFP fusion protein which was expressed at low levels in bacterial
superantant.
8.2 Phage display of peptides
Phage display was used to discover novel peptide sequences that bound to the
therapeutic monoclonal antibody C595.  A number of biopanning experiments were
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conducted using a T7 phage library (displaying ~415 copies of each peptide), with the
anti-MUC1 mAb C595 and the anti-steroid hormone mAb 4155 as the target receptor.
No enrichment of titer of eluted phage was observed when mAb 4155 was used as the
target receptor.  A 500-fold level of enrichment was observed when mAb C595 was
used as the target receptor.  Although no enrichment of phage titre was observed
using the T7 library to screen for novel peptides reactive with mAb 4155, using a
filamentous phage library (each phage also displaying hundreds of copies of each
peptide), peptide sequences that bound to the antibody have been identified (see
chapter 6).  Clearly since both libraries were polyvalent- displaying a large number of
peptides fused to the phage coat proteins, it appears that the number of peptides
displayed using a particular system is not the only factor influencing the successful
isolation of binding peptides.  The two libraries are structurally distinct – in the T7
library 9-mer constrained peptides were displayed on the icosahedral capsid head
(Rosenberg, et al. 1996);  whereas filamentous bacteriophage such as f1 consist of a
long cylindrical structure comprising of the pVIII coat protein (Kay, 1996).  This
difference in the supporting structure has a significant bearing on the arrangement of
displayed peptides on the surface of the bacteriophage, and thus has a significant
effect on how the peptides are presented to the target molecule.
These results illustrate how the choice of a particular phage type to display a peptide
library has an important bearing on whether peptide sequences are isolated, and
demonstrates the advantage of using several different types of library in the selection
process.
Further experiments were then conducted to determine if the observed overall
enrichment was the result of a specific growth advantage conferred to the phage (as a
result of a displayed peptide sequence being beneficial to phage growth), or the
selective enrichment of specific phage clones based on affinity.  Analysis of phage
populations from each of the four rounds of biopanning revealed that affinity-based
enrichment was occurring, with eluted phage recovered from each round producing a
much larger signal in a phage capture ELISA compared with naïve library and
bacteriophage with no degenerate oligonucleotide insert.  Using Surface Plasmon
Resonance (SPR), the real-time binding of a phage clone displaying the RXXP motif,
to immobilised mAb C595 was demonstrated.
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Sequence analysis of the enriched phage clones revealed the emergence of two novel
consensus motifs: RXXP and RXP.  A possible third consensus motif of RP also
emerged, but the two clones displaying peptides containing this motif were from
separate experiments.  A predominant peptide sequence of RNREAPRGKICS
emerged in one experiment, with highest frequency in the third round of biopanning,
reducing in the fourth round of biopanning.  Sequence analysis of the phage clones
from all rounds of biopanning, also revealed the extent of mutation occuring in the
constant regions flanking the degenerate oligonucleotide insert.  The majority of
mutations were found to have occurred in the third round of biopanning, at the 5’
flanking cysteine residue.  This residue is closest to the capsid head of the phage
particle.  Only two mutations were detected at the 3’ terminal cysteine residue.
The peak of mutation frequency at the 5’ terminal cysteine residue was coincidental
with the emergence of the RNREAPRGKICS peptide sequence displayed on the
selected phage in round 3.  The phage capture ELISA also demonstrated a peak at the
third round of biopanning.  This mutation could have potentially conferred a specific
growth advantage to a particular phage clone displaying this sequence, enabling this
clone to overtake the rest of the population.  The use of ELISA experiments, could not
alone determine whether the RNREAPRGKICS peptide was isolated as a result of
affinity selection.
 These results demonstrate that a T7 phage library can be used to discover novel
peptide mimotopes and motifs not observed when using solid phase peptide libraries
or filamentous phage libraries.
8.3 Analysis of peptides derived from phage display
Experiments conducted in chapter 5 were able to demonstrate that the phage-derived
synthetic RNREAPRGKICS peptide was able to effectively bind mAb C595.  When
the mucin core peptide APDTRPAPG and the phage derived peptide
RNREAPRGKICS were linked to beaded agarose a higher level of binding was
observed for the phage derived peptide compared to the mucin core peptide.
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Affinity chromatography was performed using the phage-derived peptide
RNREAPRGKICS linked to beaded agarose and compared with affinity matrices
using:  (i) the mucin-core peptide APDTRPAPG; (ii) the mucin-core peptide with a
terminal cysteine residue (to control for dimerisation) APDTRPAPGC, and (iii) the
mucin-core peptide with a glutamic substitution (to control for binding being
enhanced by the REAP mimotope alone) APDTREAPG.  NaSCN gradient elution
profiles of columns loaded with mAb C595 were compared.  The elution profiles from
the APDTREAPG and APDTRPAPGC matrices were identical in shape and size to
the elution profile of the APDTRPAPG matrix.  The maximum of the peaks in the
elution of mAb C595 from the APDTREAPG and APDTRPAPG were directly in
line in the gradient elution profile.  The maximum of the peak from the elution of
mAb C595 from the APDTRPAPGC matrix was further up the NaSCN gradient than
any of the other maxima, this has previously been attributed to dimerisation of the
peptide leading to an increased affinity (A.  Murray, University of Nottingham –
personal communication).  The elution profile for the phage-derived peptide affinity
matrix exhibited a sharp symetrical peak, compared to the more broad, unsymmetrical
peaks observed for the other peptide affinity matrices.
Antibody purified from hybridoma supernatant using the phage-derived peptide
affinity matrix, exhibited a higher specific reactivity than antibody purified from
hybridoma supernatant using the mucin-core peptide affinity matrix.  SDS-PAGE
analysis of the purified antibody from both matrices demonstrated that the antibodies
were effectively purified from hybridoma supernatant, and contained no impurities.
This result illustrates the huge potential of using phage display to discover novel
paratope-specific peptide affinity ligands.
Affinity determination using fluorescence quenching analysis and structural analysis
using circular dichroism, of the phage-derived peptide RNREAPRGKICS, the
mucin-core peptide APDTRPAPG, and the related control peptides APDTRPAPGC
and APDTREAPG revealed a profound correlation between structual content of the
peptides and their relative equilibrium association constants.  The peptides showed a
structural content and equilibrium association constant in the following order:
RNREAPRGKICS > APDTREAPG > APDTRPAPGC > APDTRPAPG
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These results were in agreement with the relative performances of the phage-derived
peptide affinity matrix and the mucin-core peptide affinity matrix (i.e. Antibody
recovered from the phage-derived peptide affinity matrix exhibited higher specific
reactivity than antibody reovered from the mucin-core peptide affinity matrix).
The use of gradient elution using thiocyanate was demonstrated not to fit the pattern
suggested by several authors (Pullen, et al. 1986; Macdonald, et al. 1988; Ferreira and
Katzin 1995), for the interaction of mAb C595 with the phage derived peptide
RNREAPRGKICS, the mucin core peptide APDTRPAPG, and the two control
peptides APDTREAPG and APDTRPAPGC.  These authors suggest that the
tolerance of an antibody-antigen interaction to thiocyanate elution is proportional to
the strength of the antigen-antibody interaction.  From these results it is not clear why
this should be the case.  Other authors have also demonstrated that only a relatively
low concentration of sodium thiocyanate is required to elute antibody from an affinity
matrix in high yield (Murray, et al. 2001).  Analysis of the kinetics of the interaction
between the antibody with the mimotope peptide presented in this publication yielded
an association equilibrium constant (KA) = ~108 M-1.  Compare this value with that
determined for the interaction of mAb C595 with the epitope peptide APDTRPAPG,
where KA= ~106 M-1.  The kinetics of the interaction between the peptides described
above and mAb C595 merit a more in-depth kinetic analysis using SPR to determine
on and off rates, to gain more information regarding the interaction of these peptides
with the antibody.
Analysis of the interaction of mAb C595 with immobilised mucin-core peptide
APDTRPAPG using a BIAcore biosensor gave an equilibrium association constant
approximately 20x the value observed in the solution phase FQ assay.  This can be
attributed to the reduction in entropy of the immobilised peptide compared to the
solution-phase peptide.  This increased equilibrium association constant is likely to be
reflected in the real value observed on the peptide affinity matrix.  Thus the FQ assay
can be used to give relative affinities of the repective ligands, but the actual
eqilibrium constants on the column are likely to be higher as a result of the reduction
in entropy of the immobilised peptide compared to the solution-phase peptide.
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The equilibrium association constant for the interaction of mAb C595 with the MUC1
related peptide CPAHGVTSAPDTRPAPGSTAP has been determined using a
BIAcore biosensor (Karanikas, et al. 1998).  The value (KA= 5.6 x 106 M-1) is of the
same order of magnitude as the value obtained in the interaction of the mucin core
peptide APDTRPAPG (3.41 X 106 M-1) using the Langmuir model of binding.  The
author does not describe any optimisation process for immobilising the ligand onto
the sensor chip.  The only information given regarding the immobilisation process is
the chemistry used (NHS/EDC).  The larger value is likely to be the result of
immobilising too great a quantity of peptide onto the sensor chip, the result being that
re-binding of antibody can occur, reducing the value measured for kd, resulting in a
higher value for KA.  Only one antibody concentration was used to determine the
affinity constant in the published data.
These results suggest affinity selection played a part in the selection of the phage-
derived peptide RNREAPRGKICS in the four rounds of biopanning.  The fact that
all of the nucleotides were identical for all of the phage clones displaying the
RNREAPRGKICS peptide, does not prove that these clones were selected as a result
of a particular growth advantage conferred to the phage as a result of the mutation of
the 5’ terminal cysteine residue.  Measurements of the initial phage titer indicated that
311 copies of each clone would be displayed per ml of phage lysate.  A 2.5 ml aliquot
of phage lysate was used in the biopanning process, which equates to 777 copies of
each phage clone.  It is conceivable that a single clone that had acquired a point
mutation could be propagated in the amplification stages of the propagation process
and be selected for enhanced affinity.
In summary phage display was used to discover a novel peptide mimotope reactive
with mAb C595, exhibiting an enhanced affinity and increased structural content
compared to the mucin core peptide APDTRPAPG.  The application of the novel
mimotope peptide in peptide mimotope affinity chromatography demonstrated an
improved chromatographic performance compared to peptide epitope chromatography
using the mucin core peptide (i.e. antibody purified using the mimotope peptide
exhibited a higher specific reactivity than antibody purified using the epitope peptide).
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8.4 Mimotope peptides cross reactive with an anti-steroid hormone
antibody
Chapter 6 illustrated how, using a combination of phage display and small peptide
libraries, the equilibrium association constant (KA) for a weakly binding synthetic
peptide (the sequence selected from a phage library) could be enhanced by employing
a systematic optimisation methodology, to yield a novel peptide mimotope exhibiting
an increased equilibrium association constant (KA).  (An improved method for
screening small synthetic peptide libraries using a competitive approach to measure
binding was also demonstrated.)  The optimised mimotope peptide was capable of
purifying monoclonal antibodies from biological feedstocks.  Furthermore the target
antibody was an antibody raised against a non-proteinaceous molecule – estriol-3-
glucouronide - a metabolite of the steroid hormone estrone.
In an example given by Meloen, et al. (2000), the affinity of a weak-binding phage-
displayed mimotope peptide for a monoclonal antibody (anti-glucoseoxidase) was
also enhanced through a process of optimisation using small synthetic peptide
libraries to produce a higher affinity ligand capable of functioning as an affinity
ligand for use in the paratope-specific purification of monoclonal antibodies.  Note
that the antibody was raised against a proteinaceous target.  The results in chapter 6
demonstrated that a similar process applied to a weak-binding mimotope peptide
reactive with a monoclonal antibody raised against a non-proteinaceous target
molecule, can be used to produce a small peptide exhibiting enhanced affinity, which
can be used as a paratope-specific affinity ligand for the purification of monoclonal
antibodies.
This result is completely unique, no other publications describing the use of a
synthetic peptide to purify a monoclonal antibody against a non-proteinaceous ligand
were discovered at the time of writing.
An empirical analysis of the equilibrium association constants for the interactions of
the phage-derived mimotope peptide, the optimised peptide and estrone, demonstrated
that the optimisation process had resulted in a peptide displaying an increased
equilibrium association constant over the phage-derived mimotope peptide.  The
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results from an inhibition ELISA were in agreement with the results from the previous
assay to determine the relative KA values for the peptides.  The results of the
inhibition ELISA also demonstrated that the phage-derived mimotope peptide and the
optimised peptide bound specifically to the paratope of mAb 4155 – the anti-E-3-G
antibody.
Chapter 6 also demonstrated the application of peptide mimotopes in an assay to
determine the free concentration of E-3-G in solution.  The use of a peptide mimotope
possessing a lower equilibrium association constant (KA) in the interaction with
antibody than the target antigen, was demonstrated to be of utility by enabling the
sensitivity of a competition assay to be increased.
Fluorescence quenching could not be conducted using mAb 4155, since the peptide
mimotopes contained aromatic amino acid residues essential for binding, masking any
observable quenching effects.
The interaction of mAb 4155 with a BSA-conjugate of the optimised peptide
mimotope ((d) DYFLG) was conducted using Surface Plasmon Resonance.  An
equilibrium association rate constant (KA) of order of magnitude 108 M-1. Was
obtained for the interaction.  The effect of temperature on the interaction was also
investigated.  Increasing the temperature in the range 10oC to 30oC was found to lead
to an increase in the on-rate (kon), and a decrease in the off-rate (koff), resulting in an
increase in the equilibrium association rate constant (KA) with increase in
temperature.  This could be the result of the peptide adopting a more favourable high-
energy conformation at the higher temperatures, or the more effective elimination of
water from hydrophilic regions around the binding pocket.
In summary, the ability to produce a peptide ligand that is capable of purifying
monoclonal antibodies raised against a non-proteinaceous analyte is a significant
achievement.  No other examples of using a peptide ligand to purify monoclonal
antibodies using peptide mimotope affinity chromatography have been found in the
research literature at the time of writing.  The advantages of using paratope-specific
peptide mimotope affinity chromatography for the purification of antibodies from
biological feedstocks were outlined in chapter 1.  The use the peptide ligand in place
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of estrone (which has previously been used as an affinity ligand for the purification of
mAb 4155), means that use of a competitive elution procedure in the purification
protocol (see section 1.5.3.4) can be eliminated.  The use of a peptide ligand in place
of estrone also has advantages in terms of the cost of matrix production, and
simplification of the ligand immobilisation chemistry.  The use of (d) amino acid
residues in place of the naturally occurring (l) amino acid residues should also
improve the stability of the peptide to proteolysis in biological feedstocks.
Peptide mimotopes could also provide valuable reagents for use in biosensors which
measure non-protein analytes, offering advantages in terms of stability,
reproducibility, and the ability to fine-tune the antibody recognition process for a
particular assay requirement (e.g. qualitative or quantitative assays).
8.5 Towards the production of scFv-GFP fusion protein
The advantages associated with the use of genetically engineered antibody fragments
(scFv) for use in cancer therapy were outlined.  These advanatages included
potentially enhanced tumour penetration, rapid clearance from the circulation
resulting in enhanced tumour: normal organ ratios, and the fact that such species are
potentially less immunogenic than whole antibodies.  However the key disadvantage
described, was the decrease in retention time compared to whole antibodies as a result
of the loss of the avidity effect which is present in the whole antibody.  It was also
noted that higher affinities may also lead to reduced penetration into the tumour as a
result of strong binding to tumour markers expressed on the cell surface.  The work in
chapter 7 set out to produce a scFv-GFP fusion protein which could be used as a
tumour marker and used to generate a higher affinity scFv molecule.
The existence of an “affinity ceiling” was described for antibodies produced during a
normal immune response.  It was stated that the use of scFv fragments for cancer
therapy, which were derived from such an immune response, would require
significant improvements in their affinity for the target antigen to be of potential
clinical use.  A novel method was described, using an in vitro method to enhance the
affinity of a scFv for an antigen in its natural environment.  By creating a scFv-GFP
gene fusion that could be used in a phage display system, it was envisaged that
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selection of high-affinity binding clones from this library using FACS could enable
the selection of scFv clones exhibiting a higher specific in vivo reactivity to tumour
cells over normal cells.  A scFv-GFP gene fusion was created and inserted into the
pCANTAB-5E phagemid vector.  A method was developed utilising error-prone PCR
to introduce mutations into the scFv gene at an average rate of 16.5 mutations per
gene (n=6).  Small-scale expression experiments were conducted to determine
whether it was possible to express soluble fusion protein.  Significant levels of protein
expression could not be detected using conventional ELISA techniques.
Peptide epitope affinity chromatography was then used in an attempt to concentrate
any expressed proteins which may have been present.  Analysis of eluted fractions by
ELISA, demonstrated a small peak above background, in identical fractions, for
pCANTAB-5E clones containing (i) the C595 scFv gene alone and (ii) the scFv-GFP
gene fusion.  Protein could not be observed using agarose gel electrophoresis, after
TCA precipitation of the fractions giving a signal above background.
The very low level of protein detected for both the scFv and the scFv-GFP gene
fusion suggest that the low expression levels observed may not be the result of fusing
scFv to the GFP.  Levels of scFv expression have been detected in the past using this
system at a rather low concentration of  ~80 µg/ml (Denton, et al. 1997).  However
the production of soluble scFv using this system has proven to be highly problematic
and unreliable (G Denton – Personal communication).  Current strategies for the
expression of soluble C595 scFv include the use of a pET expression vector utilising a
more tightly controlled T7 RNA polymerase promoter in place of the rather “leaky”
lac promoter.  Protein expression in the pCANTAB-5E vector, under the regulation of
the lac promoter, can occur (especially at higher temperatures) prior to induction with
IPTG (see section 7.6.1).  Such protein expression may be deleterious to cell growth
and will thus result in a much-reduced yield of protein when the culture is induced, as
a result of cell death.  This is one possible explanation for the low yields of protein
observed for both the scFv and the scFv-GFP gene fusion.  The absence of expressed
protein in the periplasmic and whole-cell extracts for clones containing the scFv and
the scFv-GFP gene fusion add further support to this hypothosis.  The use of other
expression systems should be considered to find the optimum conditions for
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expression.  R. Griep (Griep, et al. 1999) describe the use of a tetracyline promoter
which can be induced at much lower temperatures (16oC) to produce scFv-GFP fusion
proteins.  Other expression systems could be considered for the production of the
C595 scFv-GFP fusion protein such as insect cells of in other eukaryotic expression
systems in which the folding and secretion of proteins is guided by more adequate
chaperone proteins.
It is of note that peptide epitope affinity chromatography can be used as a tool for the
determination of cloned gene expression at very low levels - as was demonstrated in
this chapter.  As outlined in chapter 1, and the results presented in chpaters 5 and 6,
epitope affinity chromatography offers the advantage of concentrating antibodies
from feedstocks.  The results presented in this chapter further emphasise the great
utility of peptide epitope affinity chromatography as an analytical tool as well as a
method of purification.
8.6 Future work
The research undertaken in this thesis has met the majority of the aims and objectives
originally described, but the research has highlighted areas for further investigation.
The emergence of the phage-derived peptide RNREAPRGKICS reactive with mAb
C595, and exhibiting a more highly-ordered structure and increased affinity compared
to the mucin core peptide APDTRPAPG merits further study to investigate the
structural effects of the other residues in the phage-derived sequence.  A more
rigorous investigation into the kinetics of the interactions of the peptides described in
chapter 5 with mAb C595, using SPR to determine on- and off-rates could provide an
insight into the validity of the technique of thiocyanate elution to gauge relative
affinities for antibody-ligand interactions.  SPR could also be used to provide a more
detailed understanding of the kinetics involved in the optimisation process of lead
peptide sequences derived from phage display, as described in chapter 6 of this thesis.
Rate constants could be obtained for peptides isolated at each step of the optimisation
process to assess the relative contribution of each optimisation step to the overall
process.  The results presented in this thesis highlighted a change in rate constants
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observed with variation of temperature for the interaction of an antibody and a peptide
mimotope.  The implications of this variation with temperature for the performance of
the affinity ligand would be of interest.  The creation of a functional scFv-GFP fusion
displayed on the surface of phage, as described in chapter 7, would be of great benefit
– potentially enabling the selection of high-affinity binding scFv clones by selection
in vivo (i.e. using whole cells as the target).  Although the work described in chapter 7
focussed initially on the production of soluble scFv-GFP fusion protein, further
experiments to assess whether such a fusion protein exhibiting both binding ability
and fluorescence could be expressed on the surface of phage would be worthwhile.
The assessment of other expression systems would also be a worthwhile endeavour,
since the C595 scFv-GFP fusion protein could be a useful reagent in its own right,
with potential for use in histopathology and tumour marker assays.
8.7 Summary
The work in this thesis has demonstrated some of the vast utility of peptide epitopes,
peptide mimotopes, antibodies and antibody fragments.  Peptide mimotopes / epitopes
find application in areas such as biosensors, affinity ligands and vaccines.  To gain a
greater understanding of how to discover such mimotopes is of fundamental
importance to these areas.  This thesis has demonstrated that using phage display
alone or in tandem with small synthetic peptide libraries, it is possible to discover new
molecules, and sets of molecules exhibiting a range of affinities suitable for many
applications.  The importance of using a number of different phage types when
screening phage libraries was illustrated.  A greater insight into the processes
occurring when a phage library is screened for binders has been presented,
demonstrating that mutagenesis of the library upon successive rounds of propagation
is not necessarily a bad thing.  This thesis also presents part of the work which was
undertaken by a team investigating the processes involved in the discovery of novel
mimotopes cross reactive with an anti-steroid hormone antibody.  This is the first case
such a mimotope has been described.  The work in this thesis also demonstrated how
peptide epitope affinity chromatography can be used as a tool for the detection of low
levels of protein in bacterial supernatant.
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